ID
DB00193|APRD00028|DB00171|
名称
Tramadol
描述
Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways.[A182279] Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [duloxetine] and [venlafaxine]. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.[A4269,A183842] Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators.[A183728,A183734,A183761,A17159,A182300] Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain.[A182300] Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death.[A183830,F4679] However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.[A183836,A179926]
cas号
27203-92-5
唯一标识码
0NG5TTM63P
状态
solid
一般参考文献
Dayer P, Desmeules J, Collart L: [Pharmacology of tramadol]. Drugs. 1997;53 Suppl 2:18-24.
Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998 Jun;50(6):1842-6.
Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000 Mar-Apr;14(2):65-70.
Gobel H, Stadler T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]. Drugs. 1997;53 Suppl 2:34-9.
Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003 Jul;104(1-2):323-31.
Beakley BD, Kaye AM, Kaye AD: Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician. 2015 Jul-Aug;18(4):395-400.
Shin HW, Ju BJ, Jang YK, You HS, Kang H, Park JY: Effect of tramadol as an adjuvant to local anesthetics for brachial plexus block: A systematic review and meta-analysis. PLoS One. 2017 Sep 27;12(9):e0184649. doi: 10.1371/journal.pone.0184649. eCollection 2017.
Martyn-St James M, Cooper K, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, Hood C: Tramadol for premature ejaculation: a systematic review and meta-analysis. BMC Urol. 2015 Jan 30;15:6. doi: 10.1186/1471-2490-15-6.
Monteiro BP, Klinck MP, Moreau M, Guillot M, Steagall PV, Pelletier JP, Martel-Pelletier J, Gauvin D, Del Castillo JR, Troncy E: Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis. PLoS One. 2017 Apr 12;12(4):e0175565. doi: 10.1371/journal.pone.0175565. eCollection 2017.
Stoops WW, Lofwall MR, Nuzzo PA, Craig LB, Siegel AJ, Walsh SL: Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berl). 2012 Oct;223(4):427-38. doi: 10.1007/s00213-012-2739-4. Epub 2012 May 24.
Vazzana M, Andreani T, Fangueiro J, Faggio C, Silva C, Santini A, Garcia ML, Silva AM, Souto EB: Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8. doi: 10.1016/j.biopha.2015.01.022. Epub 2015 Feb 7.
Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
Wiffen PJ, Derry S, Moore RA: Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017 May 16;5:CD012508. doi: 10.1002/14651858.CD012508.pub2.
Xu J, Zhang XC, Lv XQ, Xu YY, Wang GX, Jiang B, Cai L, Cai XJ: Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients. Pharmazie. 2014 Feb;69(2):138-41.
Arafa MH, Atteia HH: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity. Toxicol Appl Pharmacol. 2018 May 1;346:37-44. doi: 10.1016/j.taap.2018.03.019. Epub 2018 Mar 16.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
Haeseler G, Foadi N, Ahrens J, Dengler R, Hecker H, Leuwer M: Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels. Pain. 2006 Dec 15;126(1-3):234-44. doi: 10.1016/j.pain.2006.07.003. Epub 2006 Sep 1.
Marincsak R, Toth BI, Czifra G, Szabo T, Kovacs L, Biro T: The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1. Anesth Analg. 2008 Jun;106(6):1890-6. doi: 10.1213/ane.0b013e318172fefc.
Hara K, Minami K, Sata T: The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg. 2005 May;100(5):1400-5, table of contents.
Sawynok J, Reid AR, Liu J: Spinal and peripheral adenosine A(1) receptors contribute to antinociception by tramadol in the formalin test in mice. Eur J Pharmacol. 2013 Aug 15;714(1-3):373-8. doi: 10.1016/j.ejphar.2013.07.012. Epub 2013 Jul 16.
Dean L: Tramadol Therapy and CYP2D6 Genotype .
Epstein DH, Preston KL, Jasinski DR: Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol. 2006 Jul;73(1):90-9. doi: 10.1016/j.biopsycho.2006.01.010. Epub 2006 Feb 23.
Murray BP, Carpenter JE, Dunkley CA, Moran TP, Alfaifi M, Alsukaiti WS, Kazzi Z: Seizures in tramadol overdoses reported in the ToxIC registry: predisposing factors and the role of naloxone. Clin Toxicol (Phila). 2019 Aug;57(8):692-696. doi: 10.1080/15563650.2018.1547826. Epub 2019 Jan 24.
Hassamal S, Miotto K, Dale W, Danovitch I: Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018 Nov;131(11):1382.e1-1382.e6. doi: 10.1016/j.amjmed.2018.04.025. Epub 2018 May 10.
Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, Jacoby HI, Selve N: Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1993 Oct;267(1):331-40.
Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A, Shibuya I: Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha 7 receptors. Br J Pharmacol. 2002 May;136(2):207-16.

FDA approvals
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075960
WHO reports
https://www.who.int/medicines/areas/quality_safety/6_1_Update.pdf
FDA Approved Drug Products: Ultram (tramadol hydrochloride) oral tablets
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020281s045lbl.pdf
Health Canada Monograph - Tramadol
//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/679/original/Health_Canada_Monograph_-_Tramadol.PDF?1565204435
F4679Health Canada Monograph - Tramadol//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/679/original/Health_Canada_Monograph_-_Tramadol.PDF?1565204435
approved,investigational,
指示
Tramadol is approved for the management of moderate to severe pain in adults.[L9257,F4679] Tramadol is also used off-label in the treatment of premature ejaculation.[A173986]
药效学
Tramadol modulates the descending pain pathways within the central nervous system through the binding of parent and M1 metabolite to μ-opioid receptors and the weak inhibition of the reuptake of norepinephrine and serotonin.[A173983,A173980] Apart from analgesia, tramadol may produce a constellation of symptoms (including dizziness, somnolence, nausea, constipation, sweating and pruritus) similar to that of other opioids. **Central Nervous System** In contrast to [morphine], tramadol has not been shown to cause histamine release. At therapeutic doses, tramadol has no effect on heart rate, left-ventricular function or cardiac index. Orthostatic hypotension has been observed.[L9257] Tramadol produces respiratory depression by direct action on brain stem respiratory centres. The respiratory depression involves both a reduction in the responsiveness of the brain stem centres to increases in CO2 tension and to electrical stimulation. Tramadol depresses the cough reflex by a direct effect on the cough centre in the medulla. Antitussive effects may occur with doses lower than those usually required for analgesia. Tramadol causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in the setting of oxycodone overdose.[F4679] Seizures have been reported in patients receiving tramadol within the recommended dosage range. Spontaneous post-marketing reports indicate that seizure risk is increased with doses of tramadol above the recommended range. Risk of convulsions may also increase in patients with epilepsy, those with a history of seizures or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections), or with concomitant use of other drugs known to reduce the seizure threshold.[F4679] Tramadol can cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs (e.g., anti-depressants, migraine medications). Treatment with the serotoninergic drug should be discontinued if such events (characterized by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated. Tramadol should not be used in combination with MAO inhibitors or serotonin-precursors (such as L-tryptophan, oxitriptan) and should be used with caution in combination with other serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, St. John’s Wort) due to the risk of serotonin syndrome.[F4679] **Gastrointestinal Tract and Other Smooth Muscle** Tramadol causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations in serum amylase.[F4679] **Endocrine System** Opioids may influence the hypothalamic-pituitary-adrenal or -gonadal axes. Some changes that can be seen include an increase in serum prolactin and decreases in plasma cortisol and testosterone. Clinical signs and symptoms may be manifest from these hormonal changes.[F4679] Hyponatremia has been reported very rarely with the use of tramadol, usually in patients with predisposing risk factors, such as elderly patients and/or patients using concomitant medications that may cause hyponatremia (e.g., antidepressants, benzodiazepines, diuretics). In some reports, hyponatremia appeared to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and resolved with discontinuation of tramadol and appropriate treatment (e.g., fluid restriction). During tramadol treatment, monitoring for signs and symptoms of hyponatremia is recommended for patients with predisposing risk factors.[F4679] **Cardiovascular** Tramadol administration may result in severe hypotension in patients whose ability to maintain adequate blood pressure is compromised by reduced blood volume, or concurrent administration of drugs such as phenothiazines and other tranquillizers, sedative/hypnotics, tricyclic antidepressants or general anesthetics. These patients should be monitored for signs of hypotension after initiating or titrating the dose of tramadol.[F4679] **QTc-Interval Prolongation** The maximum placebo-adjusted mean change from baseline in the QTcF interval was 5.5 ms in the 400 mg/day treatment arm and 6.5 ms in the 600 mg/day mg treatment arm, both occurring at the 8h time point. Both treatment groups were within the 10 ms threshold for QT prolongation. Post-marketing experience with the use of tramadol containing products included rare reports of QT prolongation reported with an overdose. Particular care should be exercised when administering tramadol to patients who are suspected to be at an increased risk of experiencing torsade de pointes during treatment with a QTc-prolonging drug.[F4679] **Abuse and Misuse** Like all opioids, tramadol has the potential for abuse and misuse, which can lead to overdose and death. Therefore, tramadol should be prescribed and handled with caution.[F4679] **Dependence/Tolerance** Physical dependence and tolerance reflect the neuroadaptation of the opioid receptors to chronic exposure to an opioid and are separate and distinct from abuse and addiction. Tolerance, as well as physical dependence, may develop upon repeated administration of opioids, and are not by themselves evidence of an addictive disorder or abuse. Patients on prolonged therapy should be tapered gradually from the drug if it is no longer required for pain control. Withdrawal symptoms may occur following abrupt discontinuation of therapy or upon administration of an opioid antagonist. Some of the symptoms that may be associated with abrupt withdrawal of an opioid analgesic include body aches, diarrhea, gooseflesh, loss of appetite, nausea, nervousness or restlessness, anxiety, runny nose, sneezing, tremors or shivering, stomach cramps, tachycardia, trouble with sleeping, unusual increase in sweating, palpitations, unexplained fever, weakness and yawning.[F4679]
作用机制
Tramadol is a centrally acting μ-opioid receptor agonist and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Tramadol binds weakly to κ- and δ-opioid receptors and to the μ-opioid receptor with 6000-fold less affinity than morphine.[A182300] Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.[A4269] In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in μ-opioid binding.[L9257,F4670] Tramadol has also been shown to affect a number of pain modulators including alpha2-adrenoreceptors, neurokinin 1 receptors, the voltage-gated sodium channel type II alpha subunit[A183728], transient receptor potential cation channel subfamily V member 1 (TRPV1 - also known as the capsaicin receptor)[A183734], muscarinic receptors (M1 and M3), N-methyl-D-aspartate receptor (also known as the NMDA receptor or glutamate receptor)[A17158], Adenosine A1 receptors[A183761], and nicotinic acetylcholine receptor.[A17159] In addition to the above neuronal targets, tramadol has a number of effects on inflammatory and immune mediators involved in the pain response. This includes inhibitory effects on cytokines, prostaglandin E2 (PGE2), nuclear factor-κB, and glial cells as well as a change in the polarization state of M1 macrophages.[A182300]
毒性
The reported LD50 for tramadol, when administered orally in mice, is 350 mg/kg.[A174010] In carcinogenic studies, there are reports of murine tumors which cannot be concluded to be carcinogenic in humans. On the other hand, tramadol showed no evidence to be mutagenic in different assays and does not have effects on fertility. However, there are clear reports of embryotoxicity and fetotoxicity.[L9257,F4679]
代谢
Tramadol undergoes extensive first-pass metabolism in the liver by N- and O- demethylation and conjugation. From the extensive metabolism, there have been identified at least 23 metabolites. There are two main metabolic pathways: the O-demethylation of tramadol to produce O-desmethyl-tramadol (M1) catalyzed by CYP2D6 and the N-demethylation to N-desmethyl-tramadol (M2) catalyzed by CYP3A4 and CYP2B6.[A4269,L9257,F4679] The wide variability in the pharmacokinetic properties between patients can partly be ascribed to polymorphisms within the gene for CYP2D6 that determine its enzymatic activity. CYP2D6\*1 is considered the wild-type allele associated with normal enzyme activity and the "extensive metabolizer" phenotype; 90-95% of Caucasians are considered "extensive metabolizers" (with normal CYP2D6 function) while the remaining 5-10% are considered "poor metabolizers" with reduced or non-functioning enzyme.[A182294] CYP2D6 alleles associated with non-functioning enzyme include *3, *4, *5, and *6 while alleles associated with reduced activity include *9, *10, *17, and *41.[A183812] Poor metabolizers have reduced activity of the CYP2D6 enzyme and therefore less production of tramadol metabolites M1 and M2, which ultimately results in a reduced analgesic effect as tramadol interacts with the μ-opioid receptor primarily via M1.[A4269] There are also large differences in the frequency of these alleles between different ethnicities: \*3, \*4, \*5, \*6, and \*41 are more common among Caucasians while \*17 is more common in Africans for example.[A183812] Compared to 5-10% of Caucasians, only ~1% of Asians are considered poor metabolizers, however Asian populations carry a much higher frequency (51%) of the CYP2D6\*10 allele, which is relatively rare in Caucasian populations and results in higher exposure to tramadol.[A182294] Some individuals are considered "ultra-rapid metabolizers", such as those carrying CYP2D6 gene duplications (CYP2D6*DUP) or multiplications. These individuals are at risk of intoxication or exaggerated effects of tramadol due to higher concentrations of its active metabolite (M1).[A182297] The occurrence of this phenotype is seen in approximately 1% to 2% of East Asians (Chinese, Japanese, Korean), 1% to 10% of Caucasians, 3% to 4% of African-Americans, and may be >10% in certain racial/ethnic groups (ie, Oceanian, Northern African, Middle Eastern, Ashkenazi Jews, Puerto Rican). The FDA label recommends avoiding the use of tramadol in these individuals.[L9257,F4679]
吸收
**Oral Administration** Tramadol is administered as a racemate, with both the [-] and [+] forms of both tramadol and the M1 metabolite detected in circulation. Following administration, racemic tramadol is rapidly and almost completely absorbed, with a bioavailability of 75%. This difference in absorption and bioavailability can be attributed to the 20-30% first-pass metabolism. Peak plasma concentrations of tramadol and the primary metabolite M1 occur at two and three hours, respectively.[F4679] Following a single oral dose of 100mg of tramadol, the Cmax was found to be approximately 300μg/L with a Tmax of 1.6-1.9 hours, while metabolite M1 was found to have a Cmax of 55μg/L with a Tmax of 3 hours.[A4269,L9257] Steady-state plasma concentrations of both tramadol and M1 are achieved within two days of dosing. There is no evidence of self-induction.[F4679] Following multiple oral doses, Cmax is 16% higher and AUC is 36% higher than after a single dose, demonstrating a potential role of saturable first-pass hepatic metabolism in increasing bioavailability.[A4269] **Intramuscular Administration** Tramadol is rapidly and almost completely absorbed following intramuscular administration. Following injection of 50mg of tramadol, Cmax of 166μg/L was found with a Tmax of 0.75 hours.[A4269] **Rectal Administration** Following rectal administration with suppositories containing 100mg of tramadol, Cmax of 294μg/L was found with a Tmax of 3.3 hours. The absolute bioavailability was found to be higher than oral administration (77% vs 75%), likely due to reduced first-pass metabolism with rectal administration compared to oral administration.[A4269]
半衰期
Tramadol reported a half-life of 5-6 hours while the M1 metabolite presents a half-life of 8 hours.[A173980]
分类
description:This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
direct-parent:Anisoles
kingdom:Organic compounds
superclass:Benzenoids
class:Phenol ethers
subclass:Anisoles
alternative-parent:Alkyl aryl ethers
alternative-parent:Aralkylamines
alternative-parent:Cyclic alcohols and derivatives
alternative-parent:Cyclohexanols
alternative-parent:Hydrocarbon derivatives
alternative-parent:Methoxybenzenes
alternative-parent:Organopnictogen compounds
alternative-parent:Phenoxy compounds
alternative-parent:Tertiary alcohols
alternative-parent:Trialkylamines
substituent:Alcohol
substituent:Alkyl aryl ether
substituent:Amine
substituent:Anisole
substituent:Aralkylamine
substituent:Aromatic homomonocyclic compound
substituent:Cyclic alcohol
substituent:Cyclohexanol
substituent:Ether
substituent:Hydrocarbon derivative
substituent:Methoxybenzene
substituent:Monocyclic benzene moiety
substituent:Organic nitrogen compound
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Phenoxy compound
substituent:Tertiary alcohol
substituent:Tertiary aliphatic amine
substituent:Tertiary amine
消除途径
Tramadol is eliminated primarily through metabolism by the liver and the metabolites are excreted primarily by the kidneys, accounting for 90% of the excretion while the remaining 10% is excreted through feces.[L9257,F4679,A173980] Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.[A174010] The mean terminal plasma elimination half-lives of racemic tramadol and racemic M1 are 6.3 ± 1.4 and 7.4 ± 1.4 hours, respectively. The plasma elimination half-life of racemic tramadol increased from approximately six hours to seven hours upon multiple dosing.[L9257,F4679]
种类
Agents producing tachycardia

Agents that reduce seizure threshold

Alcohols
D000438
Amines
D000588
Analgesics
D000700
Anticholinergic Agents
D018680
Antidepressive Agents
D000928
Central Nervous System Agents
D002491
Central Nervous System Depressants
D002492
Combined Inhibitors of Serotonin/Norepinephrine Reuptake

Cyclohexanes
D003510
Cyclohexanols
D003511
Cycloparaffins
D003516
Cytochrome P-450 CYP2B6 Substrates

Cytochrome P-450 CYP2D6 Substrates

Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 Substrates

Dimethylamines
D004123
Drugs that are Mainly Renally Excreted

Muscarinic Antagonists
D018727
Narcotics
D009294
Nervous System
D009420
NMDA Receptor Antagonists

Opiate Agonists

Opioid Agonist

Opioids
D000701
Peripheral Nervous System Agents
D018373
Sensory System Agents
D018689
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
D020230
Serotonin 5-HT2 Receptor Antagonists
D058830
Serotonin 5-HT2C Receptor Antagonists
D058830
Serotonin Agents
D018490
Serotonin Modulators

Serotonin Receptor Antagonists
D012702
UGT1A1 Substrates

盐类
DBSALT000181Tramadol hydrochloride9N7R477WCK36282-47-0PPKXEPBICJTCRU-XMZRARIVSA-N299.836299.165206788
蛋白质结合
About 20% of the administered dose is found to bind to plasma proteins. Protein binding appears to be independent of concentrations up to 10μg/mL. Saturation only occurs at concentrations outside of the clinical range.[F4679]
清除
In clinical trials, the clearance rate of tramadol ranged from 3.73 ml/min/kg in renal impairment patients to 8.50 ml/min/kg in healthy adults.[L9257,F4679]
同义词
language:english; code:inn; name;Tramadol
language:latin; code:inn; name;Tramadolum
国际品牌
RybixShionogi Inc.TramalGrünenthal GmbH
配送量
The volume of distribution of tramadol is reported to be in the range of 2.6-2.9 L/kg.[L9257,F4679] Tramadol has high tissue affinity; the total volume of distribution after oral administration was 306L and 203L after parenteral administration.[A182300] Tramadol crosses the blood-brain barrier with peak brain concentrations occurring 10 minutes following oral administration. It also crosses the placental barrier with umbilical concentrations being found to be ~80% of maternal concentrations.[A4269]
产品
name:Act Tramadol/acet
labeller:Actavis Pharma Company
ndc-id:
ndc-product-code:
dpd-id:02383209
ema-product-code:
ema-ma-number:
started-marketing-on:2012-05-01
ended-marketing-on:2018-06-18
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ag-acet-tramadol
labeller:Angita Pharma Inc.
ndc-id:
ndc-product-code:
dpd-id:02477092
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-tramadol
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:02426153
ema-product-code:
ema-ma-number:
started-marketing-on:2014-06-23
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-tramadol/acet
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:02336790
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-09
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Auro-tramadol
labeller:Auro Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02479672
ema-product-code:
ema-ma-number:
started-marketing-on:2019-04-11
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Auro-tramadol/acetaminophen
labeller:Auro Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02439050
ema-product-code:
ema-ma-number:
started-marketing-on:2015-04-08
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Bio-tramadol/acet
labeller:Biomed Pharma
ndc-id:
ndc-product-code:
dpd-id:02477122
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:ConZip
labeller:Vertical Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68025-053
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:2017-02-28
dosage-form:Capsule, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ConZip
labeller:Vertical Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68025-055
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:2017-03-31
dosage-form:Capsule, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ConZip
labeller:Vertical Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68025-056
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:2016-04-30
dosage-form:Capsule, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ConZip
labeller:Vertical Pharmaceuticals, LLC
ndc-id:
ndc-product-code:68025-071
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ConZip
labeller:Vertical Pharmaceuticals, LLC
ndc-id:
ndc-product-code:68025-072
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:ConZip
labeller:Vertical Pharmaceuticals, LLC
ndc-id:
ndc-product-code:68025-073
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Conzip
labeller:Advanced Rx Pharmacy of Tennessee, LLC
ndc-id:
ndc-product-code:80425-0101
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-27
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Durela
labeller:Cipher Pharmaceuticals Inc.
ndc-id:
ndc-product-code:
dpd-id:02373017
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Durela
labeller:Cipher Pharmaceuticals Inc.
ndc-id:
ndc-product-code:
dpd-id:02373033
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Durela
labeller:Cipher Pharmaceuticals Inc.
ndc-id:
ndc-product-code:
dpd-id:02373025
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-19
ended-marketing-on:
dosage-form:Capsule, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ipg-tramadol/acet
labeller:Marcan Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02387123
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Jamp Tramadol
labeller:Jamp Pharma Corporation
ndc-id:
ndc-product-code:
dpd-id:02507005
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Jamp-acet-tramadol
labeller:Jamp Pharma Corporation
ndc-id:
ndc-product-code:
dpd-id:02388308
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-05
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Lupin-tramadol/acet
labeller:Lupin Pharma
ndc-id:
ndc-product-code:
dpd-id:02407981
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mar-tramadol
labeller:Marcan Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02480859
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-18
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mar-tramadol/acet
labeller:Marcan Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02388324
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-04
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mint-tramadol/acet
labeller:Mint Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02389800
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-18
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mylan-tramadol/acet
labeller:Mylan Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02425599
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-30
ended-marketing-on:2017-05-08
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Nra-tramadol/acet
labeller:Nora Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02469650
ema-product-code:
ema-ma-number:
started-marketing-on:2018-08-28
ended-marketing-on:2019-01-02
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Pat-tramadol/acet
labeller:Patriot A Division Of Janssen Inc
ndc-id:
ndc-product-code:
dpd-id:02389274
ema-product-code:
ema-ma-number:
started-marketing-on:2012-08-14
ended-marketing-on:2014-11-11
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PMS-tramadol-acet
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:02401657
ema-product-code:
ema-ma-number:
started-marketing-on:2013-04-29
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Priva-tramadol/acet
labeller:Pharmapar Inc
ndc-id:
ndc-product-code:
dpd-id:02391554
ema-product-code:
ema-ma-number:
started-marketing-on:2013-07-09
ended-marketing-on:2020-10-13
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Qdolo
labeller:Athena Bioscience, LLC
ndc-id:
ndc-product-code:71511-301
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-09-11
ended-marketing-on:
dosage-form:Solution
strength:5 mg/1mL
route:Oral
fda-application-number:NDA214044
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ralivia
labeller:Valeant Canada Lp Valeant Canada S.E.C.
ndc-id:
ndc-product-code:
dpd-id:02299194
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-25
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ralivia
labeller:Valeant Canada Lp Valeant Canada S.E.C.
ndc-id:
ndc-product-code:
dpd-id:02299208
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-25
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ralivia
labeller:Valeant Canada Lp Valeant Canada S.E.C.
ndc-id:
ndc-product-code:
dpd-id:02299216
ema-product-code:
ema-ma-number:
started-marketing-on:2007-10-25
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Riva-tramadol/acet
labeller:Laboratoire Riva Inc
ndc-id:
ndc-product-code:
dpd-id:02424959
ema-product-code:
ema-ma-number:
started-marketing-on:2014-12-12
ended-marketing-on:2015-07-22
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Rybix ODT
labeller:Victory Pharma, Inc.
ndc-id:
ndc-product-code:68453-825
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-05-01
ended-marketing-on:2014-06-30
dosage-form:Tablet, orally disintegrating
strength:50 mg/1
route:Oral
fda-application-number:NDA021693
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Rybix ODT
labeller:Shionogi
ndc-id:
ndc-product-code:59630-825
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-05-05
ended-marketing-on:2014-07-01
dosage-form:Tablet, orally disintegrating
strength:50 mg/1
route:Oral
fda-application-number:NDA021693
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-244
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-12-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021745
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-253
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-12-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021745
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-255
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-12-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021745
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Purdue Pharma LP
ndc-id:
ndc-product-code:59011-334
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-12-15
ended-marketing-on:2013-09-30
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021745
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Purdue Pharma LP
ndc-id:
ndc-product-code:59011-335
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-12-15
ended-marketing-on:2013-09-30
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021745
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Purdue Pharma LP
ndc-id:
ndc-product-code:59011-336
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-12-15
ended-marketing-on:2013-09-30
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021745
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Pd Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-241
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-01
ended-marketing-on:2014-10-13
dosage-form:Tablet, delayed release
strength:200 mg/1
route:Oral
fda-application-number:ANDA021745
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ryzolt
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:35356-498
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-19
ended-marketing-on:2012-11-11
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021745
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Sandoz Tramadol
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02493764
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Synapryn
labeller:Fusion Pharmaceuticals LLC
ndc-id:
ndc-product-code:43093-100
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-09-14
ended-marketing-on:2010-07-20
dosage-form:Kit
strength:5 g/5g
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Synapryn
labeller:California Pharmaceuticals, Llc
ndc-id:
ndc-product-code:70332-107
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-01
ended-marketing-on:
dosage-form:Kit
strength:5.8 g/5.8g
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Taro-tramadol ER
labeller:Taro Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:
dpd-id:02450429
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-07
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Taro-tramadol ER
labeller:Taro Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:
dpd-id:02450437
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-27
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Taro-tramadol ER
labeller:Taro Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:
dpd-id:02450445
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-27
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Taro-tramadol/acet
labeller:Sun Pharma Canada Inc
ndc-id:
ndc-product-code:
dpd-id:02388197
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-tramadol/acetaminophen
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02347180
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-04
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Theratramadol-60
labeller:Physician Therapeutics Llc
ndc-id:
ndc-product-code:68405-380
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-20
ended-marketing-on:
dosage-form:Kit
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Theratramadol-90
labeller:Physician Therapeutics Llc
ndc-id:
ndc-product-code:68405-038
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-04
ended-marketing-on:
dosage-form:Kit
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Topical Pain
labeller:Dr Marc's Manufacturing And Sales
ndc-id:
ndc-product-code:70414-107
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-02-23
ended-marketing-on:2018-04-17
dosage-form:Cream
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Tramacet
labeller:Janssen Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02264846
ema-product-code:
ema-ma-number:
started-marketing-on:2005-07-22
ended-marketing-on:2020-09-25
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tramadol
labeller:Accord Healthcare Limited
ndc-id:
ndc-product-code:16729-167
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-23
ended-marketing-on:2017-10-23
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA202390
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol / Acetaminophen
labeller:Sivem Pharmaceuticals Ulc
ndc-id:
ndc-product-code:
dpd-id:02429969
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-13
ended-marketing-on:2019-08-12
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tramadol Acetaminophen
labeller:Directrx
ndc-id:
ndc-product-code:61919-335
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol ER
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-893
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-27
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol HCl
labeller:Watson Pharmaceuticals
ndc-id:
ndc-product-code:0591-0466
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-03-30
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol HCl
labeller:Northwind Pharmaceuticals
ndc-id:
ndc-product-code:51655-182
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-03
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol HCl and Acetaminophen
labeller:Ascend Laboratories, LLC
ndc-id:
ndc-product-code:67877-322
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA202076
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol HCl and Acetaminophen
labeller:Graviti Pharmaceuticals Private Limited
ndc-id:
ndc-product-code:69844-049
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-04-06
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA076914
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol HCl ER
labeller:Direct Rx
ndc-id:
ndc-product-code:61919-818
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-03
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrchloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-541
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-09
ended-marketing-on:2013-10-05
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Core Pharma, Llc
ndc-id:
ndc-product-code:65162-127
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-08-23
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-699
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-700
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Contract Pharmacy Services Pa
ndc-id:
ndc-product-code:67046-730
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-02-26
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Altura Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:63874-532
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-01
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-4263
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-08
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-6128
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-17
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Keltman Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68387-900
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-30
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Dispensing Solutions, Inc.
ndc-id:
ndc-product-code:68258-2003
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-132
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-23
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-483
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Stat Rx USA
ndc-id:
ndc-product-code:42549-527
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-23
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-229
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:H.J. Harkins Company
ndc-id:
ndc-product-code:76519-1009
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mutual Pharmaceutical
ndc-id:
ndc-product-code:53489-499
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-20
ended-marketing-on:2012-01-31
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076100
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Med Pharma Co., Ltd.
ndc-id:
ndc-product-code:51138-194
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-30
ended-marketing-on:2012-03-26
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075983
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Life Line Home Care Services
ndc-id:
ndc-product-code:75921-627
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-01
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mallinckrodt
ndc-id:
ndc-product-code:0406-7171
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-10-09
ended-marketing-on:2012-04-01
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075983
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Dispensing Solutions, Inc.
ndc-id:
ndc-product-code:66336-915
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Med Pharma Co., Ltd.
ndc-id:
ndc-product-code:51138-077
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-01
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-4705
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:2014-08-18
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:St. Marys Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-822
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-30
ended-marketing-on:2014-09-20
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Blenheim Pharmacal, Inc.
ndc-id:
ndc-product-code:10544-009
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-08-13
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Blenheim Pharmacal, Inc.
ndc-id:
ndc-product-code:10544-531
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-04-07
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rxchange Co
ndc-id:
ndc-product-code:33358-342
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-11-14
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Ready Meds
ndc-id:
ndc-product-code:64205-627
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Eon Labs, Inc.
ndc-id:
ndc-product-code:0185-0311
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-25
ended-marketing-on:2012-03-31
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075968
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rhodes Pharmaceuticals, L.P.
ndc-id:
ndc-product-code:42858-901
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:2014-10-14
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021745
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rhodes Pharmaceuticals, L.P.
ndc-id:
ndc-product-code:42858-902
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:2014-10-14
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021745
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rhodes Pharmaceuticals, L.P.
ndc-id:
ndc-product-code:42858-903
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:2014-10-14
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021745
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:62584-559
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-23
ended-marketing-on:2014-08-18
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-4638
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-21
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-5436
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-6361
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-5967
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-6385
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-105
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-880
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferreed Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-9491
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-04-02
ended-marketing-on:2014-10-01
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:43353-072
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mesource Pharmaceuticals
ndc-id:
ndc-product-code:45865-357
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-14
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Ncs Health Care Of Ky, Inc Dba Vangard Labs
ndc-id:
ndc-product-code:0615-7810
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-21
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075986
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:KLE 2, Inc.
ndc-id:
ndc-product-code:76218-0708
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:2015-10-30
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Alivio Medical Products, Llc
ndc-id:
ndc-product-code:69512-627
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-01
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/50mg
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Directrx
ndc-id:
ndc-product-code:61919-583
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-01
ended-marketing-on:
dosage-form:Capsule
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Directrx
ndc-id:
ndc-product-code:61919-002
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-01
ended-marketing-on:
dosage-form:Capsule, coated, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:35356-767
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:2015-10-01
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Apotheca, Inc.
ndc-id:
ndc-product-code:12634-786
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-077
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-17
ended-marketing-on:2011-11-18
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferreed Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-9784
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-07-17
ended-marketing-on:2016-09-19
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferreed Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-9199
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-23
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-298
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-07
ended-marketing-on:2013-05-08
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075977
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-807
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-09
ended-marketing-on:2014-01-10
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-13
ended-marketing-on:2013-05-14
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Red Pharm Drug, Inc.
ndc-id:
ndc-product-code:67296-0389
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-277
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-06-04
ended-marketing-on:2013-06-05
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lupin Pharmaceuticals
ndc-id:
ndc-product-code:68180-383
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-09-26
ended-marketing-on:2016-05-31
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lupin Pharmaceuticals
ndc-id:
ndc-product-code:68180-384
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-09-26
ended-marketing-on:2015-11-30
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lupin Pharmaceuticals
ndc-id:
ndc-product-code:68180-385
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-09-26
ended-marketing-on:2015-12-31
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Biomes Pharmaceuticals
ndc-id:
ndc-product-code:69150-020
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-02-25
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA202075
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-963
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-10
ended-marketing-on:2018-02-28
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Actavis Pharma Company
ndc-id:
ndc-product-code:0228-2714
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-19
ended-marketing-on:2008-05-31
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075960
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:North Star Rx Llc
ndc-id:
ndc-product-code:16714-111
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-16
ended-marketing-on:2018-01-31
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA078935
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-4566
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:2015-12-15
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4119
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:ALPHAPHARM PTY LTD
ndc-id:
ndc-product-code:57315-038
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-01
ended-marketing-on:2013-01-01
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075980
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:61786-891
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-09-20
ended-marketing-on:2017-11-22
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Contract Pharmacy Services Pa
ndc-id:
ndc-product-code:67046-729
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-4899
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Red Pharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1329
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:61786-199
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-02-25
ended-marketing-on:2016-10-14
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-317
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-11-27
ended-marketing-on:2014-07-13
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:53217-960
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-960
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sa3, Llc
ndc-id:
ndc-product-code:69420-1002
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-04-01
ended-marketing-on:2017-04-13
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-0822
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:2015-10-30
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferreed Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-9304
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-04-15
ended-marketing-on:2017-11-16
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:H. J. Harkins Company Inc.
ndc-id:
ndc-product-code:76519-1132
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-01-03
ended-marketing-on:
dosage-form:Tablet, coated
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:49999-129
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-07
ended-marketing-on:2014-06-01
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:H.J. Harkins Company
ndc-id:
ndc-product-code:52959-688
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-01-03
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3333
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-01
ended-marketing-on:2014-11-30
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4154
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-2537
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2013-08-31
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:53217-105
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2017-03-01
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mas Management Group, Inc.
ndc-id:
ndc-product-code:69677-316
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-07-01
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sa3, Llc
ndc-id:
ndc-product-code:69420-3002
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-04-01
ended-marketing-on:2017-12-01
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-1338
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-28
ended-marketing-on:2017-10-31
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Virtus Pharmaceuticals
ndc-id:
ndc-product-code:76439-136
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-20
ended-marketing-on:2015-10-15
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Contract Pharmacy Services Pa
ndc-id:
ndc-product-code:67046-731
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-2541
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2017-03-31
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-4791
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-23
ended-marketing-on:2016-03-31
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-6239
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-21
ended-marketing-on:2012-08-31
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075986
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mc Kesson Contract Packaging
ndc-id:
ndc-product-code:76237-253
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-21
ended-marketing-on:2017-09-30
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075986
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-4320
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Major
ndc-id:
ndc-product-code:0904-6119
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-01
ended-marketing-on:2014-11-30
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Par Pharmaceutical
ndc-id:
ndc-product-code:49884-823
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-28
ended-marketing-on:2019-02-28
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Par Pharmaceutical
ndc-id:
ndc-product-code:49884-822
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-28
ended-marketing-on:2019-03-31
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Par Pharmaceutical
ndc-id:
ndc-product-code:49884-821
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-28
ended-marketing-on:2018-10-31
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-0377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-0136
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3000
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sa3, Llc
ndc-id:
ndc-product-code:69420-5150
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:2020-08-31
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-4321
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:St. Mary's Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-622
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-900
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-876
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-7284
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-17
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA205257
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-597
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-062
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4165
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-7321
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-03-12
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0806
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-6929
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-1978
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1003
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4070
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-8920
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-09-18
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4282
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-006
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-08-24
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075977
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-029
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-09-27
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2005
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-04-08
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:St. Mary's Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-319
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1649
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-8787
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Precision Dose, Inc.
ndc-id:
ndc-product-code:68094-017
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-11-22
ended-marketing-on:2019-10-31
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Clinical Solutions Wholesale, LLC
ndc-id:
ndc-product-code:58118-0319
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-5656
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-04
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075986
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8190
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-859
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-860
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-861
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-531
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA091607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-533
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA091607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:47335-537
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA091607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-4152
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-16
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA205257
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-4153
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-16
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA205257
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-4154
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-16
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA205257
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Advagen Pharma Limited
ndc-id:
ndc-product-code:72888-007
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA208708
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Advagen Pharma Limited
ndc-id:
ndc-product-code:72888-008
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Tablet, coated
strength:100 mg/1
route:Oral
fda-application-number:ANDA208708
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1319
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Contract Pharmacy Services-PA
ndc-id:
ndc-product-code:67046-887
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-09-24
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-1671
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-18
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5078
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-18
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:35356-790
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:St. Mary's Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-10-06
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0886
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-12-04
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:68382-319
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:65841-754
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:65162-627
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-066
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6365
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-26
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:65862-667
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-31
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA203494
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-293
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Macleods Pharmaceuticals Limited
ndc-id:
ndc-product-code:33342-201
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-07
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA205702
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-4151
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-21
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075986
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:57664-377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:TruPharma LLC
ndc-id:
ndc-product-code:52817-195
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA208708
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:TruPharma LLC
ndc-id:
ndc-product-code:52817-196
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Tablet, coated
strength:100 mg/1
route:Oral
fda-application-number:ANDA208708
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Denton Pharma, Inc. Dba Northwind Pharmaceuticals
ndc-id:
ndc-product-code:70934-461
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-10-31
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Par Pharmaceutical, Inc.
ndc-id:
ndc-product-code:10370-221
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-27
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Par Pharmaceutical, Inc.
ndc-id:
ndc-product-code:10370-222
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-27
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Par Pharmaceutical, Inc.
ndc-id:
ndc-product-code:10370-223
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-27
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-063
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Virtus Pharmaceuticals LLC
ndc-id:
ndc-product-code:69543-136
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lupin Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68180-697
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lupin Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68180-698
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lupin Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68180-699
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:NCS HealthCare of KY, Inc dba Vangard Labs
ndc-id:
ndc-product-code:0615-8005
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4716
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Teva Pharmaceuticals USA, Inc.
ndc-id:
ndc-product-code:0093-0058
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-20
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075977
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-588
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-19
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075977
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-709
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:65862-683
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-20
ended-marketing-on:2019-12-30
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA204421
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:65862-733
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-20
ended-marketing-on:2019-12-30
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA204421
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:65862-734
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-20
ended-marketing-on:2019-12-30
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA204421
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-969
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-976
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5142
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Direct_Rx
ndc-id:
ndc-product-code:61919-229
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-08-20
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Direct Rx
ndc-id:
ndc-product-code:61919-073
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Direct Rx
ndc-id:
ndc-product-code:61919-895
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-12-01
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0521
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1402
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-07
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA205702
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1021
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-563
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Sta3, Llc
ndc-id:
ndc-product-code:69467-1001
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:2020-08-31
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7601
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-06
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7609
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-13
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-615
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-808
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-05
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-4802
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-392
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-303
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5204
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-412
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0118
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-01-12
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aphena Pharma Solutions - Tennessee, LLC
ndc-id:
ndc-product-code:71610-398
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-016
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Mylan Institutional Inc.
ndc-id:
ndc-product-code:51079-991
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-08-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075986
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1766
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075986
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0258
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-02-23
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-389
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0891
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-12-12
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0942
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-09
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1498
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals,inc.
ndc-id:
ndc-product-code:68071-5261
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Clinical Solutions Wholesale, LLC
ndc-id:
ndc-product-code:58118-0377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Polygen Pharmaceuticals Inc.
ndc-id:
ndc-product-code:52605-010
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA206706
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-4394
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-7373
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-08-22
ended-marketing-on:2019-04-09
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-4900
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-055
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2018-11-16
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-719
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2018-11-16
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-0821
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:2017-12-31
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2100
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2019-03-31
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:24236-609
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-02-07
ended-marketing-on:2015-02-04
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0807
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:2018-10-11
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-6831
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2018-03-30
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Rising Health, Llc
ndc-id:
ndc-product-code:57237-238
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-31
ended-marketing-on:2019-04-18
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA203494
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-1325
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-14
ended-marketing-on:2015-06-30
dosage-form:Capsule, extended release
strength:150 mg/1
route:Oral
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2215
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:2018-09-26
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3501
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-04-06
ended-marketing-on:2019-09-30
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:McKesson Corporation dba SKY Packaging
ndc-id:
ndc-product-code:63739-671
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2019-04-30
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:66267-843
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2019-12-31
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1254
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-13
ended-marketing-on:2020-04-16
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-0054
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-12-12
ended-marketing-on:2018-02-22
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-8921
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-09-22
ended-marketing-on:2019-11-15
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3280
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:2019-12-31
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2099
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2019-03-31
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-487
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-24
ended-marketing-on:2017-08-31
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Apotex Corp.
ndc-id:
ndc-product-code:60505-0171
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-07-10
ended-marketing-on:2016-05-30
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA075981
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:35356-546
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-06-01
ended-marketing-on:2019-10-11
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:35356-547
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-06-01
ended-marketing-on:2019-10-11
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3321
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-31
ended-marketing-on:2019-12-31
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Patriot Pharmaceuticals, LLC
ndc-id:
ndc-product-code:10147-0901
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-01-16
ended-marketing-on:2017-03-31
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Patriot Pharmaceuticals, LLC
ndc-id:
ndc-product-code:10147-0902
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-01-16
ended-marketing-on:2017-03-31
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021692
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Patriot Pharmaceuticals, LLC
ndc-id:
ndc-product-code:10147-0903
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-01-16
ended-marketing-on:2017-03-31
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021692
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:NorthStar Rx LLC
ndc-id:
ndc-product-code:16714-481
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-04-06
ended-marketing-on:2020-03-01
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-9237
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-06
ended-marketing-on:2019-04-09
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-9232
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-06
ended-marketing-on:2019-04-09
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-2868
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:2017-03-30
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-0824
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:2017-12-31
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA091607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-8788
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-30
ended-marketing-on:2017-12-31
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA091607
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:35356-659
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-11-23
ended-marketing-on:2019-10-11
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-0823
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-28
ended-marketing-on:2017-12-31
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA078783
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-247
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-04-01
ended-marketing-on:2017-08-03
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Unichem Pharmaceuticals (USA), Inc.
ndc-id:
ndc-product-code:29300-355
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-08-09
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA211825
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Direct Rx
ndc-id:
ndc-product-code:61919-893
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-01
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8319
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8323
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-463
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7763
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-22
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7762
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-22
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:71205-468
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2795
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-24
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Asclemed Usa, Inc.
ndc-id:
ndc-product-code:76420-127
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA091498
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8324
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1676
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1675
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-12
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Denton Pharma, Inc. Dba Northwind Pharmaceuticals
ndc-id:
ndc-product-code:70934-531
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-30
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Directrx
ndc-id:
ndc-product-code:61919-597
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-23
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA090404
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:59651-441
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-09-23
ended-marketing-on:
dosage-form:Tablet, film coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA203494
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Quality Care Products, LLC
ndc-id:
ndc-product-code:55700-864
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-09-25
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:Direct Rx
ndc-id:
ndc-product-code:72189-154
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-11-10
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-120
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-01
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-115
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-01
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-236
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-04-21
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA076475
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Keltman Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68387-497
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-10-19
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA076475
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5291
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-05-12
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA076475
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Rebel Distributors
ndc-id:
ndc-product-code:42254-051
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-230
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Stat Rx USA
ndc-id:
ndc-product-code:42549-569
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-16
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:H.J. Harkins Company
ndc-id:
ndc-product-code:52959-814
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-16
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:33261-389
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Amerincan Health Packaging
ndc-id:
ndc-product-code:68084-496
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-01
ended-marketing-on:2014-08-18
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:53217-040
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-5680
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Rxchange Co
ndc-id:
ndc-product-code:33358-343
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-11-20
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Av Pak
ndc-id:
ndc-product-code:50268-773
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-05-19
ended-marketing-on:2014-07-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:IVAX Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:0172-6359
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-04-15
ended-marketing-on:2014-10-31
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Alvogen, Inc.
ndc-id:
ndc-product-code:47781-219
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-04-30
ended-marketing-on:2013-08-15
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA202076
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-4901
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Directrx
ndc-id:
ndc-product-code:61919-067
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Preferreed Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-0985
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-853
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-05
ended-marketing-on:2012-12-05
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:ALPHAPHARM PTY LTD
ndc-id:
ndc-product-code:57315-119
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-01-01
ended-marketing-on:2013-01-01
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA077858
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:53217-180
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-791
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-07-31
ended-marketing-on:2012-08-31
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077858
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Lake Erie Medical Dba Quality Care Produts Llc
ndc-id:
ndc-product-code:35356-661
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-15
ended-marketing-on:2013-10-21
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride and acetaminophen
labeller:Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc
ndc-id:
ndc-product-code:35356-660
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-04-21
ended-marketing-on:2014-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA076475
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Pd Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-895
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:2018-07-24
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:St. Mary's Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-053
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:2019-01-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:St. Mary's Medical Park Pharmacy
ndc-id:
ndc-product-code:60760-335
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-12-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-084
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:AvPAK
ndc-id:
ndc-product-code:50268-774
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-01-14
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0919
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-9968
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-14
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Nucare Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68071-3044
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3705
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-16
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-825
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-3406
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0619
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:68382-334
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:65841-758
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:65862-922
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA207152
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-1672
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-11-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-8088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-11-24
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077858
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-124
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Macleods Pharmaceuticals Limited
ndc-id:
ndc-product-code:33342-202
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-03
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA206885
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Sun Pharmaceutical Industries, Inc.
ndc-id:
ndc-product-code:57664-537
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-16
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride and acetaminophen
labeller:Par Pharmaceutical, Inc.
ndc-id:
ndc-product-code:49884-946
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-04-21
ended-marketing-on:2022-01-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA076475
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Micro Labs Limited
ndc-id:
ndc-product-code:42571-119
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-12-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA201952
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Amneal Pharmaceuticals of New York Llc
ndc-id:
ndc-product-code:53746-617
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:65162-617
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:medsource pharmaceuticals
ndc-id:
ndc-product-code:45865-469
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:AvKARE
ndc-id:
ndc-product-code:42291-832
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-27
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0111
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-0151
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-16
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Direct Rx
ndc-id:
ndc-product-code:61919-230
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-01
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Proficient Rx LP
ndc-id:
ndc-product-code:63187-585
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-10-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride and acetaminophen
labeller:Apotex Corp.
ndc-id:
ndc-product-code:60505-2644
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-30
ended-marketing-on:2021-03-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078778
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride and acetaminophen
labeller:Golden State Medical Supply
ndc-id:
ndc-product-code:60429-500
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-04-07
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078778
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7652
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-28
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077858
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-599
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:2018-11-16
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride and acetaminophen
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-782
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-30
ended-marketing-on:2018-11-16
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078778
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol hydrochloride and acetaminophen
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2730
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-30
ended-marketing-on:2018-06-30
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA078778
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-837
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-16
ended-marketing-on:2018-11-16
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0920
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:2015-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3248
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-22
ended-marketing-on:2019-02-28
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA207152
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-8088
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-02-10
ended-marketing-on:2017-05-24
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077858
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:49999-693
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-09
ended-marketing-on:2017-04-10
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Unit Dose Services
ndc-id:
ndc-product-code:50436-6291
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-12-17
ended-marketing-on:2017-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:ANDA090485
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-363
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-09
ended-marketing-on:2018-06-12
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA090460
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-9267
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-12-23
ended-marketing-on:2019-04-09
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077858
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-9261
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-11-11
ended-marketing-on:2019-04-09
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA077184
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Preferred Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68788-7712
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA201952
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2784
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-12
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA201952
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:Asclemed Usa, Inc.
ndc-id:
ndc-product-code:76420-105
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-12-15
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA201952
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride and Acetaminophen
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:71335-1742
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-03-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:
route:Oral
fda-application-number:ANDA207152
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride ER
labeller:H.J. Harkins Company, Inc.
ndc-id:
ndc-product-code:76519-1142
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-15
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride ER
labeller:Directrx
ndc-id:
ndc-product-code:61919-892
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-01
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA201384
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended Release
labeller:Galephar Pharmaceutical Research Inc.
ndc-id:
ndc-product-code:66277-252
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:100 mg/1
route:Not applicable
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended Release
labeller:Galephar Pharmaceutical Research Inc.
ndc-id:
ndc-product-code:66277-322
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:150 mg/1
route:Not applicable
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended Release
labeller:Galephar Pharmaceutical Research Inc.
ndc-id:
ndc-product-code:66277-253
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:200 mg/1
route:Not applicable
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended Release
labeller:Galephar Pharmaceutical Research Inc.
ndc-id:
ndc-product-code:66277-254
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-08-31
ended-marketing-on:
dosage-form:Capsule, extended release
strength:300 mg/1
route:Not applicable
fda-application-number:NDA022370
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended-Release
labeller:Trigen Laboratories, LLC
ndc-id:
ndc-product-code:13811-689
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-06-22
ended-marketing-on:
dosage-form:Capsule
strength:100 mg/1
route:Oral
fda-application-number:NDA022370
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended-Release
labeller:Trigen Laboratories, LLC
ndc-id:
ndc-product-code:13811-690
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-06-22
ended-marketing-on:
dosage-form:Capsule
strength:200 mg/1
route:Oral
fda-application-number:NDA022370
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended-Release
labeller:Trigen Laboratories, LLC
ndc-id:
ndc-product-code:13811-691
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-06-22
ended-marketing-on:
dosage-form:Capsule
strength:300 mg/1
route:Oral
fda-application-number:NDA022370
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended-Release
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-583
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-27
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended-Release
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-584
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-27
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:200 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol Hydrochloride Extended-Release
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-585
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-27
ended-marketing-on:
dosage-form:Tablet, film coated, extended release
strength:300 mg/1
route:Oral
fda-application-number:ANDA200491
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tramadol-acet
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:02417502
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-03
ended-marketing-on:2019-09-11
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tramadol/acet
labeller:Sanis Health Inc
ndc-id:
ndc-product-code:
dpd-id:02426803
ema-product-code:
ema-ma-number:
started-marketing-on:2014-07-25
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tramapap
labeller:Living Well Pharmacy, Inc.
ndc-id:
ndc-product-code:64038-059
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-04-07
ended-marketing-on:
dosage-form:Kit
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Tramaphen-odan
labeller:Odan Laboratories Ltd
ndc-id:
ndc-product-code:
dpd-id:02388294
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-05
ended-marketing-on:2014-10-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tridural
labeller:Paladin Labs Inc
ndc-id:
ndc-product-code:
dpd-id:02296381
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-14
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tridural
labeller:Paladin Labs Inc
ndc-id:
ndc-product-code:
dpd-id:02296403
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-14
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tridural
labeller:Paladin Labs Inc
ndc-id:
ndc-product-code:
dpd-id:02296411
ema-product-code:
ema-ma-number:
started-marketing-on:2007-08-14
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ultracet
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-143
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-15
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultracet
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-4703
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-10-30
ended-marketing-on:
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultracet
labeller:McNeil Pharmaceuticals
ndc-id:
ndc-product-code:0045-0650
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-30
ended-marketing-on:2011-10-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultracet
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-5308
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultracet
labeller:Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc
ndc-id:
ndc-product-code:49999-118
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-20
ended-marketing-on:2014-12-31
dosage-form:Tablet
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultracet
labeller:Janssen Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:50458-650
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultracet
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-617
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-15
ended-marketing-on:2018-11-16
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultracet
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0748
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-08-15
ended-marketing-on:2017-01-31
dosage-form:Tablet, coated
strength:
route:Oral
fda-application-number:NDA021123
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Ortho-McNeil-Janssen Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:0045-0659
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-03-03
ended-marketing-on:2012-03-31
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:NDA020281
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Ortho McNeil Pharmaceuticals
ndc-id:
ndc-product-code:0062-0660
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-05-05
ended-marketing-on:2006-05-01
dosage-form:Tablet, orally disintegrating
strength:50 mg/1
route:Oral
fda-application-number:NDA021693
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-3605
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-02-10
ended-marketing-on:2012-06-30
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:NDA020281
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Northwind Pharmaceuticals
ndc-id:
ndc-product-code:51655-185
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-13
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/201
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:A S Medication Solutions
ndc-id:
ndc-product-code:54569-4089
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-03-03
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:NDA020281
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0531
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-03-03
ended-marketing-on:2017-02-28
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:NDA020281
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Janssen Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:50458-659
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-03-03
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:NDA020281
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-650
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-03-03
ended-marketing-on:2018-11-16
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:NDA020281
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:49999-022
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-20
ended-marketing-on:2018-09-26
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:NDA020281
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Advanced Rx Pharmacy of Tennessee, LLC
ndc-id:
ndc-product-code:80425-0057
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-15
ended-marketing-on:
dosage-form:Tablet, coated
strength:50 mg/1
route:Oral
fda-application-number:ANDA076003
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Advanced Rx Pharmacy of Tennessee, LLC
ndc-id:
ndc-product-code:80425-0058
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-06-22
ended-marketing-on:
dosage-form:Tablet
strength:50 mg/1
route:Oral
fda-application-number:ANDA075964
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Advanced Rx Pharmacy of Tennessee, LLC
ndc-id:
ndc-product-code:80425-0108
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-08-19
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:ANDA200503
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram
labeller:Janssen Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02349469
ema-product-code:
ema-ma-number:
started-marketing-on:2010-06-28
ended-marketing-on:2020-09-25
dosage-form:Tablet
strength:50 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ultram ER
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-292
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-09-08
ended-marketing-on:
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-563
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-09-08
ended-marketing-on:
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-913
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-09-08
ended-marketing-on:
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5584
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-02
ended-marketing-on:2012-06-30
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5790
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-02
ended-marketing-on:2012-06-30
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-5791
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-05-02
ended-marketing-on:2012-06-30
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Ortho-McNeil-Janssen Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0062-0653
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-10-01
ended-marketing-on:2011-05-31
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Ortho-McNeil-Janssen Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0062-0655
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-10-01
ended-marketing-on:2011-10-31
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Ortho-McNeil-Janssen Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0062-0657
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-10-01
ended-marketing-on:2011-11-30
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-845
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-10-25
ended-marketing-on:2016-10-25
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc
ndc-id:
ndc-product-code:35356-056
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-27
ended-marketing-on:2016-12-31
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc
ndc-id:
ndc-product-code:35356-055
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-27
ended-marketing-on:2014-06-01
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc
ndc-id:
ndc-product-code:49999-896
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-03-20
ended-marketing-on:2016-06-01
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Janssen Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:50458-657
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-10-01
ended-marketing-on:2018-05-30
dosage-form:Tablet, extended release
strength:300 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Janssen Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:50458-655
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-10-01
ended-marketing-on:2018-05-30
dosage-form:Tablet, extended release
strength:200 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Ultram ER
labeller:Janssen Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:50458-653
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-10-01
ended-marketing-on:2018-05-30
dosage-form:Tablet, extended release
strength:100 mg/1
route:Oral
fda-application-number:NDA021692
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Zytram XL
labeller:Purdue Pharma
ndc-id:
ndc-product-code:
dpd-id:02286424
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-07
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Zytram XL
labeller:Purdue Pharma
ndc-id:
ndc-product-code:
dpd-id:02286432
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-07
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Zytram XL
labeller:Purdue Pharma
ndc-id:
ndc-product-code:
dpd-id:02286440
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-07
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Zytram XL
labeller:Purdue Pharma
ndc-id:
ndc-product-code:
dpd-id:02286459
ema-product-code:
ema-ma-number:
started-marketing-on:2006-12-07
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Zytram XL
labeller:Purdue Pharma
ndc-id:
ndc-product-code:
dpd-id:02360322
ema-product-code:
ema-ma-number:
started-marketing-on:2011-03-02
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Zytram XL
labeller:Purdue Pharma
ndc-id:
ndc-product-code:
dpd-id:02360349
ema-product-code:
ema-ma-number:
started-marketing-on:2011-03-02
ended-marketing-on:
dosage-form:Tablet, extended release
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
混合物
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol HCl
ingredients:Tramadol
name:Synapryn
ingredients:Tramadol
name:Tramapap
ingredients:Acetaminophen + Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol ER
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Theratramadol-90
ingredients:gamma-Aminobutyric acid + Tramadol
name:Theratramadol-60
ingredients:gamma-Aminobutyric acid + Tramadol
name:Ryzolt
ingredients:Tramadol
name:Ryzolt
ingredients:Tramadol
name:Ryzolt
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Ultram
ingredients:Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ryzolt
ingredients:Tramadol
name:Ryzolt
ingredients:Tramadol
name:Ryzolt
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Rybix ODT
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ryzolt
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Rybix ODT
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ryzolt
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol HCl and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrchloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:ConZip
ingredients:Tramadol
name:ConZip
ingredients:Tramadol
name:ConZip
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol HCl
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Synapryn
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride and acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride ER
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride Extended-Release
ingredients:Tramadol
name:Tramadol Hydrochloride Extended-Release
ingredients:Tramadol
name:Tramadol Hydrochloride Extended-Release
ingredients:Tramadol
name:ConZip
ingredients:Tramadol
name:ConZip
ingredients:Tramadol
name:ConZip
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride and acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride Extended-Release
ingredients:Tramadol
name:Tramadol Hydrochloride Extended-Release
ingredients:Tramadol
name:Tramadol Hydrochloride Extended-Release
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol HCl ER
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride Extended Release
ingredients:Tramadol
name:Tramadol Hydrochloride Extended Release
ingredients:Tramadol
name:Tramadol Hydrochloride Extended Release
ingredients:Tramadol
name:Tramadol Hydrochloride Extended Release
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride ER
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride and acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride and acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Ultram ER
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol hydrochloride and acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol hydrochloride and acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Topical Pain
ingredients:Diazepam + Hydrocodone + Ibuprofen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultracet
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol HCl and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Qdolo
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Conzip
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Tramadol Hydrochloride
ingredients:Tramadol
name:Tramadol Hydrochloride and Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Zytram XL
ingredients:Tramadol
name:Zytram XL
ingredients:Tramadol
name:Zytram XL
ingredients:Tramadol
name:Zytram XL
ingredients:Tramadol
name:Tridural
ingredients:Tramadol
name:Tridural
ingredients:Tramadol
name:Tridural
ingredients:Tramadol
name:Ralivia
ingredients:Tramadol
name:Ralivia
ingredients:Tramadol
name:Ralivia
ingredients:Tramadol
name:Ultram
ingredients:Tramadol
name:Zytram XL
ingredients:Tramadol
name:Zytram XL
ingredients:Tramadol
name:Durela
ingredients:Tramadol
name:Durela
ingredients:Tramadol
name:Tramacet
ingredients:Acetaminophen + Tramadol
name:Apo-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Teva-tramadol/acetaminophen
ingredients:Acetaminophen + Tramadol
name:Taro-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Jamp-acet-tramadol
ingredients:Acetaminophen + Tramadol
name:PMS-tramadol-acet
ingredients:Acetaminophen + Tramadol
name:Tramadol-acet
ingredients:Acetaminophen + Tramadol
name:Tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Tramadol / Acetaminophen
ingredients:Acetaminophen + Tramadol
name:Auro-tramadol/acetaminophen
ingredients:Acetaminophen + Tramadol
name:Tramaphen-odan
ingredients:Acetaminophen + Tramadol
name:Pat-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Riva-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Ipg-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Lupin-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Mylan-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Act Tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Mar-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Mint-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Nra-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Apo-tramadol
ingredients:Tramadol
name:Durela
ingredients:Tramadol
name:Priva-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Taro-tramadol ER
ingredients:Tramadol
name:Taro-tramadol ER
ingredients:Tramadol
name:Taro-tramadol ER
ingredients:Tramadol
name:Bio-tramadol/acet
ingredients:Acetaminophen + Tramadol
name:Ag-acet-tramadol
ingredients:Acetaminophen + Tramadol
name:Auro-tramadol
ingredients:Tramadol
name:Mar-tramadol
ingredients:Tramadol
name:Sandoz Tramadol
ingredients:Tramadol
name:Jamp Tramadol
ingredients:Tramadol
包装者
name:4uOrtho LLC
url:http://www.4udr.com
name:Able Laboratories Inc.
url:http://www.ablelabs.com
name:Advanced Pharmaceutical Services Inc.
url:
name:Alphapharm Party Ltd.
url:http://www.alphapharm.com.au
name:Altura Pharmaceuticals Inc.
url:http://www.alturapharma.com
name:Amerisource Health Services Corp.
url:http://www.amerisourcebergen.com
name:Amneal Pharmaceuticals
url:http://www.amneal.com
name:Apotex Inc.
url:http://www.apotex.com
name:Apotheca Inc.
url:
name:A-S Medication Solutions LLC
url:http://orders.a-smeds.com
name:Atlantic Biologicals Corporation
url:http://www.atlanticbiologicals.com
name:BC Vision Inc.
url:
name:Biovail Pharmaceuticals
url:http://www.biovail.com
name:Blenheim Pharmacal
url:http://www.bpipack.com
name:Bryant Ranch Prepack
url:http://bryantranchprepack.com
name:Caraco Pharmaceutical Labs
url:http://www.caraco.com
name:Cardinal Health
url:http://www.cardinal.com
name:Concern Stirol
url:http://www.stirol.net
name:Confab Laboratories Inc.
url:http://www.confab.ca
name:Corepharma LLC
url:http://www.corepharma.com
name:Coupler Enterprises Inc.
url:
name:D.M. Graham Laboratories Inc.
url:
name:Deca Pharmaceuticals LLC
url:http://www.decapharma.com
name:DHHS Program Support Center Supply Service Center
url:
name:Direct Dispensing Inc.
url:
name:DispenseXpress Inc.
url:
name:Dispensing Solutions
url:http://www.drxdispensing.com
name:Diversified Healthcare Services Inc.
url:http://www.dhscorp.com
name:Eon Labs
url:
name:Fusion Pharmaceuticals LLC
url:
name:H.J. Harkins Co. Inc.
url:http://hjharkinscompanyinc.com
name:Heartland Repack Services LLC
url:
name:Innoviant Pharmacy Inc.
url:http://www.innoviantpharmacy.com
name:Ivax Pharmaceuticals
url:
name:Janssen-Ortho Inc.
url:http://www.janssen-ortho.com
name:Kali Laboratories Inc.
url:
name:Keltman Pharmaceuticals Inc.
url:http://www.keltman.com
name:Labopharm Inc.
url:http://www.labopharm.com
name:Lake Erie Medical and Surgical Supply
url:
name:Liberty Pharmaceuticals
url:
name:Major Pharmaceuticals
url:http://www.majorpharmaceuticals.com
name:Mallinckrodt Inc.
url:http://www.mallinckrodt.com
name:McNeil Laboratories
url:
name:Medisca Inc.
url:http://www.medisca.com
name:Medvantx Inc.
url:http://www.medvantx.com
name:Murfreesboro Pharmaceutical Nursing Supply
url:http://www.unitdosesupply.com
name:Mutual Pharmaceutical Co.
url:
name:Mylan
url:http://www.mylan.com
name:Novopharm Ltd.
url:
name:Nucare Pharmaceuticals Inc.
url:http://www.nucarerx.com
name:Ortho Mcneil Janssen Pharmaceutical Inc.
url:http://www.ortho-mcneil.com
name:Ortho-McNeil-Janssen Pharmaceuticals Inc.
url:http://www.ortho-mcneil.com
name:Palmetto Pharmaceuticals Inc.
url:http://www.palmettopharm.com
name:Par Pharmaceuticals
url:http://www.parpharm.com
name:Patriot Pharmaceuticals
url:http://www.patriotpharmaceuticals.com
name:PD-Rx Pharmaceuticals Inc.
url:http://www.pdrx.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Piramal Healthcare
url:http://www.piramalpharmasolutions.com
name:Pliva Inc.
url:http://www.pliva.com
name:Preferred Pharmaceuticals Inc.
url:http://www.preferredpharmaceuticals.com
name:Prepackage Specialists
url:
name:Prepak Systems Inc.
url:http://www.prepaksys.com
name:Prescription Dispensing Service Inc.
url:
name:Purdue Pharma LP
url:http://www.purduepharma.com
name:Rebel Distributors Corp.
url:http://www.rebelrx.com
name:Redpharm Drug
url:
name:Remedy Repack
url:http://www.remedyrepack.com
name:Resource Optimization and Innovation LLC
url:
name:Ropack Inc.
url:http://www.ropack.com
name:Sandhills Packaging Inc.
url:http://www.sandhillspackaging.com
name:Southwood Pharmaceuticals
url:http://www.southwoodhealthcare.com
name:St Mary's Medical Park Pharmacy
url:
name:Stat Rx Usa
url:http://statrxusa.exporterus.com
name:Teva Pharmaceutical Industries Ltd.
url:http://www.tevapharm.com
name:Torpharm Inc.
url:
name:Trinity Laboratories Inc.
url:http://www.trinitylab.us
name:UDL Laboratories
url:http://www.udllabs.com
name:United Research Laboratories Inc.
url:http://www.urlpharma.com
name:Va Cmop Dallas
url:
name:Vangard Labs Inc.
url:
name:Watson Pharmaceuticals
url:http://www.watson.com
生产者
generic:是; url:; name;Cipher pharmaceuticals inc
generic:否; url:; name;Purdue pharma products lp
generic:是; url:; name;Par pharmaceutical
generic:否; url:; name;Biovail laboratories international srl
generic:是; url:; name;Victory pharma inc
generic:是; url:; name;Actavis elizabeth llc
generic:是; url:; name;Alphapharm party ltd
generic:是; url:; name;Amneal pharmaceuticals llc
generic:是; url:; name;Apotex inc
generic:是; url:; name;Asta medica inc
generic:是; url:; name;Caraco pharmaceutical laboratories ltd
generic:是; url:; name;Ivax pharmaceuticals inc sub teva pharmaceuticals usa
generic:是; url:; name;Mallinckrodt inc
generic:是; url:; name;Mutual pharmaceutical co inc
generic:是; url:; name;Mylan pharmaceuticals inc
generic:是; url:; name;Northstar healthcare holdings ltd
generic:是; url:; name;Pliva inc
generic:是; url:; name;Sandoz inc
generic:是; url:; name;Teva pharmaceuticals usa inc
generic:是; url:; name;Watson laboratories
generic:否; url:; name;Ortho mcneil janssen pharmaceuticals inc
价格
Tramadol-Acetaminophen 37.5-325 mg tablet
1.07(单位:USD)
tablet
Ultram 50 mg tablet
1.99(单位:USD)
tablet
TraMADol HCl 100 mg 24 Hour tablet
3.78(单位:USD)
tablet
Ultram er 100 mg tablet
4.44(单位:USD)
tablet
Ultram ER 100 mg 24 Hour tablet
4.62(单位:USD)
tablet
TraMADol HCl 200 mg 24 Hour tablet
6.25(单位:USD)
tablet
Ultram er 200 mg tablet
7.35(单位:USD)
tablet
Ultram ER 200 mg 24 Hour tablet
7.64(单位:USD)
tablet
Ultram er 300 mg tablet
10.25(单位:USD)
tablet
Ultram ER 300 mg 24 Hour tablet
10.66(单位:USD)
tablet
Tramadol hcl powder
29.08(单位:USD)
g
Tramadol hcl 50 mg tablet
0.7(单位:USD)
tablet
受影响的生物体
Humans and other mammals
剂量
form:Tablet, orally disintegrating
route:Oral
strength:50 mg
form:Tablet, film coated
route:Oral
strength:150 mg
form:Tablet, film coated
route:Oral
strength:300 mg
form:Capsule, coated
route:Oral
strength:100 mg
form:Tablet, coated
route:Oral
strength:150 mg
form:Tablet, extended release
route:Oral
strength:
form:Injection, solution
route:
strength:100 mg/2mL
form:Tablet
route:Oral
strength:
form:Tablet
route:Oral
strength:37.5 mg
form:Injection
route:
strength:50 MG/ML
form:Capsule, coated
route:Oral
strength:25 mg
form:Solution
route:Oral
strength:25 mg
form:Tablet
route:Sublingual
strength:25 mg
form:Solution
route:Intramuscular; Intravenous
strength:25 mg
form:Tablet, soluble
route:
strength:50 MG
form:Injection
route:Parenteral
strength:100 mg/2ml
form:Solution / drops
route:Oral
strength:100 mg/ml
form:Tablet, effervescent
route:Oral
strength:50 mg
form:Capsule, extended release
route:Oral
strength:100 mg/1
form:Capsule, extended release
route:Oral
strength:200 mg/1
form:Capsule, extended release
route:Oral
strength:300 mg/1
form:Tablet
route:Oral
strength:25 mg
form:Tablet
route:Oral
strength:75 mg
form:Tablet, orally disintegrating
route:Oral
strength:325 mg
form:Tablet, effervescent
route:Oral
strength:325 mg
form:Tablet, multilayer
route:Oral
strength:75 mg
form:Solution
route:Intramuscular; Intravenous; Parenteral; Subcutaneous
strength:100 mg
form:Injection, solution
route:Intramuscular; Intravenous
strength:100 mg
form:Injection, solution
route:Intramuscular; Intravenous
strength:50 mg
form:Solution / drops
route:Oral
strength:10 %
form:Tablet
route:Oral
strength:100 MG
form:Solution
route:Intravenous
strength:10 mg
form:Capsule, coated
route:Oral
strength:10 mg
form:Tablet, coated
route:Oral
strength:37.5 MG
form:Tablet, effervescent
route:Oral
strength:37.5 MG
form:Tablet, film coated
route:Oral
strength:100 mg
form:Tablet, film coated
route:Oral
strength:200 mg
form:Tablet, film coated
route:Oral
strength:25 MG
form:Capsule, liquid filled
route:Oral
strength:325 mg
form:Injection, solution
route:Intramuscular; Intravenous
strength:50 MG/ML
form:Solution
route:Oral
strength:5 mg/1mL
form:Injection
route:Intramuscular; Intravenous
strength:100 mg/2ml
form:Tablet, delayed release
route:Oral
strength:200 mg/1
form:Tablet, coated
route:Oral
strength:25 mg
form:Tablet, film coated
route:Oral
strength:75 mg
form:Granule, for solution
route:Oral
strength:25 mg
form:Kit
route:Oral
strength:5 g/5g
form:Kit
route:Oral
strength:5.8 g/5.8g
form:Capsule, extended release
route:Oral
strength:100 MG
form:Capsule, extended release
route:Oral
strength:150 MG
form:Capsule, extended release
route:Oral
strength:200 MG
form:Cream
route:Topical
strength:
form:Tablet
route:Oral
strength:325 mg
form:Tablet
route:Oral
strength:500 mg
form:Injection, solution
route:Intramuscular; Intravenous; Subcutaneous
strength:50 mg/ml
form:Tablet, film coated
route:Oral
strength:50 mg
form:Injection, solution
route:Intramuscular; Intravenous; Subcutaneous
strength:100 mg/2ml
form:Capsule
route:Oral
strength:100 MG
form:Capsule
route:Oral
strength:150 MG
form:Capsule
route:Oral
strength:200 MG
form:Injection
route:Parenteral
strength:50 MG/ML
form:Capsule, extended release
route:Oral
strength:
form:Injection, solution
route:Parenteral
strength:
form:Solution
route:Oral
strength:
form:Capsule
route:Oral
strength:
form:Injection, solution
route:Parenteral
strength:100 MG
form:Solution
route:Intramuscular; Intravenous
strength:50 mg
form:Injection, solution
route:Parenteral
strength:50 MG
form:Solution
route:Oral
strength:100 MG/ML
form:Tablet, extended release
route:Oral
strength:100 MG
form:Tablet, extended release
route:Oral
strength:150 MG
form:Tablet, extended release
route:Oral
strength:200 MG
form:Solution
route:Intramuscular
strength:100 mg
form:Solution
route:Intramuscular; Intravenous; Subcutaneous
strength:100 mg
form:Solution
route:Oral
strength:113.9 mg
form:Capsule, liquid filled
route:Oral
strength:50 mg
form:Solution
route:Intramuscular; Intravenous
strength:100 mg
form:Injection
route:Intramuscular; Intravenous; Subcutaneous
strength:100 mg
form:Tablet, effervescent
route:Oral
strength:
form:Tablet
route:Oral
strength:50 mg/1
form:Capsule
route:Oral
strength:150 mg/1
form:Capsule, coated, extended release
route:Oral
strength:150 mg/1
form:Capsule, extended release
route:Oral
strength:150 mg/1
form:Tablet
route:Oral
strength:50 mg/50mg
form:Tablet, coated
route:Oral
strength:100 mg/1
form:Tablet, coated
route:Oral
strength:200 mg/1
form:Tablet, film coated
route:Oral
strength:50 mg/1
form:Tablet, film coated, extended release
route:Oral
strength:100 mg/1
form:Tablet, film coated, extended release
route:Oral
strength:200 mg/1
form:Tablet, film coated, extended release
route:Oral
strength:300 mg/1
form:Tablet, film coated
route:Oral
strength:
form:Capsule, extended release
route:Not applicable
strength:100 mg/1
form:Capsule, extended release
route:Not applicable
strength:150 mg/1
form:Capsule, extended release
route:Not applicable
strength:200 mg/1
form:Capsule, extended release
route:Not applicable
strength:300 mg/1
form:Capsule
route:Oral
strength:100 mg/1
form:Capsule
route:Oral
strength:200 mg/1
form:Capsule
route:Oral
strength:300 mg/1
form:Solution
route:Intramuscular; Intravenous; Subcutaneous
strength:50 mg
form:Solution
route:Oral
strength:100 MG
form:Tablet, extended release
route:Oral
strength:50 MG
form:Injection
route:Parenteral
strength:100 MG
form:Injection
route:Parenteral
strength:50 MG
form:Capsule, extended release
route:Oral
strength:50 MG
form:Capsule
route:Oral
strength:50 MG
form:Injection, solution
route:Parenteral
strength:50 MG/ML
form:Injection, solution
route:Parenteral
strength:100 MG/2ML
form:Tablet, effervescent
route:Oral
strength:100 MG
form:Suppository
route:
strength:100 MG
form:Tablet
route:Oral
strength:50 MG
form:Solution / drops
route:Oral
strength:100 mg/1mL
form:Tablet, film coated
route:Oral
strength:650 mg
form:Solution
route:Parenteral
strength:50 mg
form:Capsule, coated
route:Oral
strength:50 mg
form:Injection, solution
route:
strength:50 MG/ML
form:Tablet, extended release
route:Oral
strength:300 MG
form:Tablet
route:Oral
strength:150 mg
form:Tablet
route:Oral
strength:200 mg
form:Injection, solution
route:
strength:50 mg/1mL
form:Tablet, film coated, extended release
route:Oral
strength:100 mg
form:Tablet, film coated, extended release
route:Oral
strength:150 mg
form:Tablet, film coated, extended release
route:Oral
strength:200 mg
form:Kit
route:Oral
strength:
form:Solution
route:Intramuscular; Intravenous; Subcutaneous
strength:100 mg/2ml
form:Capsule, gelatin coated
route:Oral
strength:50 mg
form:Tablet, film coated
route:Oral
strength:
form:Tablet
route:Oral
strength:91.67 mg
form:Tablet, extended release
route:Oral
strength:400 MG
form:Capsule
route:Oral
strength:5 mg
form:Tablet
route:Oral
strength:
form:Tablet, coated
route:Oral
strength:
form:Tablet, coated
route:Oral
strength:325 mg
form:Tablet, film coated
route:Oral
strength:325 mg
form:Tablet, coated
route:Oral
strength:50 mg/201
form:Tablet, coated
route:Oral
strength:50 mg/1
form:Tablet, orally disintegrating
route:Oral
strength:50 mg/1
form:Tablet
route:Oral
strength:100 mg/1
form:Tablet, extended release
route:Oral
strength:100 mg/1
form:Tablet, extended release
route:Oral
strength:200 mg/1
form:Tablet, extended release
route:Oral
strength:300 mg/1
form:Solution
route:Parenteral
strength:100 mg
form:Tablet, film coated
route:Oral
strength:37.5 mg
atc代码
Opioids in combination with non-opioid analgesics
OPIOIDS
ANALGESICS
NERVOUS SYSTEM
Opioids in combination with non-opioid analgesics
OPIOIDS
ANALGESICS
NERVOUS SYSTEM
Other opioids
OPIOIDS
ANALGESICS
NERVOUS SYSTEM
fda标签
//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00193.pdf?1265922808
化学品安全技术说明书
//s3-us-west-2.amazonaws.com/drugbank/msds/DB00193.pdf?1265922745
专利
number:5464632
country:United States
approved:1995-11-07
expires:2013-03-22
pediatric-extension:否
number:2476201
country:Canada
approved:2009-09-01
expires:2023-02-21
pediatric-extension:否
number:2123160
country:Canada
approved:2003-04-29
expires:2014-05-09
pediatric-extension:否
number:6339105
country:United States
approved:2002-01-15
expires:2020-04-12
pediatric-extension:是
number:6106861
country:United States
approved:2000-08-22
expires:2017-12-05
pediatric-extension:否
number:6607748
country:United States
approved:2003-08-19
expires:2020-06-29
pediatric-extension:否
number:7988998
country:United States
approved:2011-08-02
expires:2023-10-27
pediatric-extension:否
number:7858118
country:United States
approved:2010-12-28
expires:2022-04-11
pediatric-extension:否
食物相互作用
Avoid alcohol. Co-administration of alcohol may potentiate the CNS effects of tramadol.Take with or without food. Co-administration of food does not affect pharmacokinetics.
药物相互作用
DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
DB00557
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
DB00653
The therapeutic efficacy of Tramadol can be increased when used in combination with Magnesium sulfate.
DB00765
Tramadol may increase the sedative activities of Metyrosine.
DB01017
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
DB00413
Tramadol may increase the sedative activities of Pramipexole.
DB09034
Tramadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
DB01041
Tramadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DB00425
Tramadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DB06274
The risk or severity of adverse effects can be increased when Tramadol is combined with Alvimopan.
DB00564
The therapeutic efficacy of Carbamazepine can be decreased when used in combination with Tramadol.
DB00924
The risk or severity of serotonin syndrome and seizure can be increased when Cyclobenzaprine is combined with Tramadol.
DB00035
The risk or severity of hyponatremia can be increased when Tramadol is combined with Desmopressin.
DB08897
The risk or severity of adverse effects can be increased when Tramadol is combined with Aclidinium.
DB08893
The risk or severity of urinary retention can be increased when Tramadol is combined with Mirabegron.
DB00761
The risk or severity of gastrointestinal ulceration can be increased when Tramadol is combined with Potassium chloride.
DB01278
The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Tramadol.
DB09527
The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Tramadol.
DB01409
The risk or severity of adverse effects can be increased when Tramadol is combined with Tiotropium.
DB00273
The risk or severity of hyperthermia and oligohydrosis can be increased when Tramadol is combined with Topiramate.
DB09076
The risk or severity of adverse effects can be increased when Tramadol is combined with Umeclidinium.
DB00333
The risk or severity of adverse effects can be increased when Methadone is combined with Tramadol.
DB00986
The risk or severity of adverse effects can be increased when Tramadol is combined with Glycopyrronium.
DB01043
The risk or severity of adverse effects can be increased when Tramadol is combined with Memantine.
DB00601
The risk or severity of serotonin syndrome and seizure can be increased when Linezolid is combined with Tramadol.
DB00182
The risk or severity of serotonin syndrome and seizure can be increased when Amphetamine is combined with Tramadol.
DB00614
The risk or severity of serotonin syndrome and seizure can be increased when Furazolidone is combined with Tramadol.
DB00752
The risk or severity of serotonin syndrome and seizure can be increased when Tranylcypromine is combined with Tramadol.
DB00780
The risk or severity of serotonin syndrome and seizure can be increased when Phenelzine is combined with Tramadol.
DB00805
The risk or severity of serotonin syndrome and seizure can be increased when Minaprine is combined with Tramadol.
DB01037
The risk or severity of serotonin syndrome and seizure can be increased when Selegiline is combined with Tramadol.
DB01168
The risk or severity of serotonin syndrome and seizure can be increased when Procarbazine is combined with Tramadol.
DB01171
The risk or severity of serotonin syndrome and seizure can be increased when Moclobemide is combined with Tramadol.
DB01247
The risk or severity of serotonin syndrome and seizure can be increased when Isocarboxazid is combined with Tramadol.
DB01367
The risk or severity of serotonin syndrome and seizure can be increased when Rasagiline is combined with Tramadol.
DB01626
The risk or severity of serotonin syndrome and seizure can be increased when Pargyline is combined with Tramadol.
DB04017
The risk or severity of serotonin syndrome and seizure can be increased when Clorgiline is combined with Tramadol.
DB04818
The risk or severity of serotonin syndrome and seizure can be increased when Iproniazid is combined with Tramadol.
DB04820
The risk or severity of serotonin syndrome and seizure can be increased when Nialamide is combined with Tramadol.
DB06654
The risk or severity of serotonin syndrome and seizure can be increased when Safinamide is combined with Tramadol.
DB08550
The risk or severity of serotonin syndrome and seizure can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tramadol.
DB09243
The risk or severity of serotonin syndrome and seizure can be increased when Hydracarbazine is combined with Tramadol.
DB09244
The risk or severity of serotonin syndrome and seizure can be increased when Pirlindole is combined with Tramadol.
DB09245
The risk or severity of serotonin syndrome and seizure can be increased when Toloxatone is combined with Tramadol.
DB09246
The risk or severity of serotonin syndrome and seizure can be increased when Benmoxin is combined with Tramadol.
DB09248
The risk or severity of serotonin syndrome and seizure can be increased when Mebanazine is combined with Tramadol.
DB09249
The risk or severity of serotonin syndrome and seizure can be increased when Octamoxin is combined with Tramadol.
DB09250
The risk or severity of serotonin syndrome and seizure can be increased when Pheniprazine is combined with Tramadol.
DB09251
The risk or severity of serotonin syndrome and seizure can be increased when Phenoxypropazine is combined with Tramadol.
DB09252
The risk or severity of serotonin syndrome and seizure can be increased when Pivhydrazine is combined with Tramadol.
DB09253
The risk or severity of serotonin syndrome and seizure can be increased when Safrazine is combined with Tramadol.
DB09254
The risk or severity of serotonin syndrome and seizure can be increased when Caroxazone is combined with Tramadol.
DB13875
The risk or severity of serotonin syndrome and seizure can be increased when Harmaline is combined with Tramadol.
DB13876
The risk or severity of serotonin syndrome and seizure can be increased when Brofaromine is combined with Tramadol.
DB09241
The risk or severity of serotonin syndrome and seizure can be increased when Tramadol is combined with Methylene blue.
DB00266
The risk or severity of adverse effects can be increased when Tramadol is combined with Dicoumarol.
DB00498
The risk or severity of adverse effects can be increased when Tramadol is combined with Phenindione.
DB04665
The risk or severity of adverse effects can be increased when Tramadol is combined with Coumarin.
DB13451
The risk or severity of adverse effects can be increased when Tramadol is combined with Tioclomarol.
DB00946
The risk or severity of adverse effects can be increased when Tramadol is combined with Phenprocoumon.
DB03410
The risk or severity of adverse effects can be increased when Tramadol is combined with 4-hydroxycoumarin.
DB08794
The risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl biscoumacetate.
DB13136
The risk or severity of adverse effects can be increased when Tramadol is combined with Fluindione.
DB13275
The risk or severity of adverse effects can be increased when Tramadol is combined with Clorindione.
DB13347
The risk or severity of adverse effects can be increased when Tramadol is combined with Diphenadione.
DB00304
The metabolism of Tramadol can be increased when combined with Desogestrel.
DB00495
The metabolism of Tramadol can be increased when combined with Zidovudine.
DB00977
The metabolism of Tramadol can be increased when combined with Ethinylestradiol.
DB01420
The metabolism of Tramadol can be increased when combined with Testosterone propionate.
DB09042
The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Tramadol.
DB00083
The risk or severity of adverse effects can be increased when Tramadol is combined with Botulinum toxin type A.
DB00040
Tramadol may increase the gastrointestinal motility reducing activities of Glucagon.
DB00370
Tramadol may increase the serotonergic activities of Mirtazapine.
DB09272
The risk or severity of constipation can be increased when Tramadol is combined with Eluxadoline.
DB00898
Tramadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
DB00972
Tramadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DB01566
Methylenedioxyethamphetamine may increase the analgesic activities of Tramadol.
DB01090
The risk or severity of adverse effects can be increased when Pentolinium is combined with Tramadol.
DB01116
The risk or severity of adverse effects can be increased when Trimethaphan is combined with Tramadol.
DB01161
The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tramadol.
DB01496
The risk or severity of adverse effects can be increased when Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione is combined with Tramadol.
DB01288
The risk or severity of adverse effects can be increased when Tramadol is combined with Fenoterol.
DB00392
The risk or severity of adverse effects can be increased when Profenamine is combined with Tramadol.
DB00219
The risk or severity of adverse effects can be increased when Tramadol is combined with Oxyphenonium.
DB00245
The risk or severity of adverse effects can be increased when Tramadol is combined with Benzatropine.
DB00280
The risk or severity of adverse effects can be increased when Tramadol is combined with Disopyramide.
DB00340
The risk or severity of adverse effects can be increased when Tramadol is combined with Metixene.
DB00354
The risk or severity of adverse effects can be increased when Tramadol is combined with Buclizine.
DB00376
The risk or severity of adverse effects can be increased when Tramadol is combined with Trihexyphenidyl.
DB00383
The risk or severity of adverse effects can be increased when Tramadol is combined with Oxyphencyclimine.
DB00387
The risk or severity of adverse effects can be increased when Tramadol is combined with Procyclidine.
DB00424
The risk or severity of adverse effects can be increased when Tramadol is combined with Hyoscyamine.
DB00462
The risk or severity of adverse effects can be increased when Tramadol is combined with Methscopolamine bromide.
DB00505
The risk or severity of adverse effects can be increased when Tramadol is combined with Tridihexethyl.
DB00517
The risk or severity of adverse effects can be increased when Tramadol is combined with Anisotropine methylbromide.
DB00572
The risk or severity of adverse effects can be increased when Tramadol is combined with Atropine.
DB00670
The risk or severity of adverse effects can be increased when Tramadol is combined with Pirenzepine.
DB00725
The risk or severity of adverse effects can be increased when Tramadol is combined with Homatropine methylbromide.
DB00767
The risk or severity of adverse effects can be increased when Tramadol is combined with Benzquinamide.
DB00782
The risk or severity of adverse effects can be increased when Tramadol is combined with Propantheline.
DB00804
The risk or severity of adverse effects can be increased when Tramadol is combined with Dicyclomine.
DB00940
The risk or severity of adverse effects can be increased when Tramadol is combined with Methantheline.
DB00942
The risk or severity of adverse effects can be increased when Tramadol is combined with Cycrimine.
DB01036
The risk or severity of adverse effects can be increased when Tramadol is combined with Tolterodine.
DB01148
The risk or severity of adverse effects can be increased when Tramadol is combined with Flavoxate.
DB01231
The risk or severity of adverse effects can be increased when Tramadol is combined with Diphenidol.
DB01591
The risk or severity of adverse effects can be increased when Tramadol is combined with Solifenacin.
DB01625
The risk or severity of adverse effects can be increased when Tramadol is combined with Isopropamide.
DB04843
The risk or severity of adverse effects can be increased when Tramadol is combined with Mepenzolate.
DB06702
The risk or severity of adverse effects can be increased when Tramadol is combined with Fesoterodine.
DB06787
The risk or severity of adverse effects can be increased when Tramadol is combined with Hexocyclium.
DB08801
The risk or severity of adverse effects can be increased when Tramadol is combined with Dimetindene.
DB08997
The risk or severity of adverse effects can be increased when Tramadol is combined with Dexetimide.
DB09089
The risk or severity of adverse effects can be increased when Tramadol is combined with Trimebutine.
DB09262
The risk or severity of adverse effects can be increased when Tramadol is combined with Imidafenacin.
DB09300
The risk or severity of adverse effects can be increased when Tramadol is combined with Butylscopolamine.
DB11235
The risk or severity of adverse effects can be increased when Tramadol is combined with Thonzylamine.
DB11315
The risk or severity of adverse effects can be increased when Tramadol is combined with Methscopolamine.
DB12086
The risk or severity of adverse effects can be increased when Tramadol is combined with Oxitropium.
DB12278
The risk or severity of adverse effects can be increased when Tramadol is combined with Propiverine.
DB12526
The risk or severity of adverse effects can be increased when Tramadol is combined with Batefenterol.
DB12554
The risk or severity of adverse effects can be increased when Tramadol is combined with Mebeverine.
DB13252
The risk or severity of adverse effects can be increased when Tramadol is combined with Tropatepine.
DB13254
The risk or severity of adverse effects can be increased when Tramadol is combined with Prifinium.
DB13351
The risk or severity of adverse effects can be increased when Tramadol is combined with Piperidolate.
DB13369
The risk or severity of adverse effects can be increased when Tramadol is combined with Benzilone.
DB13380
The risk or severity of adverse effects can be increased when Tramadol is combined with Difemerine.
DB13413
The risk or severity of adverse effects can be increased when Tramadol is combined with Phenglutarimide.
DB13448
The risk or severity of adverse effects can be increased when Tramadol is combined with Mazaticol.
DB13468
The risk or severity of adverse effects can be increased when Tramadol is combined with Etybenzatropine.
DB13500
The risk or severity of adverse effects can be increased when Tramadol is combined with Otilonium.
DB13507
The risk or severity of adverse effects can be increased when Tramadol is combined with Poldine.
DB13542
The risk or severity of adverse effects can be increased when Tramadol is combined with Bevonium.
DB13581
The risk or severity of adverse effects can be increased when Tramadol is combined with Rociverine.
DB13619
The risk or severity of adverse effects can be increased when Tramadol is combined with Bornaprine.
DB13636
The risk or severity of adverse effects can be increased when Tramadol is combined with Etanautine.
DB13666
The risk or severity of adverse effects can be increased when Tramadol is combined with Tiemonium iodide.
DB13678
The risk or severity of adverse effects can be increased when Tramadol is combined with Dihexyverine.
DB13695
The risk or severity of adverse effects can be increased when Tramadol is combined with Penthienate.
DB13720
The risk or severity of adverse effects can be increased when Tramadol is combined with Diphemanil.
DB13738
The risk or severity of adverse effects can be increased when Tramadol is combined with Camylofin.
DB13759
The risk or severity of adverse effects can be increased when Tramadol is combined with Fenpiverinium.
DB13769
The risk or severity of adverse effects can be increased when Tramadol is combined with Emetonium iodide.
DB13844
The risk or severity of adverse effects can be increased when Tramadol is combined with Pipenzolate.
DB13850
The risk or severity of adverse effects can be increased when Tramadol is combined with Timepidium.
DB11855
The risk or severity of adverse effects can be increased when Tramadol is combined with Revefenacin.
DB00657
The risk or severity of adverse effects can be increased when Tramadol is combined with Mecamylamine.
DB15465
The risk or severity of adverse effects can be increased when Tramadol is combined with Benzhydrocodone.
DB08838
The risk or severity of adverse effects can be increased when Agmatine is combined with Tramadol.
DB09007
The risk or severity of adverse effects can be increased when Tramadol is combined with Chlorphenoxamine.
DB00809
The risk or severity of adverse effects can be increased when Tramadol is combined with Tropicamide.
DB00979
The risk or severity of adverse effects can be increased when Tramadol is combined with Cyclopentolate.
DB11181
The risk or severity of adverse effects can be increased when Tramadol is combined with Homatropine.
DB09271
The risk or severity of adverse effects can be increased when Tramadol is combined with Cimetropium.
DB00332
The risk or severity of adverse effects can be increased when Tramadol is combined with Ipratropium.
DB00382
The therapeutic efficacy of Tramadol can be decreased when used in combination with Tacrine.
DB00527
The therapeutic efficacy of Tramadol can be decreased when used in combination with Cinchocaine.
DB00545
The therapeutic efficacy of Tramadol can be decreased when used in combination with Pyridostigmine.
DB00585
The therapeutic efficacy of Tramadol can be decreased when used in combination with Nizatidine.
DB00674
The therapeutic efficacy of Tramadol can be decreased when used in combination with Galantamine.
DB00677
The therapeutic efficacy of Tramadol can be decreased when used in combination with Isoflurophate.
DB00711
The therapeutic efficacy of Tramadol can be decreased when used in combination with Diethylcarbamazine.
DB00871
The therapeutic efficacy of Tramadol can be decreased when used in combination with Terbutaline.
DB00888
The therapeutic efficacy of Tramadol can be decreased when used in combination with Mechlorethamine.
DB00944
The therapeutic efficacy of Tramadol can be decreased when used in combination with Demecarium.
DB00981
The therapeutic efficacy of Tramadol can be decreased when used in combination with Physostigmine.
DB00989
The therapeutic efficacy of Tramadol can be decreased when used in combination with Rivastigmine.
DB01010
The therapeutic efficacy of Tramadol can be decreased when used in combination with Edrophonium.
DB01122
The therapeutic efficacy of Tramadol can be decreased when used in combination with Ambenonium.
DB01381
The therapeutic efficacy of Tramadol can be decreased when used in combination with Ginkgo biloba.
DB01400
The therapeutic efficacy of Tramadol can be decreased when used in combination with Neostigmine.
DB01408
The therapeutic efficacy of Tramadol can be decreased when used in combination with Bambuterol.
DB02365
The therapeutic efficacy of Tramadol can be decreased when used in combination with 1,10-Phenanthroline.
DB04864
The therapeutic efficacy of Tramadol can be decreased when used in combination with Huperzine A.
DB04892
The therapeutic efficacy of Tramadol can be decreased when used in combination with Phenserine.
DB05386
The therapeutic efficacy of Tramadol can be decreased when used in combination with Regramostim.
DB06692
The therapeutic efficacy of Tramadol can be decreased when used in combination with Aprotinin.
DB06756
The therapeutic efficacy of Tramadol can be decreased when used in combination with Glycine betaine.
DB11390
The therapeutic efficacy of Tramadol can be decreased when used in combination with Coumaphos.
DB11397
The therapeutic efficacy of Tramadol can be decreased when used in combination with Dichlorvos.
DB11412
The therapeutic efficacy of Tramadol can be decreased when used in combination with Fenthion.
DB11473
The therapeutic efficacy of Tramadol can be decreased when used in combination with Metrifonate.
DB12482
The therapeutic efficacy of Tramadol can be decreased when used in combination with Acotiamide.
DB13058
The therapeutic efficacy of Tramadol can be decreased when used in combination with Methanesulfonyl Fluoride.
DB13495
The therapeutic efficacy of Tramadol can be decreased when used in combination with Paraoxon.
DB13503
The therapeutic efficacy of Tramadol can be decreased when used in combination with Tyrothricin.
DB13668
The therapeutic efficacy of Tramadol can be decreased when used in combination with Ipidacrine.
DB13694
The therapeutic efficacy of Tramadol can be decreased when used in combination with Distigmine.
DB14031
The therapeutic efficacy of Tramadol can be decreased when used in combination with Tretamine.
DB15317
The therapeutic efficacy of Tramadol can be decreased when used in combination with Posiphen.
DB02845
The therapeutic efficacy of Tramadol can be decreased when used in combination with Methylphosphinic Acid.
DB00581
The therapeutic efficacy of Lactulose can be decreased when used in combination with Tramadol.
DB01377
The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Tramadol.
DB01378
The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Tramadol.
DB01593
The therapeutic efficacy of Zinc can be decreased when used in combination with Tramadol.
DB04816
The therapeutic efficacy of Dantron can be decreased when used in combination with Tramadol.
DB04823
The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Tramadol.
DB04824
The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Tramadol.
DB07715
The therapeutic efficacy of Emodin can be decreased when used in combination with Tramadol.
DB08890
The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tramadol.
DB09020
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tramadol.
DB09311
The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Tramadol.
DB09413
The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Tramadol.
DB09414
The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Tramadol.
DB09449
The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tramadol.
DB09484
The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Tramadol.
DB11057
The therapeutic efficacy of Mineral oil can be decreased when used in combination with Tramadol.
DB11059
The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Tramadol.
DB11089
The therapeutic efficacy of Docusate can be decreased when used in combination with Tramadol.
DB11097
The therapeutic efficacy of Plantago seed can be decreased when used in combination with Tramadol.
DB11110
The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Tramadol.
DB11113
The therapeutic efficacy of Castor oil can be decreased when used in combination with Tramadol.
DB11189
The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Tramadol.
DB11228
The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Tramadol.
DB11365
The therapeutic efficacy of Sennosides can be decreased when used in combination with Tramadol.
DB12942
The therapeutic efficacy of Lactitol can be decreased when used in combination with Tramadol.
DB13170
The therapeutic efficacy of Plecanatide can be decreased when used in combination with Tramadol.
DB13486
The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Tramadol.
DB13526
The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Tramadol.
DB13707
The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Tramadol.
DB14232
The therapeutic efficacy of Deacetylbisacodyl can be decreased when used in combination with Tramadol.
DB14482
The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Tramadol.
DB14502
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tramadol.
DB14503
The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Tramadol.
DB14504
The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Tramadol.
DB14513
The therapeutic efficacy of Magnesium can be decreased when used in combination with Tramadol.
DB14585
The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Tramadol.
DB14627
The therapeutic efficacy of Oxyphenisatin acetate can be decreased when used in combination with Tramadol.
DB14684
The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Tramadol.
DB14963
The therapeutic efficacy of Konjac mannan can be decreased when used in combination with Tramadol.
DB15477
The therapeutic efficacy of Alloin can be decreased when used in combination with Tramadol.
DB15478
The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Tramadol.
DB11622
The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Tramadol.
DB09287
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tramadol.
DB09462
The therapeutic efficacy of Glycerin can be decreased when used in combination with Tramadol.
DB15982
The metabolism of Tramadol can be decreased when combined with Berotralstat.
DB09195
The risk or severity of adverse effects can be increased when Tramadol is combined with Lorpiprazole.
DB00230
The therapeutic efficacy of Tramadol can be increased when used in combination with Pregabalin.
DB11642
The serum concentration of Tramadol can be decreased when it is combined with Pitolisant.
DB09532
The therapeutic efficacy of Secretin human can be decreased when used in combination with Tramadol.
DB09409
The therapeutic efficacy of Magnesium acetate tetrahydrate can be decreased when used in combination with Tramadol.
DB09483
The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Tramadol.
DB13180
The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Tramadol.
DB13996
The therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Tramadol.
DB14516
The therapeutic efficacy of Sodium cation can be decreased when used in combination with Tramadol.
DB14546
The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Tramadol.
DB00159
Icosapent may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00229
Cefotiam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00244
Mesalazine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00267
Cefmenoxime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00274
Cefmetazole may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00282
Pamidronic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00300
Tenofovir disoproxil may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00328
Indomethacin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00369
Cidofovir may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00430
Cefpiramide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00438
Ceftazidime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00447
Loracarbef may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00456
Cefalotin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00461
Nabumetone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00465
Ketorolac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00469
Tenoxicam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00493
Cefotaxime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00500
Tolmetin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00529
Foscarnet may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00554
Piroxicam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00567
Cephalexin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00573
Fenoprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00577
Valaciclovir may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00580
Valdecoxib may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00586
Diclofenac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00605
Sulindac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00626
Bacitracin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00689
Cephaloglycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00718
Adefovir dipivoxil may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00738
Pentamidine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00742
Mannitol may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00749
Etodolac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00784
Mefenamic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00787
Acyclovir may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00788
Naproxen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00795
Sulfasalazine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00814
Meloxicam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00821
Carprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00833
Cefaclor may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00861
Diflunisal may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00923
Ceforanide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00936
Salicylic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00939
Meclofenamic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00945
Acetylsalicylic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00958
Carboplatin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00991
Oxaprozin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01009
Ketoprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01014
Balsalazide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01066
Cefditoren may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01111
Colistimethate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01112
Cefuroxime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01139
Cefapirin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01140
Cefadroxil may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01150
Cefprozil may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01212
Ceftriaxone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01250
Olsalazine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01283
Lumiracoxib may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01326
Cefamandole may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01327
Cefazolin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01328
Cefonicid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01329
Cefoperazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01330
Cefotetan may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01331
Cefoxitin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01332
Ceftizoxime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01397
Magnesium salicylate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01399
Salsalate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01401
Choline magnesium trisalicylate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01413
Cefepime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01414
Cefacetrile may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01415
Ceftibuten may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01416
Cefpodoxime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01419
Antrafenine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01424
Aminophenazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01600
Tiaprofenic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB02247
Hydrolyzed Cephalothin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB03450
Cephalothin Group may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB03585
Oxyphenbutazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04570
Latamoxef may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04743
Nimesulide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04812
Benoxaprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04828
Zomepirac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04918
Ceftobiprole may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB05095
Cimicoxib may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB06590
Ceftaroline fosamil may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB06725
Lornoxicam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB06736
Aceclofenac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB06737
Zaltoprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB07402
Azapropazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08439
Parecoxib may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08797
Salicylamide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08940
Kebuzone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08942
Isoxicam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08951
Indoprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08955
Ibuproxam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08976
Floctafenine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08981
Fenbufen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08984
Etofenamate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08991
Epirizole may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09008
Cefaloridine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09062
Cefminox may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09084
Benzydamine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09213
Dexibuprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09215
Droxicam may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09216
Tolfenamic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09217
Firocoxib may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09218
Clonixin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09285
Morniflumate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09288
Propacetamol may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09295
Talniflumate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09299
Tenofovir alafenamide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB11367
Cefroxadine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB11455
Robenacoxib may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB11466
Tepoxalin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB11518
Flunixin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB11935
Flomoxef may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB12151
Brincidofovir may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB12445
Nitroaspirin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB12545
Indobufen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13001
Tinoridine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13167
Alclofenac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13217
Fentiazac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13232
Suxibuzone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13266
Cefatrizine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13286
Bumadizone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13314
Alminoprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13371
Difenpiramide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13407
Nifenazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13432
Lonazolac may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13461
Cefcapene may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13470
Cefodizime may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13481
Tenidap may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13499
Cefsulodin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13504
Cefetamet may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13524
Propyphenazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13527
Proglumetacin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13538
Guacetisal may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13544
Ethenzamide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13612
Carbaspirin calcium may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13629
Mofebutazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13638
Cefbuperazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13649
Proquazone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13657
Benorilate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13667
Cefozopran may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13682
Cefpirome may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13722
Pirprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13778
Cefazedone may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13783
Acemetacin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13821
Ceftezole may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13860
Imidazole salicylate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13868
Adefovir may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB14059
SC-236 may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB14060
NS-398 may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB14126
Tenofovir may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB14713
Inotersen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01438
Phenazopyridine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09214
Dexketoprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01050
Ibuprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00563
Methotrexate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB14507
Lithium citrate may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB09212
Loxoprofen may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00452
Framycetin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01421
Paromomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04263
Geneticin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04626
Apramycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04808
Neamine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB08437
Puromycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB11512
Dihydrostreptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB11520
Hygromycin B may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB06767
Ammonium chloride may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01046
Tramadol may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB01638
Tramadol may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB09104
Tramadol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB09219
Tramadol may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB09268
Tramadol may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB09281
Tramadol may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB09472
Tramadol may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB09481
Tramadol may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB14499
Tramadol may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB00007
Leuprolide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00014
Goserelin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00017
Salmon calcitonin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00080
Daptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00081
Tositumomab may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00115
Cyanocobalamin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00158
Folic acid may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00165
Pyridoxine may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00185
Cevimeline may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00190
Carbidopa may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00198
Tramadol may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00200
Tramadol may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00225
Tramadol may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00235
Tramadol may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00254
Tramadol may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00262
Tramadol may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00271
Tramadol may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00279
Tramadol may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00284
Tramadol may decrease the excretion rate of Acarbose which could result in a higher serum level.
DB00286
Tramadol may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00290
Tramadol may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00294
Tramadol may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00303
Tramadol may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00308
Tramadol may decrease the excretion rate of Ibutilide which could result in a higher serum level.
DB00319
Tramadol may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00322
Tramadol may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00325
Tramadol may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
DB00330
Tramadol may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00331
Tramadol may decrease the excretion rate of Metformin which could result in a higher serum level.
DB00339
Tramadol may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00355
Tramadol may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00359
Tramadol may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
DB00364
Tramadol may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00373
Tramadol may decrease the excretion rate of Timolol which could result in a higher serum level.
DB00380
Tramadol may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00415
Tramadol may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00422
Tramadol may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
DB00432
Tramadol may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00437
Tramadol may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00441
Tramadol may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00480
Tramadol may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00492
Tramadol may decrease the excretion rate of Fosinopril which could result in a higher serum level.
DB00499
Tramadol may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00535
Tramadol may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00548
Tramadol may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00553
Tramadol may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00558
Tramadol may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00569
Tramadol may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00583
Tramadol may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00597
Tramadol may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00612
Tramadol may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
DB00631
Tramadol may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00651
Tramadol may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00665
Tramadol may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00672
Tramadol may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
DB00688
Tramadol may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
DB00692
Tramadol may decrease the excretion rate of Phentolamine which could result in a higher serum level.
DB00698
Tramadol may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00706
Tramadol may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00709
Tramadol may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00713
Tramadol may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00716
Tramadol may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00722
Tramadol may decrease the excretion rate of Lisinopril which could result in a higher serum level.
DB00730
Tramadol may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00731
Tramadol may decrease the excretion rate of Nateglinide which could result in a higher serum level.
DB00733
Tramadol may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00743
Tramadol may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
DB00760
Tramadol may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00775
Tramadol may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00789
Tramadol may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00800
Tramadol may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
DB00806
Tramadol may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
DB00811
Tramadol may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00828
Tramadol may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00839
Tramadol may decrease the excretion rate of Tolazamide which could result in a higher serum level.
DB00841
Tramadol may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00851
Tramadol may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00853
Tramadol may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00894
Tramadol may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00900
Tramadol may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00911
Tramadol may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00928
Tramadol may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00961
Tramadol may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00968
Tramadol may decrease the excretion rate of Methyldopa which could result in a higher serum level.
DB00988
Tramadol may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00993
Tramadol may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00995
Tramadol may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB01001
Tramadol may decrease the excretion rate of Salbutamol which could result in a higher serum level.
DB01002
Tramadol may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB01004
Tramadol may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
DB01020
Tramadol may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB01022
Tramadol may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB01024
Tramadol may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB01048
Tramadol may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB01060
Tramadol may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB01067
Tramadol may decrease the excretion rate of Glipizide which could result in a higher serum level.
DB01099
Tramadol may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB01101
Tramadol may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB01124
Tramadol may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
DB01133
Tramadol may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
DB01157
Tramadol may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB01166
Tramadol may decrease the excretion rate of Cilostazol which could result in a higher serum level.
DB01170
Tramadol may decrease the excretion rate of Guanethidine which could result in a higher serum level.
DB01203
Tramadol may decrease the excretion rate of Nadolol which could result in a higher serum level.
DB01205
Tramadol may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB01213
Tramadol may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB01240
Tramadol may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
DB01249
Tramadol may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB01261
Tramadol may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
DB01273
Tramadol may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB01274
Tramadol may decrease the excretion rate of Arformoterol which could result in a higher serum level.
DB01427
Tramadol may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB01428
Tramadol may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB01431
Tramadol may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
DB01550
Tramadol may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB01610
Tramadol may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB01656
Tramadol may decrease the excretion rate of Roflumilast which could result in a higher serum level.
DB04574
Tramadol may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB04895
Tramadol may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB05018
Tramadol may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB06154
Tramadol may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB06186
Tramadol may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB06196
Tramadol may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB06203
Tramadol may decrease the excretion rate of Alogliptin which could result in a higher serum level.
DB06211
Tramadol may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB06262
Tramadol may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB06335
Tramadol may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
DB06402
Tramadol may decrease the excretion rate of Telavancin which could result in a higher serum level.
DB06623
Tramadol may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB06695
Tramadol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB06705
Tramadol may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB06782
Tramadol may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB06796
Tramadol may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB06809
Tramadol may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB06813
Tramadol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DB06823
Tramadol may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB06824
Tramadol may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB08824
Tramadol may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB08826
Tramadol may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB08840
Tramadol may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB08877
Tramadol may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DB08894
Tramadol may decrease the excretion rate of Peginesatide which could result in a higher serum level.
DB08900
Tramadol may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB08932
Tramadol may decrease the excretion rate of Macitentan which could result in a higher serum level.
DB08934
Tramadol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB09050
Tramadol may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB09066
Tramadol may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
DB09075
Tramadol may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB09081
Tramadol may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB09082
Tramadol may decrease the excretion rate of Vilanterol which could result in a higher serum level.
DB09091
Tramadol may decrease the excretion rate of Tixocortol which could result in a higher serum level.
DB09103
Tramadol may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB09106
Tramadol may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB09111
Tramadol may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB09121
Tramadol may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB09123
Tramadol may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB09129
Tramadol may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB09132
Tramadol may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB09133
Tramadol may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB09134
Tramadol may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB09135
Tramadol may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB09136
Tramadol may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB09137
Tramadol may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB09139
Tramadol may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB09148
Tramadol may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB09149
Tramadol may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB09156
Tramadol may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB09163
Tramadol may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB09165
Tramadol may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB09204
Tramadol may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB09205
Tramadol may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB09209
Tramadol may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB09210
Tramadol may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB09220
Tramadol may decrease the excretion rate of Nicorandil which could result in a higher serum level.
DB09255
Tramadol may decrease the excretion rate of Dextran which could result in a higher serum level.
DB09256
Tramadol may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB09257
Tramadol may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB09264
Tramadol may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB09265
Tramadol may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
DB09277
Tramadol may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
DB09292
Tramadol may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB09301
Tramadol may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB09317
Tramadol may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB09318
Tramadol may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB09320
Tramadol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB09324
Tramadol may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB09325
Tramadol may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB09329
Tramadol may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB09344
Tramadol may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB09357
Tramadol may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB09394
Tramadol may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB09395
Tramadol may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB09407
Tramadol may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB09418
Tramadol may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB09477
Tramadol may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
DB09488
Tramadol may decrease the excretion rate of Acrivastine which could result in a higher serum level.
DB09496
Tramadol may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB09502
Tramadol may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB09546
Tramadol may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB11077
Tramadol may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB11098
Tramadol may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB11102
Tramadol may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB11114
Tramadol may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB11127
Tramadol may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB11135
Tramadol may decrease the excretion rate of Selenium which could result in a higher serum level.
DB11136
Tramadol may decrease the excretion rate of Chromium which could result in a higher serum level.
DB11145
Tramadol may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB11164
Tramadol may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB11251
Tramadol may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB11278
Tramadol may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB11328
Tramadol may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB11338
Tramadol may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB11358
Tramadol may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB11364
Tramadol may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB11560
Tramadol may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB11577
Tramadol may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB11587
Tramadol may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB11598
Tramadol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB11817
Tramadol may decrease the excretion rate of Baricitinib which could result in a higher serum level.
DB11915
Tramadol may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB11989
Tramadol may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB12007
Tramadol may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB12107
Tramadol may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB12161
Tramadol may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
DB12783
Tramadol may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB13156
Tramadol may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB13178
Tramadol may decrease the excretion rate of Inositol which could result in a higher serum level.
DB13185
Tramadol may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB13191
Tramadol may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB13269
Tramadol may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB13293
Tramadol may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB13595
Tramadol may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB13873
Tramadol may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB13884
Tramadol may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB13909
Tramadol may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB13967
Tramadol may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB14006
Tramadol may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB14007
Tramadol may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB14498
Tramadol may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB14526
Tramadol may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB14527
Tramadol may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB14528
Tramadol may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB14529
Tramadol may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB14530
Tramadol may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB06815
Tramadol may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB11121
Tramadol may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB11085
Tramadol may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB11090
Tramadol may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB00296
Tramadol may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00820
Tramadol may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB15593
Tramadol may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB06480
Tramadol may decrease the excretion rate of Prucalopride which could result in a higher serum level.
DB00213
Tramadol may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00351
Tramadol may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00401
Tramadol may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
DB00440
Tramadol may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00783
Tramadol may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB01039
Tramadol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
DB01137
Tramadol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
DB01169
Tramadol may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
DB06228
Tramadol may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB09027
Tramadol may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB00635
Tramadol may decrease the excretion rate of Prednisone which could result in a higher serum level.
DB00879
Tramadol may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB14506
Tramadol may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB09570
Tramadol may decrease the excretion rate of Ixazomib which could result in a higher serum level.
DB00790
Tramadol may decrease the excretion rate of Perindopril which could result in a higher serum level.
DB13987
Tramadol may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
DB04890
Tramadol may decrease the excretion rate of Bepotastine which could result in a higher serum level.
DB00982
Tramadol may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB09095
Tramadol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.
DB00515
Cisplatin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00479
Amikacin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00684
Tobramycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00798
Gentamicin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00955
Netilmicin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00994
Neomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01082
Streptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB01172
Kanamycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB03615
Ribostamycin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB04729
Gentamicin C1a may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB06696
Arbekacin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB12604
Sisomicin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB13540
Isepamicin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00552
Tramadol may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB13145
Tramadol may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00314
Tramadol may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00512
Tramadol may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00642
Tramadol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB12615
Tramadol may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00803
Colistin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00524
Tramadol may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00695
Tramadol may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00808
Tramadol may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00887
Tramadol may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB09338
Tramadol may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00700
Eplerenone may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.
DB06292
Tramadol may increase the excretion rate of Dapagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
DB08907
Tramadol may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
DB06212
Tolvaptan may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.
DB01345
Tramadol may increase the excretion rate of Potassium cation which could result in a lower serum level and potentially a reduction in efficacy.
DB09046
The metabolism of Tramadol can be increased when combined with Metreleptin.
DB00173
The metabolism of Tramadol can be decreased when combined with Adenine.
DB00712
The metabolism of Tramadol can be decreased when combined with Flurbiprofen.
DB01241
The metabolism of Tramadol can be decreased when combined with Gemfibrozil.
DB06210
The metabolism of Tramadol can be decreased when combined with Eltrombopag.
DB09183
The metabolism of Tramadol can be decreased when combined with Dasabuvir.
DB09276
The metabolism of Tramadol can be decreased when combined with Sodium aurothiomalate.
DB09296
The metabolism of Tramadol can be decreased when combined with Ombitasvir.
DB09297
The metabolism of Tramadol can be decreased when combined with Paritaprevir.
DB09298
The metabolism of Tramadol can be decreased when combined with Silibinin.
DB11827
The metabolism of Tramadol can be decreased when combined with Ertugliflozin.
DB13878
The metabolism of Tramadol can be decreased when combined with Pibrentasvir.
DB13879
The metabolism of Tramadol can be decreased when combined with Glecaprevir.
DB12978
The metabolism of Tramadol can be decreased when combined with Pexidartinib.
DB04572
The metabolism of Tramadol can be decreased when combined with Thiotepa.
DB00184
The metabolism of Tramadol can be decreased when combined with Nicotine.
DB00379
The metabolism of Mexiletine can be decreased when combined with Tramadol.
DB00568
The metabolism of Cinnarizine can be decreased when combined with Tramadol.
DB00755
The metabolism of Tretinoin can be decreased when combined with Tramadol.
DB00762
The metabolism of Irinotecan can be decreased when combined with Tramadol.
DB04975
The metabolism of Banoxantrone can be decreased when combined with Tramadol.
DB06176
The metabolism of Romidepsin can be decreased when combined with Tramadol.
DB06209
The metabolism of Prasugrel can be decreased when combined with Tramadol.
DB06710
The metabolism of Methyltestosterone can be decreased when combined with Tramadol.
DB11613
The metabolism of Velpatasvir can be decreased when combined with Tramadol.
DB13132
The metabolism of Artemisinin can be decreased when combined with Tramadol.
DB11757
The metabolism of Istradefylline can be decreased when combined with Tramadol.
DB14975
The metabolism of Voxelotor can be decreased when combined with Tramadol.
DB00655
The metabolism of Estrone can be decreased when combined with Tramadol.
DB04930
The metabolism of Permethrin can be decreased when combined with Tramadol.
DB15035
The metabolism of Zanubrutinib can be decreased when combined with Tramadol.
DB09555
The metabolism of Tramadol can be decreased when combined with Dexchlorpheniramine maleate.
DB00528
The metabolism of Lercanidipine can be decreased when combined with Tramadol.
DB01562
The metabolism of Tramadol can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB14009
The metabolism of Tramadol can be decreased when combined with Medical Cannabis.
DB00187
The metabolism of Tramadol can be decreased when combined with Esmolol.
DB00195
The metabolism of Betaxolol can be decreased when combined with Tramadol.
DB00335
The metabolism of Atenolol can be decreased when combined with Tramadol.
DB00592
The metabolism of Piperazine can be decreased when combined with Tramadol.
DB00699
The metabolism of Nicergoline can be decreased when combined with Tramadol.
DB00914
The metabolism of Phenformin can be decreased when combined with Tramadol.
DB00983
The metabolism of Formoterol can be decreased when combined with Tramadol.
DB01177
The metabolism of Idarubicin can be decreased when combined with Tramadol.
DB01228
The metabolism of Encainide can be decreased when combined with Tramadol.
DB01295
The metabolism of Bevantolol can be decreased when combined with Tramadol.
DB01297
The metabolism of Practolol can be decreased when combined with Tramadol.
DB01429
The metabolism of Aprindine can be decreased when combined with Tramadol.
DB04844
The metabolism of Tetrabenazine can be decreased when combined with Tramadol.
DB06608
The metabolism of Tafenoquine can be decreased when combined with Tramadol.
DB06726
The metabolism of Bufuralol can be decreased when combined with Tramadol.
DB06735
The metabolism of Enclomiphene can be decreased when combined with Tramadol.
DB08807
The metabolism of Bopindolol can be decreased when combined with Tramadol.
DB08808
The metabolism of Bupranolol can be decreased when combined with Tramadol.
DB08952
The metabolism of Indenolol can be decreased when combined with Tramadol.
DB09351
The metabolism of Levobetaxolol can be decreased when combined with Tramadol.
DB11785
The metabolism of Anisodamine can be decreased when combined with Tramadol.
DB12212
The metabolism of Landiolol can be decreased when combined with Tramadol.
DB12752
The metabolism of Bucindolol can be decreased when combined with Tramadol.
DB13443
The metabolism of Esatenolol can be decreased when combined with Tramadol.
DB13508
The metabolism of Cloranolol can be decreased when combined with Tramadol.
DB13530
The metabolism of Mepindolol can be decreased when combined with Tramadol.
DB13757
The metabolism of Epanolol can be decreased when combined with Tramadol.
DB13775
The metabolism of Tertatolol can be decreased when combined with Tramadol.
DB06506
The metabolism of Repinotan can be decreased when combined with Tramadol.
DB09173
The metabolism of Butyrfentanyl can be decreased when combined with Tramadol.
DB04889
The metabolism of Bicifadine can be decreased when combined with Tramadol.
DB00297
The metabolism of Bupivacaine can be decreased when combined with Tramadol.
DB01410
The metabolism of Ciclesonide can be decreased when combined with Tramadol.
DB03783
The metabolism of Phenacetin can be decreased when combined with Tramadol.
DB04861
The metabolism of Nebivolol can be decreased when combined with Tramadol.
DB09053
The metabolism of Ibrutinib can be decreased when combined with Tramadol.
DB11614
The metabolism of Rupatadine can be decreased when combined with Tramadol.
DB00203
The metabolism of Sildenafil can be decreased when combined with Tramadol.
DB00590
The metabolism of Doxazosin can be decreased when combined with Tramadol.
DB01136
The metabolism of Carvedilol can be decreased when combined with Tramadol.
DB04840
The metabolism of Debrisoquine can be decreased when combined with Tramadol.
DB04846
The metabolism of Celiprolol can be decreased when combined with Tramadol.
DB11770
The metabolism of Talinolol can be decreased when combined with Tramadol.
DB11979
The metabolism of Elagolix can be decreased when combined with Tramadol.
DB00188
The metabolism of Tramadol can be decreased when combined with Bortezomib.
DB11718
The metabolism of Encorafenib can be decreased when combined with Tramadol.
DB00489
The metabolism of Sotalol can be decreased when combined with Tramadol.
DB01035
The metabolism of Procainamide can be decreased when combined with Tramadol.
DB00277
The metabolism of Theophylline can be decreased when combined with Tramadol.
DB05109
The metabolism of Trabectedin can be decreased when combined with Tramadol.
DB08901
The metabolism of Ponatinib can be decreased when combined with Tramadol.
DB00641
The metabolism of Simvastatin can be increased when combined with Tramadol.
DB14631
The metabolism of Tramadol can be increased when combined with Prednisolone phosphate.
DB05077
The risk or severity of adverse effects can be increased when SLV319 is combined with Tramadol.
DB06155
The risk or severity of adverse effects can be increased when Rimonabant is combined with Tramadol.
DB06624
The risk or severity of adverse effects can be increased when Taranabant is combined with Tramadol.
DB11903
The risk or severity of adverse effects can be increased when GW842166 is combined with Tramadol.
DB12193
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Tramadol.
DB12649
The risk or severity of adverse effects can be increased when Ibipinabant is combined with Tramadol.
DB13070
The risk or severity of adverse effects can be increased when Surinabant is combined with Tramadol.
DB14011
The risk or severity of adverse effects can be increased when Nabiximols is combined with Tramadol.
DB14043
The risk or severity of adverse effects can be increased when Palmidrol is combined with Tramadol.
DB14737
The risk or severity of adverse effects can be increased when Cannabinol is combined with Tramadol.
DB00504
The therapeutic efficacy of Tramadol can be decreased when used in combination with Levallorphan.
DB01548
The therapeutic efficacy of Tramadol can be decreased when used in combination with Diprenorphine.
DB06230
The therapeutic efficacy of Tramadol can be decreased when used in combination with Nalmefene.
DB06800
The therapeutic efficacy of Tramadol can be decreased when used in combination with Methylnaltrexone.
DB11490
The therapeutic efficacy of Tramadol can be decreased when used in combination with Nalorphine.
DB11691
The therapeutic efficacy of Tramadol can be decreased when used in combination with Naldemedine.
DB12013
The therapeutic efficacy of Tramadol can be decreased when used in combination with Axelopran.
DB12341
The therapeutic efficacy of Tramadol can be decreased when used in combination with LY-2456302.
DB12543
The therapeutic efficacy of Tramadol can be decreased when used in combination with Samidorphan.
DB12585
The therapeutic efficacy of Tramadol can be decreased when used in combination with Ondelopran.
DB00455
Tramadol may increase the anticholinergic activities of Loratadine.
DB11640
The risk or severity of seizure can be increased when Tramadol is combined with Amifampridine.
DB12141
The therapeutic efficacy of Tramadol can be decreased when used in combination with Gilteritinib.
DB00005
The metabolism of Tramadol can be increased when combined with Etanercept.
DB00026
The metabolism of Tramadol can be increased when combined with Anakinra.
DB00051
The metabolism of Tramadol can be increased when combined with Adalimumab.
DB00065
The metabolism of Tramadol can be increased when combined with Infliximab.
DB01281
The metabolism of Tramadol can be increased when combined with Abatacept.
DB04956
The metabolism of Tramadol can be increased when combined with Afelimomab.
DB05676
The metabolism of Tramadol can be increased when combined with Apremilast.
DB06168
The metabolism of Tramadol can be increased when combined with Canakinumab.
DB06372
The metabolism of Tramadol can be increased when combined with Rilonacept.
DB06674
The metabolism of Tramadol can be increased when combined with Golimumab.
DB08904
The metabolism of Tramadol can be increased when combined with Certolizumab pegol.
DB09029
The metabolism of Tramadol can be increased when combined with Secukinumab.
DB14724
The metabolism of Tramadol can be increased when combined with Emapalumab.
DB00217
The risk or severity of Tachycardia can be increased when Tramadol is combined with Bethanidine.
DB00221
The risk or severity of Tachycardia can be increased when Tramadol is combined with Isoetharine.
DB00261
The risk or severity of Tachycardia can be increased when Tramadol is combined with Anagrelide.
DB00368
The risk or severity of Tachycardia can be increased when Tramadol is combined with Norepinephrine.
DB00388
The risk or severity of Tachycardia can be increased when Tramadol is combined with Phenylephrine.
DB00397
The risk or severity of Tachycardia can be increased when Tramadol is combined with Phenylpropanolamine.
DB00610
The risk or severity of Tachycardia can be increased when Tramadol is combined with Metaraminol.
DB00629
The risk or severity of Tachycardia can be increased when Tramadol is combined with Guanabenz.
DB00640
The risk or severity of Tachycardia can be increased when Tramadol is combined with Adenosine.
DB00723
The risk or severity of Tachycardia can be increased when Tramadol is combined with Methoxamine.
DB00816
The risk or severity of Tachycardia can be increased when Tramadol is combined with Orciprenaline.
DB00830
The risk or severity of Tachycardia can be increased when Tramadol is combined with Phenmetrazine.
DB00867
The risk or severity of Tachycardia can be increased when Tramadol is combined with Ritodrine.
DB00901
The risk or severity of Tachycardia can be increased when Tramadol is combined with Bitolterol.
DB00935
The risk or severity of Tachycardia can be increased when Tramadol is combined with Oxymetazoline.
DB01064
The risk or severity of Tachycardia can be increased when Tramadol is combined with Isoprenaline.
DB01102
The risk or severity of Tachycardia can be increased when Tramadol is combined with Arbutamine.
DB01291
The risk or severity of Tachycardia can be increased when Tramadol is combined with Pirbuterol.
DB01363
The risk or severity of Tachycardia can be increased when Tramadol is combined with Ephedra sinica root.
DB01364
The risk or severity of Tachycardia can be increased when Tramadol is combined with Ephedrine.
DB01366
The risk or severity of Tachycardia can be increased when Tramadol is combined with Procaterol.
DB01407
The risk or severity of Tachycardia can be increased when Tramadol is combined with Clenbuterol.
DB01579
The risk or severity of Tachycardia can be increased when Tramadol is combined with Phendimetrazine.
DB05395
The risk or severity of Tachycardia can be increased when Tramadol is combined with Amibegron.
DB06190
The risk or severity of Tachycardia can be increased when Tramadol is combined with Solabegron.
DB06694
The risk or severity of Tachycardia can be increased when Tramadol is combined with Xylometazoline.
DB06706
The risk or severity of Tachycardia can be increased when Tramadol is combined with Isometheptene.
DB06707
The risk or severity of Tachycardia can be increased when Tramadol is combined with Levonordefrin.
DB06764
The risk or severity of Tachycardia can be increased when Tramadol is combined with Tetryzoline.
DB06814
The risk or severity of Tachycardia can be increased when Tramadol is combined with Protokylol.
DB08841
The risk or severity of Tachycardia can be increased when Tramadol is combined with Tyramine.
DB08925
The risk or severity of Tachycardia can be increased when Tramadol is combined with Adrafinil.
DB08941
The risk or severity of Tachycardia can be increased when Tramadol is combined with Isoxsuprine.
DB08957
The risk or severity of Tachycardia can be increased when Tramadol is combined with Hexoprenaline.
DB08985
The risk or severity of Tachycardia can be increased when Tramadol is combined with Etilefrine.
DB09080
The risk or severity of Tachycardia can be increased when Tramadol is combined with Olodaterol.
DB09202
The risk or severity of Tachycardia can be increased when Tramadol is combined with Cirazoline.
DB09203
The risk or severity of Tachycardia can be increased when Tramadol is combined with Synephrine.
DB09242
The risk or severity of Tachycardia can be increased when Tramadol is combined with Moxonidine.
DB09273
The risk or severity of Tachycardia can be increased when Tramadol is combined with Doxofylline.
DB11124
The risk or severity of Tachycardia can be increased when Tramadol is combined with Racepinephrine.
DB11373
The risk or severity of Tachycardia can be increased when Tramadol is combined with Amitraz.
DB11541
The risk or severity of Tachycardia can be increased when Tramadol is combined with Ractopamine.
DB11738
The risk or severity of Tachycardia can be increased when Tramadol is combined with Rilmenidine.
DB11871
The risk or severity of Tachycardia can be increased when Tramadol is combined with PF-00610355.
DB12100
The risk or severity of Tachycardia can be increased when Tramadol is combined with Abediterol.
DB12248
The risk or severity of Tachycardia can be increased when Tramadol is combined with Tulobuterol.
DB12313
The risk or severity of Tachycardia can be increased when Tramadol is combined with Dopexamine.
DB12779
The risk or severity of Tachycardia can be increased when Tramadol is combined with Higenamine.
DB12846
The risk or severity of Tachycardia can be increased when Tramadol is combined with Reproterol.
DB13064
The risk or severity of Tachycardia can be increased when Tramadol is combined with Tramazoline.
DB13251
The risk or severity of Tachycardia can be increased when Tramadol is combined with Octopamine.
DB13341
The risk or severity of Tachycardia can be increased when Tramadol is combined with Fenozolone.
DB13378
The risk or severity of Tachycardia can be increased when Tramadol is combined with Norfenefrine.
DB13398
The risk or severity of Tachycardia can be increased when Tramadol is combined with Oxyfedrine.
DB13559
The risk or severity of Tachycardia can be increased when Tramadol is combined with Rimiterol.
DB13692
The risk or severity of Tachycardia can be increased when Tramadol is combined with Tretoquinol.
DB13777
The risk or severity of Tachycardia can be increased when Tramadol is combined with Prenalterol.
DB13781
The risk or severity of Tachycardia can be increased when Tramadol is combined with Xamoterol.
DB13852
The risk or severity of Tachycardia can be increased when Tramadol is combined with Mefenorex.
DB00211
The risk or severity of Tachycardia can be increased when Tramadol is combined with Midodrine.
DB00938
The risk or severity of Tachycardia can be increased when Tramadol is combined with Salmeterol.
DB06152
The risk or severity of Tachycardia can be increased when Tramadol is combined with Nylidrin.
DB05039
The risk or severity of Tachycardia can be increased when Tramadol is combined with Indacaterol.
DB01184
The therapeutic efficacy of Domperidone can be decreased when used in combination with Tramadol.
DB06678
The risk or severity of serotonin syndrome and seizure can be increased when Esmirtazapine is combined with Tramadol.
DB11481
The risk or severity of serotonin syndrome and seizure can be increased when Atipamezole is combined with Tramadol.
DB12057
The risk or severity of serotonin syndrome and seizure can be increased when ORM-12741 is combined with Tramadol.
DB12551
The risk or severity of serotonin syndrome and seizure can be increased when Idazoxan is combined with Tramadol.
DB13074
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Tramadol.
DB11823
The risk or severity of adverse effects can be increased when Tramadol is combined with Esketamine.
DB00395
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Tramadol.
DB00214
The therapeutic efficacy of Torasemide can be decreased when used in combination with Tramadol.
DB00232
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tramadol.
DB00310
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tramadol.
DB00311
The therapeutic efficacy of Ethoxzolamide can be decreased when used in combination with Tramadol.
DB00384
The therapeutic efficacy of Triamterene can be decreased when used in combination with Tramadol.
DB00421
The therapeutic efficacy of Spironolactone can be decreased when used in combination with Tramadol.
DB00436
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tramadol.
DB00562
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tramadol.
DB00594
The therapeutic efficacy of Amiloride can be decreased when used in combination with Tramadol.
DB00606
The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Tramadol.
DB00774
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tramadol.
DB00880
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tramadol.
DB00903
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tramadol.
DB00999
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tramadol.
DB01021
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tramadol.
DB01119
The therapeutic efficacy of Diazoxide can be decreased when used in combination with Tramadol.
DB01144
The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Tramadol.
DB01324
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Tramadol.
DB01325
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Tramadol.
DB01395
The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tramadol.
DB01412
The therapeutic efficacy of Theobromine can be decreased when used in combination with Tramadol.
DB02925
The therapeutic efficacy of Piretanide can be decreased when used in combination with Tramadol.
DB04831
The therapeutic efficacy of Tienilic acid can be decreased when used in combination with Tramadol.
DB05034
The therapeutic efficacy of Ularitide can be decreased when used in combination with Tramadol.
DB08961
The therapeutic efficacy of Azosemide can be decreased when used in combination with Tramadol.
DB09015
The therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Tramadol.
DB09125
The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Tramadol.
DB09401
The therapeutic efficacy of Isosorbide can be decreased when used in combination with Tramadol.
DB12221
The therapeutic efficacy of Canrenone can be decreased when used in combination with Tramadol.
DB12670
The therapeutic efficacy of Rolofylline can be decreased when used in combination with Tramadol.
DB12704
The therapeutic efficacy of Spiradoline can be decreased when used in combination with Tramadol.
DB12766
The therapeutic efficacy of Cicletanine can be decreased when used in combination with Tramadol.
DB13284
The therapeutic efficacy of Meticrane can be decreased when used in combination with Tramadol.
DB13405
The therapeutic efficacy of Mefruside can be decreased when used in combination with Tramadol.
DB13430
The therapeutic efficacy of Mebutizide can be decreased when used in combination with Tramadol.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tramadol.
DB13617
The therapeutic efficacy of Clorexolone can be decreased when used in combination with Tramadol.
DB13663
The therapeutic efficacy of Clofenamide can be decreased when used in combination with Tramadol.
DB13708
The therapeutic efficacy of Fenquizone can be decreased when used in combination with Tramadol.
DB13792
The therapeutic efficacy of Clopamide can be decreased when used in combination with Tramadol.
DB13801
The therapeutic efficacy of Muzolimine can be decreased when used in combination with Tramadol.
DB13803
The therapeutic efficacy of Xipamide can be decreased when used in combination with Tramadol.
DB13989
The therapeutic efficacy of Epitizide can be decreased when used in combination with Tramadol.
DB14018
The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Tramadol.
DB14500
The therapeutic efficacy of Potassium can be decreased when used in combination with Tramadol.
DB00703
The therapeutic efficacy of Methazolamide can be decreased when used in combination with Tramadol.
DB14754
The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Tramadol.
DB06711
Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
DB00402
The risk or severity of CNS depression can be increased when Tramadol is combined with Eszopiclone.
DB00758
Tramadol can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00575
The risk or severity of sedation can be increased when Clonidine is combined with Tramadol.
DB00843
The therapeutic efficacy of Tramadol can be decreased when used in combination with Donepezil.
DB06637
The risk or severity of seizure can be increased when Tramadol is combined with Dalfampridine.
DB15066
The serum concentration of Tramadol can be increased when it is combined with Givosiran.
DB01156
The risk or severity of seizure can be increased when Bupropion is combined with Tramadol.
DB06119
The serum concentration of Cenobamate can be decreased when it is combined with Tramadol.
DB11951
The serum concentration of Tramadol can be decreased when it is combined with Lemborexant.
DB01173
The metabolism of Orphenadrine can be decreased when combined with Tramadol.
DB00623
The metabolism of Tramadol can be decreased when combined with Fluphenazine.
DB00850
The metabolism of Tramadol can be decreased when combined with Perphenazine.
DB01621
The metabolism of Tramadol can be decreased when combined with Pipotiazine.
DB00358
The metabolism of Tramadol can be decreased when combined with Mefloquine.
DB00209
The metabolism of Trospium can be decreased when combined with Tramadol.
DB00283
The metabolism of Tramadol can be decreased when combined with Clemastine.
DB00494
The metabolism of Tramadol can be decreased when combined with Entacapone.
DB00363
The metabolism of Clozapine can be decreased when combined with Tramadol.
DB06512
The metabolism of Deramciclane can be decreased when combined with Tramadol.
DB00208
The metabolism of Tramadol can be decreased when combined with Ticlopidine.
DB00763
The metabolism of Tramadol can be decreased when combined with Methimazole.
DB00281
The metabolism of Lidocaine can be decreased when combined with Tramadol.
DB04938
The metabolism of Ospemifene can be decreased when combined with Tramadol.
DB00349
The metabolism of Clobazam can be decreased when combined with Tramadol.
DB00234
The metabolism of Tramadol can be decreased when combined with Reboxetine.
DB00317
The metabolism of Tramadol can be decreased when combined with Gefitinib.
DB00338
The metabolism of Tramadol can be decreased when combined with Omeprazole.
DB00448
The metabolism of Tramadol can be decreased when combined with Lansoprazole.
DB00468
The metabolism of Tramadol can be decreased when combined with Quinine.
DB00570
The metabolism of Tramadol can be decreased when combined with Vinblastine.
DB00571
The metabolism of Tramadol can be decreased when combined with Propranolol.
DB00613
The metabolism of Tramadol can be decreased when combined with Amodiaquine.
DB00619
The metabolism of Tramadol can be decreased when combined with Imatinib.
DB00622
The metabolism of Tramadol can be decreased when combined with Nicardipine.
DB00661
The metabolism of Tramadol can be decreased when combined with Verapamil.
DB00675
The metabolism of Tramadol can be decreased when combined with Tamoxifen.
DB00834
The metabolism of Tramadol can be decreased when combined with Mifepristone.
DB00997
The metabolism of Tramadol can be decreased when combined with Doxorubicin.
DB01087
The metabolism of Tramadol can be decreased when combined with Primaquine.
DB01110
The metabolism of Tramadol can be decreased when combined with Miconazole.
DB01244
The metabolism of Tramadol can be decreased when combined with Bepridil.
DB00361
The metabolism of Vinorelbine can be decreased when combined with Tramadol.
DB00439
The metabolism of Cerivastatin can be decreased when combined with Tramadol.
DB00482
The metabolism of Tramadol can be decreased when combined with Celecoxib.
DB01435
The metabolism of Tramadol can be decreased when combined with Antipyrine.
DB01628
The metabolism of Tramadol can be decreased when combined with Etoricoxib.
DB00264
The metabolism of Metoprolol can be decreased when combined with Tramadol.
DB00608
The metabolism of Chloroquine can be decreased when combined with Tramadol.
DB01093
The metabolism of Dimethyl sulfoxide can be decreased when combined with Tramadol.
DB01129
The metabolism of Rabeprazole can be decreased when combined with Tramadol.
DB13139
The metabolism of Levosalbutamol can be decreased when combined with Tramadol.
DB00398
The metabolism of Tramadol can be decreased when combined with Sorafenib.
DB12332
The metabolism of Tramadol can be decreased when combined with Rucaparib.
DB13874
The metabolism of Tramadol can be decreased when combined with Enasidenib.
DB02703
The metabolism of Tramadol can be decreased when combined with Fusidic acid.
DB00705
The metabolism of Tramadol can be decreased when combined with Delavirdine.
DB01026
The metabolism of Tramadol can be decreased when combined with Ketoconazole.
DB04868
The metabolism of Tramadol can be decreased when combined with Nilotinib.
DB00169
The metabolism of Tramadol can be decreased when combined with Cholecalciferol.
DB01074
The metabolism of Tramadol can be decreased when combined with Perhexiline.
DB05812
The metabolism of Tramadol can be decreased when combined with Abiraterone.
DB06603
The metabolism of Tramadol can be decreased when combined with Panobinostat.
DB06729
The metabolism of Tramadol can be decreased when combined with Sulfaphenazole.
DB06819
The metabolism of Tramadol can be decreased when combined with Phenylbutyric acid.
DB09238
The metabolism of Tramadol can be decreased when combined with Manidipine.
DB09291
The metabolism of Tramadol can be decreased when combined with Rolapitant.
DB11586
The metabolism of Tramadol can be decreased when combined with Asunaprevir.
DB13174
The metabolism of Tramadol can be decreased when combined with Rhein.
DB01012
The metabolism of Tramadol can be decreased when combined with Cinacalcet.
DB01182
The metabolism of Tramadol can be decreased when combined with Propafenone.
DB01218
The metabolism of Tramadol can be decreased when combined with Halofantrine.
DB06691
The metabolism of Tramadol can be decreased when combined with Mepyramine.
DB08909
The metabolism of Tramadol can be decreased when combined with Glycerol phenylbutyrate.
DB11963
The metabolism of Tramadol can be decreased when combined with Dacomitinib.
DB00857
The metabolism of Tramadol can be decreased when combined with Terbinafine.
DB06708
The metabolism of Tramadol can be decreased when combined with Lumefantrine.
DB01388
The metabolism of Tramadol can be decreased when combined with Mibefradil.
DB00091
The metabolism of Cyclosporine can be decreased when combined with Tramadol.
DB00227
The metabolism of Lovastatin can be decreased when combined with Tramadol.
DB00342
The metabolism of Terfenadine can be decreased when combined with Tramadol.
DB00496
The metabolism of Darifenacin can be decreased when combined with Tramadol.
DB00908
The metabolism of Quinidine can be decreased when combined with Tramadol.
DB00932
The metabolism of Tipranavir can be decreased when combined with Tramadol.
DB01023
The metabolism of Felodipine can be decreased when combined with Tramadol.
DB01100
The metabolism of Pimozide can be decreased when combined with Tramadol.
DB01118
The metabolism of Amiodarone can be decreased when combined with Tramadol.
DB01232
The metabolism of Saquinavir can be decreased when combined with Tramadol.
DB01264
The metabolism of Darunavir can be decreased when combined with Tramadol.
DB01590
The metabolism of Everolimus can be decreased when combined with Tramadol.
DB04855
The metabolism of Dronedarone can be decreased when combined with Tramadol.
DB06287
The metabolism of Temsirolimus can be decreased when combined with Tramadol.
DB08864
The metabolism of Rilpivirine can be decreased when combined with Tramadol.
DB00412
The metabolism of Tramadol can be decreased when combined with Rosiglitazone.
DB00598
The metabolism of Tramadol can be decreased when combined with Labetalol.
DB00633
The metabolism of Tramadol can be decreased when combined with Dexmedetomidine.
DB00792
The metabolism of Tramadol can be decreased when combined with Tripelennamine.
DB00810
The metabolism of Tramadol can be decreased when combined with Biperiden.
DB01005
The metabolism of Tramadol can be decreased when combined with Hydroxyurea.
DB01128
The metabolism of Tramadol can be decreased when combined with Bicalutamide.
DB01193
The metabolism of Tramadol can be decreased when combined with Acebutolol.
DB01580
The metabolism of Tramadol can be decreased when combined with Oxprenolol.
DB01611
The metabolism of Tramadol can be decreased when combined with Hydroxychloroquine.
DB06217
The metabolism of Tramadol can be decreased when combined with Vernakalant.
DB06727
The metabolism of Tramadol can be decreased when combined with Sparteine.
DB09078
The metabolism of Tramadol can be decreased when combined with Lenvatinib.
DB09224
The metabolism of Tramadol can be decreased when combined with Melperone.
DB11638
The metabolism of Tramadol can be decreased when combined with Artenimol.
DB11994
The metabolism of Tramadol can be decreased when combined with Diacerein.
DB12523
The metabolism of Tramadol can be decreased when combined with Mizolastine.
DB13679
The metabolism of Tramadol can be decreased when combined with Dexchlorpheniramine.
DB00022
The metabolism of Tramadol can be decreased when combined with Peginterferon alfa-2b.
DB01195
The metabolism of Flecainide can be decreased when combined with Tramadol.
DB01131
The metabolism of Tramadol can be decreased when combined with Proguanil.
DB01623
The metabolism of Tramadol can be decreased when combined with Thiothixene.
DB00220
The metabolism of Nelfinavir can be decreased when combined with Tramadol.
DB01096
The metabolism of Tramadol can be decreased when combined with Oxamniquine.
DB09039
The metabolism of Tramadol can be decreased when combined with Eliglustat.
DB00238
The metabolism of Nevirapine can be decreased when combined with Tramadol.
DB00863
The metabolism of Tramadol can be decreased when combined with Ranitidine.
DB09065
The metabolism of Tramadol can be decreased when combined with Cobicistat.
DB11753
The metabolism of Tramadol can be decreased when combined with Rifamycin.
DB01062
The metabolism of Tramadol can be decreased when combined with Oxybutynin.
DB06370
The metabolism of Tramadol can be decreased when combined with Indisulam.
DB06412
The metabolism of Tramadol can be decreased when combined with Oxymetholone.
DB09049
The metabolism of Tramadol can be decreased when combined with Naloxegol.
DB09118
The metabolism of Tramadol can be decreased when combined with Stiripentol.
DB12245
The metabolism of Tramadol can be decreased when combined with Triclabendazole.
DB13975
The metabolism of Tramadol can be decreased when combined with Black cohosh.
DB14635
The metabolism of Tramadol can be decreased when combined with Curcumin sulfate.
DB06595
The metabolism of Tramadol can be decreased when combined with Midostaurin.
DB00627
The metabolism of Tramadol can be decreased when combined with Niacin.
DB02701
The metabolism of Tramadol can be decreased when combined with Nicotinamide.
DB08881
The metabolism of Tramadol can be decreased when combined with Vemurafenib.
DB11837
The metabolism of Osilodrostat can be decreased when combined with Tramadol.
DB12500
The metabolism of Tramadol can be decreased when combined with Fedratinib.
DB06731
The metabolism of Seproxetine can be decreased when combined with Tramadol.
DB06774
The metabolism of Tramadol can be decreased when combined with Capsaicin.
DB00599
The metabolism of Tramadol can be decreased when combined with Thiopental.
DB00819
The metabolism of Tramadol can be decreased when combined with Acetazolamide.
DB06458
The metabolism of Tramadol can be decreased when combined with Remacemide.
DB11400
The metabolism of Tramadol can be decreased when combined with Doramectin.
DB00502
The metabolism of Haloperidol can be decreased when combined with Tramadol.
DB00481
The metabolism of Tramadol can be decreased when combined with Raloxifene.
DB00778
The metabolism of Tramadol can be decreased when combined with Roxithromycin.
DB13950
The metabolism of Tramadol can be decreased when combined with WIN 55212-2.
DB00683
The metabolism of Midazolam can be decreased when combined with Tramadol.
DB00829
The metabolism of Diazepam can be decreased when combined with Tramadol.
DB01587
The metabolism of Ketazolam can be decreased when combined with Tramadol.
DB08811
The metabolism of Tofisopam can be decreased when combined with Tramadol.
DB09235
The metabolism of Efonidipine can be decreased when combined with Tramadol.
DB09036
The metabolism of Tramadol can be decreased when combined with Siltuximab.
DB00196
The metabolism of Tramadol can be decreased when combined with Fluconazole.
DB00199
The metabolism of Tramadol can be decreased when combined with Erythromycin.
DB00270
The metabolism of Tramadol can be decreased when combined with Isradipine.
DB00343
The metabolism of Tramadol can be decreased when combined with Diltiazem.
DB00678
The metabolism of Tramadol can be decreased when combined with Losartan.
DB00694
The metabolism of Tramadol can be decreased when combined with Daunorubicin.
DB00773
The metabolism of Tramadol can be decreased when combined with Etoposide.
DB00845
The metabolism of Tramadol can be decreased when combined with Clofazimine.
DB00916
The metabolism of Tramadol can be decreased when combined with Metronidazole.
DB01016
The metabolism of Tramadol can be decreased when combined with Glyburide.
DB01204
The metabolism of Tramadol can be decreased when combined with Mitoxantrone.
DB01259
The metabolism of Tramadol can be decreased when combined with Lapatinib.
DB01268
The metabolism of Tramadol can be decreased when combined with Sunitinib.
DB04905
The metabolism of Tramadol can be decreased when combined with Tesmilifene.
DB05928
The metabolism of Tramadol can be decreased when combined with Dovitinib.
DB06290
The metabolism of Tramadol can be decreased when combined with Simeprevir.
DB06616
The metabolism of Tramadol can be decreased when combined with Bosutinib.
DB06636
The metabolism of Tramadol can be decreased when combined with Isavuconazonium.
DB07348
The metabolism of Tramadol can be decreased when combined with Brefeldin A.
DB08820
The metabolism of Tramadol can be decreased when combined with Ivacaftor.
DB08865
The metabolism of Tramadol can be decreased when combined with Crizotinib.
DB08882
The metabolism of Tramadol can be decreased when combined with Linagliptin.
DB09048
The metabolism of Tramadol can be decreased when combined with Netupitant.
DB09073
The metabolism of Tramadol can be decreased when combined with Palbociclib.
DB11581
The metabolism of Tramadol can be decreased when combined with Venetoclax.
DB12015
The metabolism of Tramadol can be decreased when combined with Alpelisib.
DB12070
The metabolism of Tramadol can be decreased when combined with Letermovir.
DB13943
The metabolism of Tramadol can be decreased when combined with Testosterone cypionate.
DB13944
The metabolism of Tramadol can be decreased when combined with Testosterone enanthate.
DB13946
The metabolism of Tramadol can be decreased when combined with Testosterone undecanoate.
DB00104
The metabolism of Tramadol can be decreased when combined with Octreotide.
DB00255
The metabolism of Diethylstilbestrol can be decreased when combined with Tramadol.
DB00444
The metabolism of Teniposide can be decreased when combined with Tramadol.
DB00537
The metabolism of Ciprofloxacin can be decreased when combined with Tramadol.
DB00588
The metabolism of Fluticasone propionate can be decreased when combined with Tramadol.
DB00701
The metabolism of Amprenavir can be decreased when combined with Tramadol.
DB00759
The metabolism of Tetracycline can be decreased when combined with Tramadol.
DB01030
The metabolism of Topotecan can be decreased when combined with Tramadol.
DB01248
The metabolism of Docetaxel can be decreased when combined with Tramadol.
DB05773
The metabolism of Trastuzumab emtansine can be decreased when combined with Tramadol.
DB08906
The metabolism of Fluticasone furoate can be decreased when combined with Tramadol.
DB09063
The metabolism of Ceritinib can be decreased when combined with Tramadol.
DB09074
The metabolism of Olaparib can be decreased when combined with Tramadol.
DB09099
The metabolism of Somatostatin can be decreased when combined with Tramadol.
DB09330
The metabolism of Osimertinib can be decreased when combined with Tramadol.
DB11574
The metabolism of Elbasvir can be decreased when combined with Tramadol.
DB13867
The metabolism of Fluticasone can be decreased when combined with Tramadol.
DB00681
The metabolism of Tramadol can be decreased when combined with Amphotericin B.
DB00041
The metabolism of Tramadol can be decreased when combined with Aldesleukin.
DB00435
The metabolism of Nitric Oxide can be decreased when combined with Tramadol.
DB01011
The metabolism of Metyrapone can be decreased when combined with Tramadol.
DB01015
The metabolism of Sulfamethoxazole can be decreased when combined with Tramadol.
DB01181
The metabolism of Ifosfamide can be decreased when combined with Tramadol.
DB01275
The metabolism of Hydralazine can be decreased when combined with Tramadol.
DB01685
The metabolism of Topiroxostat can be decreased when combined with Tramadol.
DB04920
The metabolism of Clevidipine can be decreased when combined with Tramadol.
DB00530
The metabolism of Tramadol can be decreased when combined with Erlotinib.
DB00818
The metabolism of Tramadol can be decreased when combined with Propofol.
DB06589
The metabolism of Tramadol can be decreased when combined with Pazopanib.
DB08896
The metabolism of Tramadol can be decreased when combined with Regorafenib.
DB12010
The metabolism of Tramadol can be decreased when combined with Fostamatinib.
DB00224
The metabolism of Indinavir can be decreased when combined with Tramadol.
DB00637
The metabolism of Astemizole can be decreased when combined with Tramadol.
DB00864
The metabolism of Tacrolimus can be decreased when combined with Tramadol.
DB00872
The metabolism of Conivaptan can be decreased when combined with Tramadol.
DB01200
The metabolism of Bromocriptine can be decreased when combined with Tramadol.
DB01254
The metabolism of Dasatinib can be decreased when combined with Tramadol.
DB08827
The metabolism of Lomitapide can be decreased when combined with Tramadol.
DB00836
The metabolism of Tramadol can be decreased when combined with Loperamide.
DB01072
The metabolism of Tramadol can be decreased when combined with Atazanavir.
DB01167
The metabolism of Tramadol can be decreased when combined with Itraconazole.
DB01211
The metabolism of Tramadol can be decreased when combined with Clarithromycin.
DB01234
The metabolism of Tramadol can be decreased when combined with Dexamethasone.
DB01263
The metabolism of Tramadol can be decreased when combined with Posaconazole.
DB05521
The metabolism of Tramadol can be decreased when combined with Telaprevir.
DB08873
The metabolism of Tramadol can be decreased when combined with Boceprevir.
DB09054
The metabolism of Tramadol can be decreased when combined with Idelalisib.
DB13179
The metabolism of Tramadol can be decreased when combined with Troleandomycin.
DB00582
The metabolism of Tramadol can be decreased when combined with Voriconazole.
DB00625
The metabolism of Tramadol can be decreased when combined with Efavirenz.
DB01394
The metabolism of Tramadol can be decreased when combined with Colchicine.
DB00776
The metabolism of Oxcarbazepine can be decreased when combined with Tramadol.
DB01183
The metabolism of Naloxone can be decreased when combined with Tramadol.
DB01095
The metabolism of Tramadol can be decreased when combined with Fluvastatin.
DB13941
The metabolism of Tramadol can be decreased when combined with Piperaquine.
DB01071
The metabolism of Mequitazine can be decreased when combined with Tramadol.
DB00668
The metabolism of Epinephrine can be decreased when combined with Tramadol.
DB00259
The metabolism of Tramadol can be decreased when combined with Sulfanilamide.
DB00353
The metabolism of Tramadol can be decreased when combined with Methylergometrine.
DB00446
The metabolism of Tramadol can be decreased when combined with Chloramphenicol.
DB00549
The metabolism of Tramadol can be decreased when combined with Zafirlukast.
DB00673
The metabolism of Tramadol can be decreased when combined with Aprepitant.
DB00954
The metabolism of Tramadol can be decreased when combined with Dirithromycin.
DB00976
The metabolism of Tramadol can be decreased when combined with Telithromycin.
DB01007
The metabolism of Tramadol can be decreased when combined with Tioconazole.
DB01029
The metabolism of Tramadol can be decreased when combined with Irbesartan.
DB01059
The metabolism of Tramadol can be decreased when combined with Norfloxacin.
DB01085
The metabolism of Tramadol can be decreased when combined with Pilocarpine.
DB01127
The metabolism of Tramadol can be decreased when combined with Econazole.
DB01152
The metabolism of Tramadol can be decreased when combined with Candicidin.
DB01369
The metabolism of Tramadol can be decreased when combined with Quinupristin.
DB01384
The metabolism of Tramadol can be decreased when combined with Paramethasone.
DB01406
The metabolism of Tramadol can be decreased when combined with Danazol.
DB01698
The metabolism of Tramadol can be decreased when combined with Rutin.
DB01764
The metabolism of Tramadol can be decreased when combined with Dalfopristin.
DB01873
The metabolism of Tramadol can be decreased when combined with Epothilone D.
DB02520
The metabolism of Tramadol can be decreased when combined with Ditiocarb.
DB02709
The metabolism of Tramadol can be decreased when combined with Resveratrol.
DB03010
The metabolism of Tramadol can be decreased when combined with Patupilone.
DB04070
The metabolism of Tramadol can be decreased when combined with 6-Deoxyerythronolide B.
DB04839
The metabolism of Tramadol can be decreased when combined with Cyproterone acetate.
DB04894
The metabolism of Tramadol can be decreased when combined with Vapreotide.
DB05482
The metabolism of Tramadol can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
DB05814
The metabolism of Tramadol can be decreased when combined with GPI-1485.
DB05903
The metabolism of Tramadol can be decreased when combined with KOS-1584.
DB06174
The metabolism of Tramadol can be decreased when combined with Noscapine.
DB06233
The metabolism of Tramadol can be decreased when combined with Ridaforolimus.
DB06268
The metabolism of Tramadol can be decreased when combined with Sitaxentan.
DB06318
The metabolism of Tramadol can be decreased when combined with AVE9633.
DB06342
The metabolism of Tramadol can be decreased when combined with Coltuximab ravtansine.
DB06419
The metabolism of Tramadol can be decreased when combined with Cethromycin.
DB06469
The metabolism of Tramadol can be decreased when combined with Lestaurtinib.
DB06587
The metabolism of Tramadol can be decreased when combined with Mitemcinal.
DB06663
The metabolism of Tramadol can be decreased when combined with Pasireotide.
DB06712
The metabolism of Tramadol can be decreased when combined with Nilvadipine.
DB06717
The metabolism of Tramadol can be decreased when combined with Fosaprepitant.
DB06791
The metabolism of Tramadol can be decreased when combined with Lanreotide.
DB08870
The metabolism of Tramadol can be decreased when combined with Brentuximab vedotin.
DB09101
The metabolism of Tramadol can be decreased when combined with Elvitegravir.
DB09227
The metabolism of Tramadol can be decreased when combined with Barnidipine.
DB09231
The metabolism of Tramadol can be decreased when combined with Benidipine.
DB09308
The metabolism of Tramadol can be decreased when combined with Solithromycin.
DB09309
The metabolism of Tramadol can be decreased when combined with Kitasamycin.
DB11198
The metabolism of Tramadol can be decreased when combined with Peppermint oil.
DB11383
The metabolism of Tramadol can be decreased when combined with Carbomycin.
DB11405
The metabolism of Tramadol can be decreased when combined with Eprinomectin.
DB11442
The metabolism of Tramadol can be decreased when combined with Oleandomycin.
DB11459
The metabolism of Tramadol can be decreased when combined with Selamectin.
DB11470
The metabolism of Tramadol can be decreased when combined with Tildipirosin.
DB11471
The metabolism of Tramadol can be decreased when combined with Tilmicosin.
DB11475
The metabolism of Tramadol can be decreased when combined with Tylosin.
DB11554
The metabolism of Tramadol can be decreased when combined with Tylvalosin.
DB11703
The metabolism of Tramadol can be decreased when combined with Acalabrutinib.
DB11730
The metabolism of Tramadol can be decreased when combined with Ribociclib.
DB11752
The metabolism of Tramadol can be decreased when combined with Bryostatin 1.
DB11767
The metabolism of Tramadol can be decreased when combined with Sarilumab.
DB11779
The metabolism of Tramadol can be decreased when combined with Danoprevir.
DB11805
The metabolism of Tramadol can be decreased when combined with Saracatinib.
DB12089
The metabolism of Tramadol can be decreased when combined with Lorvotuzumab mertansine.
DB12266
The metabolism of Tramadol can be decreased when combined with Epofolate.
DB12391
The metabolism of Tramadol can be decreased when combined with Sagopilone.
DB12489
The metabolism of Tramadol can be decreased when combined with Mirvetuximab Soravtansine.
DB12532
The metabolism of Tramadol can be decreased when combined with Oxetacaine.
DB13338
The metabolism of Tramadol can be decreased when combined with Flurithromycin.
DB13409
The metabolism of Tramadol can be decreased when combined with Rokitamycin.
DB13456
The metabolism of Tramadol can be decreased when combined with Midecamycin.
DB13633
The metabolism of Tramadol can be decreased when combined with Mepartricin.
DB14019
The metabolism of Tramadol can be decreased when combined with Fosnetupitant.
DB00243
The metabolism of Tramadol can be decreased when combined with Ranolazine.
DB11633
The metabolism of Tramadol can be decreased when combined with Isavuconazole.
DB01601
The metabolism of Tramadol can be decreased when combined with Lopinavir.
DB04794
The metabolism of Tramadol can be decreased when combined with Bifonazole.
DB00337
The metabolism of Tramadol can be decreased when combined with Pimecrolimus.
DB15822
The metabolism of Tramadol can be decreased when combined with Pralsetinib.
DB14761
The metabolism of Tramadol can be decreased when combined with Remdesivir.
DB06448
The metabolism of Tramadol can be decreased when combined with Lonafarnib.
DB08883
The metabolism of Tramadol can be increased when combined with Perampanel.
DB06201
The metabolism of Tramadol can be increased when combined with Rufinamide.
DB00082
The metabolism of Pegvisomant can be increased when combined with Tramadol.
DB01221
The metabolism of Tramadol can be increased when combined with Ketamine.
DB00241
The metabolism of Tramadol can be increased when combined with Butalbital.
DB00418
The metabolism of Tramadol can be increased when combined with Secobarbital.
DB00474
The metabolism of Tramadol can be increased when combined with Methohexital.
DB00754
The metabolism of Tramadol can be increased when combined with Ethotoin.
DB00849
The metabolism of Tramadol can be increased when combined with Methylphenobarbital.
DB00949
The metabolism of Tramadol can be increased when combined with Felbamate.
DB01351
The metabolism of Tramadol can be increased when combined with Amobarbital.
DB01352
The metabolism of Tramadol can be increased when combined with Aprobarbital.
DB01483
The metabolism of Tramadol can be increased when combined with Barbital.
DB09001
The metabolism of Tramadol can be increased when combined with Barbexaclone.
DB09119
The metabolism of Tramadol can be increased when combined with Eslicarbazepine acetate.
DB14575
The metabolism of Tramadol can be increased when combined with Eslicarbazepine.
DB00531
The metabolism of Cyclophosphamide can be increased when combined with Tramadol.
DB06697
The metabolism of Artemether can be increased when combined with Tramadol.
DB06739
The metabolism of Seratrodast can be increased when combined with Tramadol.
DB06273
The metabolism of Tramadol can be increased when combined with Tocilizumab.
DB09280
The metabolism of Tramadol can be increased when combined with Lumacaftor.
DB00396
The metabolism of Tramadol can be increased when combined with Progesterone.
DB00624
The metabolism of Tramadol can be increased when combined with Testosterone.
DB01645
The metabolism of Tramadol can be increased when combined with Genistein.
DB14568
The metabolism of Tramadol can be increased when combined with Ivosidenib.
DB00443
The metabolism of Betamethasone can be increased when combined with Tramadol.
DB00741
The metabolism of Hydrocortisone can be increased when combined with Tramadol.
DB00860
The metabolism of Prednisolone can be increased when combined with Tramadol.
DB00959
The metabolism of Methylprednisolone can be increased when combined with Tramadol.
DB08912
The metabolism of Dabrafenib can be increased when combined with Tramadol.
DB13952
The metabolism of Estradiol acetate can be increased when combined with Tramadol.
DB13953
The metabolism of Estradiol benzoate can be increased when combined with Tramadol.
DB13954
The metabolism of Estradiol cypionate can be increased when combined with Tramadol.
DB13955
The metabolism of Estradiol dienanthate can be increased when combined with Tramadol.
DB13956
The metabolism of Estradiol valerate can be increased when combined with Tramadol.
DB00533
The metabolism of Tramadol can be increased when combined with Rofecoxib.
DB00812
The metabolism of Tramadol can be increased when combined with Phenylbutazone.
DB01333
The metabolism of Tramadol can be increased when combined with Cefradine.
DB04817
The metabolism of Tramadol can be increased when combined with Metamizole.
DB00591
The metabolism of Fluocinolone acetonide can be increased when combined with Tramadol.
DB00603
The metabolism of Medroxyprogesterone acetate can be increased when combined with Tramadol.
DB08905
The metabolism of Formestane can be increased when combined with Tramadol.
DB08911
The metabolism of Trametinib can be increased when combined with Tramadol.
DB11943
The metabolism of Delafloxacin can be increased when combined with Tramadol.
DB01032
The metabolism of Tramadol can be increased when combined with Probenecid.
DB01609
The metabolism of Tramadol can be increased when combined with Deferasirox.
DB04911
The metabolism of Tramadol can be increased when combined with Oritavancin.
DB06413
The metabolism of Tramadol can be increased when combined with Armodafinil.
DB01229
The metabolism of Paclitaxel can be increased when combined with Tramadol.
DB12130
The metabolism of Tramadol can be increased when combined with Lorlatinib.
DB00648
The metabolism of Tramadol can be increased when combined with Mitotane.
DB01045
The metabolism of Tramadol can be increased when combined with Rifampicin.
DB08899
The metabolism of Tramadol can be increased when combined with Enzalutamide.
DB00745
The metabolism of Tramadol can be increased when combined with Modafinil.
DB00252
The metabolism of Phenytoin can be increased when combined with Tramadol.
DB01174
The metabolism of Phenobarbital can be increased when combined with Tramadol.
DB00394
The metabolism of Beclomethasone dipropionate can be increased when combined with Tramadol.
DB01222
The metabolism of Budesonide can be increased when combined with Tramadol.
DB00197
The metabolism of Tramadol can be increased when combined with Troglitazone.
DB01138
The metabolism of Tramadol can be increased when combined with Sulfinpyrazone.
DB01201
The metabolism of Tramadol can be increased when combined with Rifapentine.
DB00312
The metabolism of Tramadol can be increased when combined with Pentobarbital.
DB00794
The metabolism of Tramadol can be increased when combined with Primidone.
DB01320
The metabolism of Tramadol can be increased when combined with Fosphenytoin.
DB00615
The metabolism of Tramadol can be increased when combined with Rifabutin.
DB00136
The metabolism of Tramadol can be increased when combined with Calcitriol.
DB00163
The metabolism of Tramadol can be increased when combined with Vitamin E.
DB00180
The metabolism of Tramadol can be increased when combined with Flunisolide.
DB00301
The metabolism of Tramadol can be increased when combined with Flucloxacillin.
DB00307
The metabolism of Tramadol can be increased when combined with Bexarotene.
DB00357
The metabolism of Tramadol can be increased when combined with Aminoglutethimide.
DB00400
The metabolism of Tramadol can be increased when combined with Griseofulvin.
DB00485
The metabolism of Tramadol can be increased when combined with Dicloxacillin.
DB00559
The metabolism of Tramadol can be increased when combined with Bosentan.
DB00607
The metabolism of Tramadol can be increased when combined with Nafcillin.
DB00620
The metabolism of Tramadol can be increased when combined with Triamcinolone.
DB00636
The metabolism of Tramadol can be increased when combined with Clofibrate.
DB00769
The metabolism of Tramadol can be increased when combined with Hydrocortamate.
DB00957
The metabolism of Tramadol can be increased when combined with Norgestimate.
DB01083
The metabolism of Tramadol can be increased when combined with Orlistat.
DB01220
The metabolism of Tramadol can be increased when combined with Rifaximin.
DB01285
The metabolism of Tramadol can be increased when combined with Corticotropin.
DB01380
The metabolism of Tramadol can be increased when combined with Cortisone acetate.
DB06414
The metabolism of Tramadol can be increased when combined with Etravirine.
DB06442
The metabolism of Tramadol can be increased when combined with Avasimibe.
DB11487
The metabolism of Tramadol can be increased when combined with Dexamethasone isonicotinate.
DB12267
The metabolism of Tramadol can be increased when combined with Brigatinib.
DB14539
The metabolism of Tramadol can be increased when combined with Hydrocortisone acetate.
DB14545
The metabolism of Tramadol can be increased when combined with Hydrocortisone succinate.
DB11901
The metabolism of Apalutamide can be increased when combined with Tramadol.
DB01115
The metabolism of Nifedipine can be increased when combined with Tramadol.
DB01013
The metabolism of Tramadol can be increased when combined with Clobetasol propionate.
DB14540
The metabolism of Tramadol can be increased when combined with Hydrocortisone butyrate.
DB00764
The metabolism of Tramadol can be increased when combined with Mometasone.
DB11750
The metabolism of Tramadol can be increased when combined with Clobetasol.
DB15566
The metabolism of Tramadol can be increased when combined with Prednisolone acetate.
DB00450
The risk or severity of CNS depression can be increased when Droperidol is combined with Tramadol.
DB09117
The risk or severity of CNS depression can be increased when Tramadol is combined with Paraldehyde.
DB00268
The risk or severity of CNS depression can be increased when Tramadol is combined with Ropinirole.
DB09072
The risk or severity of CNS depression can be increased when Sodium oxybate is combined with Tramadol.
DB01452
The risk or severity of CNS depression can be increased when Tramadol is combined with Diamorphine.
DB01531
The risk or severity of CNS depression can be increased when Tramadol is combined with Desomorphine.
DB15360
The risk or severity of CNS depression can be increased when Tramadol is combined with Carfentanil, C-11.
DB00202
The risk or severity of CNS depression can be increased when Succinylcholine is combined with Tramadol.
DB00969
The risk or severity of CNS depression can be increased when Alosetron is combined with Tramadol.
DB11699
The risk or severity of CNS depression can be increased when Tropisetron is combined with Tramadol.
DB00391
The risk or severity of CNS depression can be increased when Tramadol is combined with Sulpiride.
DB00042
The risk or severity of CNS depression can be increased when Tramadol is combined with Botulinum Toxin Type B.
DB09290
The risk or severity of CNS depression can be increased when Tramadol is combined with Ramosetron.
DB00484
The risk or severity of CNS depression can be increased when Brimonidine is combined with Tramadol.
DB00372
The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Tramadol.
DB00433
The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Tramadol.
DB00680
The risk or severity of CNS depression can be increased when Moricizine is combined with Tramadol.
DB00831
The risk or severity of CNS depression can be increased when Trifluoperazine is combined with Tramadol.
DB00933
The risk or severity of CNS depression can be increased when Mesoridazine is combined with Tramadol.
DB01063
The risk or severity of CNS depression can be increased when Acetophenazine is combined with Tramadol.
DB01246
The risk or severity of CNS depression can be increased when Alimemazine is combined with Tramadol.
DB01608
The risk or severity of CNS depression can be increased when Periciazine is combined with Tramadol.
DB01614
The risk or severity of CNS depression can be increased when Acepromazine is combined with Tramadol.
DB01615
The risk or severity of CNS depression can be increased when Aceprometazine is combined with Tramadol.
DB01622
The risk or severity of CNS depression can be increased when Thioproperazine is combined with Tramadol.
DB05687
The risk or severity of CNS depression can be increased when BL-1020 is combined with Tramadol.
DB09000
The risk or severity of CNS depression can be increased when Cyamemazine is combined with Tramadol.
DB11540
The risk or severity of CNS depression can be increased when Propiopromazine is combined with Tramadol.
DB12710
The risk or severity of CNS depression can be increased when Perazine is combined with Tramadol.
DB13213
The risk or severity of CNS depression can be increased when Butaperazine is combined with Tramadol.
DB13382
The risk or severity of CNS depression can be increased when Chlorproethazine is combined with Tramadol.
DB13420
The risk or severity of CNS depression can be increased when Thiazinam is combined with Tramadol.
DB13784
The risk or severity of CNS depression can be increased when Dixyrazine is combined with Tramadol.
DB14651
The risk or severity of CNS depression can be increased when Perphenazine enanthate is combined with Tramadol.
DB00483
The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Tramadol.
DB00508
The risk or severity of CNS depression can be increased when Triflupromazine is combined with Tramadol.
DB00941
The risk or severity of CNS depression can be increased when Hexafluronium is combined with Tramadol.
DB01199
The risk or severity of CNS depression can be increased when Tubocurarine is combined with Tramadol.
DB01245
The risk or severity of CNS depression can be increased when Decamethonium is combined with Tramadol.
DB01337
The risk or severity of CNS depression can be increased when Pancuronium is combined with Tramadol.
DB01338
The risk or severity of CNS depression can be increased when Pipecuronium is combined with Tramadol.
DB00181
The risk or severity of CNS depression can be increased when Baclofen is combined with Tramadol.
DB00189
The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Tramadol.
DB00434
The risk or severity of CNS depression can be increased when Tramadol is combined with Cyproheptadine.
DB00728
The risk or severity of CNS depression can be increased when Tramadol is combined with Rocuronium.
DB00771
The risk or severity of CNS depression can be increased when Tramadol is combined with Clidinium.
DB00777
The risk or severity of CNS depression can be increased when Tramadol is combined with Propiomazine.
DB00835
The risk or severity of CNS depression can be increased when Tramadol is combined with Brompheniramine.
DB01135
The risk or severity of CNS depression can be increased when Tramadol is combined with Doxacurium.
DB01226
The risk or severity of CNS depression can be increased when Tramadol is combined with Mivacurium.
DB01336
The risk or severity of CNS depression can be increased when Tramadol is combined with Metocurine.
DB04834
The risk or severity of CNS depression can be increased when Tramadol is combined with Rapacuronium.
DB09023
The risk or severity of CNS depression can be increased when Tramadol is combined with Benactyzine.
DB13505
The risk or severity of CNS depression can be increased when Tramadol is combined with Emepronium.
DB00228
The risk or severity of CNS depression can be increased when Enflurane is combined with Tramadol.
DB00237
The risk or severity of CNS depression can be increased when Butabarbital is combined with Tramadol.
DB00292
The risk or severity of CNS depression can be increased when Etomidate is combined with Tramadol.
DB00306
The risk or severity of CNS depression can be increased when Talbutal is combined with Tramadol.
DB00323
The risk or severity of CNS depression can be increased when Tolcapone is combined with Tramadol.
DB00341
The risk or severity of CNS depression can be increased when Cetirizine is combined with Tramadol.
DB00347
The risk or severity of CNS depression can be increased when Trimethadione is combined with Tramadol.
DB00356
The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Tramadol.
DB00371
The risk or severity of CNS depression can be increased when Meprobamate is combined with Tramadol.
DB00405
The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Tramadol.
DB00409
The risk or severity of CNS depression can be increased when Remoxipride is combined with Tramadol.
DB00416
The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Tramadol.
DB00423
The risk or severity of CNS depression can be increased when Methocarbamol is combined with Tramadol.
DB00427
The risk or severity of CNS depression can be increased when Triprolidine is combined with Tramadol.
DB00463
The risk or severity of CNS depression can be increased when Metharbital is combined with Tramadol.
DB00565
The risk or severity of CNS depression can be increased when Cisatracurium is combined with Tramadol.
DB00617
The risk or severity of CNS depression can be increased when Paramethadione is combined with Tramadol.
DB00645
The risk or severity of CNS depression can be increased when Dyclonine is combined with Tramadol.
DB00662
The risk or severity of CNS depression can be increased when Trimethobenzamide is combined with Tramadol.
DB00697
The risk or severity of CNS depression can be increased when Tizanidine is combined with Tramadol.
DB00732
The risk or severity of CNS depression can be increased when Atracurium besylate is combined with Tramadol.
DB00737
The risk or severity of CNS depression can be increased when Meclizine is combined with Tramadol.
DB00740
The risk or severity of CNS depression can be increased when Riluzole is combined with Tramadol.
DB00748
The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Tramadol.
DB00832
The risk or severity of CNS depression can be increased when Phensuximide is combined with Tramadol.
DB00837
The risk or severity of CNS depression can be increased when Progabide is combined with Tramadol.
DB00906
The risk or severity of CNS depression can be increased when Tiagabine is combined with Tramadol.
DB00909
The risk or severity of CNS depression can be increased when Zonisamide is combined with Tramadol.
DB00962
The risk or severity of CNS depression can be increased when Zaleplon is combined with Tramadol.
DB00980
The risk or severity of CNS depression can be increased when Ramelteon is combined with Tramadol.
DB00985
The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with Tramadol.
DB00996
The risk or severity of CNS depression can be increased when Gabapentin is combined with Tramadol.
DB01018
The risk or severity of CNS depression can be increased when Guanfacine is combined with Tramadol.
DB01028
The risk or severity of CNS depression can be increased when Methoxyflurane is combined with Tramadol.
DB01065
The risk or severity of CNS depression can be increased when Melatonin is combined with Tramadol.
DB01080
The risk or severity of CNS depression can be increased when Vigabatrin is combined with Tramadol.
DB01106
The risk or severity of CNS depression can be increased when Levocabastine is combined with Tramadol.
DB01107
The risk or severity of CNS depression can be increased when Methyprylon is combined with Tramadol.
DB01121
The risk or severity of CNS depression can be increased when Phenacemide is combined with Tramadol.
DB01154
The risk or severity of CNS depression can be increased when Thiamylal is combined with Tramadol.
DB01159
The risk or severity of CNS depression can be increased when Halothane is combined with Tramadol.
DB01176
The risk or severity of CNS depression can be increased when Cyclizine is combined with Tramadol.
DB01178
The risk or severity of CNS depression can be increased when Chlormezanone is combined with Tramadol.
DB01189
The risk or severity of CNS depression can be increased when Desflurane is combined with Tramadol.
DB01198
The risk or severity of CNS depression can be increased when Zopiclone is combined with Tramadol.
DB01219
The risk or severity of CNS depression can be increased when Dantrolene is combined with Tramadol.
DB01236
The risk or severity of CNS depression can be increased when Sevoflurane is combined with Tramadol.
DB01353
The risk or severity of CNS depression can be increased when Butobarbital is combined with Tramadol.
DB01354
The risk or severity of CNS depression can be increased when Heptabarbital is combined with Tramadol.
DB01355
The risk or severity of CNS depression can be increased when Hexobarbital is combined with Tramadol.
DB01437
The risk or severity of CNS depression can be increased when Glutethimide is combined with Tramadol.
DB01440
The risk or severity of CNS depression can be increased when gamma-Hydroxybutyric acid is combined with Tramadol.
DB01445
The risk or severity of CNS depression can be increased when Bufotenine is combined with Tramadol.
DB01463
The risk or severity of CNS depression can be increased when Fencamfamin is combined with Tramadol.
DB01472
The risk or severity of CNS depression can be increased when 4-Methoxyamphetamine is combined with Tramadol.
DB01495
The risk or severity of CNS depression can be increased when Dichloralphenazone is combined with Tramadol.
DB01501
The risk or severity of CNS depression can be increased when Difenoxin is combined with Tramadol.
DB01534
The risk or severity of CNS depression can be increased when Chlorhexadol is combined with Tramadol.
DB01547
The risk or severity of CNS depression can be increased when Drotebanol is combined with Tramadol.
DB01560
The risk or severity of CNS depression can be increased when Cathinone is combined with Tramadol.
DB01563
The risk or severity of CNS depression can be increased when Chloral hydrate is combined with Tramadol.
DB01618
The risk or severity of CNS depression can be increased when Molindone is combined with Tramadol.
DB01954
The risk or severity of CNS depression can be increased when Rolipram is combined with Tramadol.
DB02207
The risk or severity of CNS depression can be increased when 7-Nitroindazole is combined with Tramadol.
DB02234
The risk or severity of CNS depression can be increased when S-Ethylisothiourea is combined with Tramadol.
DB02852
The risk or severity of CNS depression can be increased when Domoic Acid is combined with Tramadol.
DB02959
The risk or severity of CNS depression can be increased when Oxitriptan is combined with Tramadol.
DB04165
The risk or severity of CNS depression can be increased when Valpromide is combined with Tramadol.
DB04325
The risk or severity of CNS depression can be increased when Phenethylamine is combined with Tramadol.
DB04599
The risk or severity of CNS depression can be increased when Aniracetam is combined with Tramadol.
DB04819
The risk or severity of CNS depression can be increased when Methapyrilene is combined with Tramadol.
DB04827
The risk or severity of CNS depression can be increased when Urethane is combined with Tramadol.
DB04833
The risk or severity of CNS depression can be increased when Methaqualone is combined with Tramadol.
DB04841
The risk or severity of CNS depression can be increased when Flunarizine is combined with Tramadol.
DB04872
The risk or severity of CNS depression can be increased when Osanetant is combined with Tramadol.
DB04888
The risk or severity of CNS depression can be increased when Bifeprunox is combined with Tramadol.
DB04903
The risk or severity of CNS depression can be increased when Pagoclone is combined with Tramadol.
DB04953
The risk or severity of CNS depression can be increased when Ezogabine is combined with Tramadol.
DB05232
The risk or severity of CNS depression can be increased when Tetrodotoxin is combined with Tramadol.
DB05246
The risk or severity of CNS depression can be increased when Methsuximide is combined with Tramadol.
DB05541
The risk or severity of CNS depression can be increased when Brivaracetam is combined with Tramadol.
DB05710
The risk or severity of CNS depression can be increased when Gantacurium is combined with Tramadol.
DB06077
The risk or severity of CNS depression can be increased when Lumateperone is combined with Tramadol.
DB06218
The risk or severity of CNS depression can be increased when Lacosamide is combined with Tramadol.
DB06264
The risk or severity of CNS depression can be increased when Tolperisone is combined with Tramadol.
DB06282
The risk or severity of CNS depression can be increased when Levocetirizine is combined with Tramadol.
DB06283
The risk or severity of CNS depression can be increased when Ziconotide is combined with Tramadol.
DB06288
The risk or severity of CNS depression can be increased when Amisulpride is combined with Tramadol.
DB06470
The risk or severity of CNS depression can be increased when Clomethiazole is combined with Tramadol.
DB06527
The risk or severity of CNS depression can be increased when Tramiprosate is combined with Tramadol.
DB06529
The risk or severity of CNS depression can be increased when Ocinaplon is combined with Tramadol.
DB06554
The risk or severity of CNS depression can be increased when Gaboxadol is combined with Tramadol.
DB06579
The risk or severity of CNS depression can be increased when Adipiplon is combined with Tramadol.
DB06582
The risk or severity of CNS depression can be increased when Dextofisopam is combined with Tramadol.
DB06690
The risk or severity of CNS depression can be increased when Nitrous oxide is combined with Tramadol.
DB06716
The risk or severity of CNS depression can be increased when Fospropofol is combined with Tramadol.
DB06753
The risk or severity of CNS depression can be increased when Triclofos is combined with Tramadol.
DB06797
The risk or severity of CNS depression can be increased when Mebutamate is combined with Tramadol.
DB08329
The risk or severity of CNS depression can be increased when Sulthiame is combined with Tramadol.
DB08872
The risk or severity of CNS depression can be increased when Gabapentin enacarbil is combined with Tramadol.
DB08892
The risk or severity of CNS depression can be increased when Arbaclofen Placarbil is combined with Tramadol.
DB08922
The risk or severity of CNS depression can be increased when Perospirone is combined with Tramadol.
DB08954
The risk or severity of CNS depression can be increased when Ifenprodil is combined with Tramadol.
DB08960
The risk or severity of CNS depression can be increased when Hexamethonium is combined with Tramadol.
DB08986
The risk or severity of CNS depression can be increased when Etifoxine is combined with Tramadol.
DB08992
The risk or severity of CNS depression can be increased when Eperisone is combined with Tramadol.
DB09011
The risk or severity of CNS depression can be increased when Beclamide is combined with Tramadol.
DB09021
The risk or severity of CNS depression can be increased when Benzoctamine is combined with Tramadol.
DB09071
The risk or severity of CNS depression can be increased when Tasimelteon is combined with Tramadol.
DB09226
The risk or severity of CNS depression can be increased when Brilaroxazine is combined with Tramadol.
DB11156
The risk or severity of CNS depression can be increased when Pyrantel is combined with Tramadol.
DB11371
The risk or severity of CNS depression can be increased when Alfaxalone is combined with Tramadol.
DB11376
The risk or severity of CNS depression can be increased when Azaperone is combined with Tramadol.
DB11428
The risk or severity of CNS depression can be increased when Medetomidine is combined with Tramadol.
DB11477
The risk or severity of CNS depression can be increased when Xylazine is combined with Tramadol.
DB11543
The risk or severity of CNS depression can be increased when Romifidine is combined with Tramadol.
DB11549
The risk or severity of CNS depression can be increased when Tiletamine is combined with Tramadol.
DB11552
The risk or severity of CNS depression can be increased when Tricaine is combined with Tramadol.
DB11555
The risk or severity of CNS depression can be increased when Zolazepam is combined with Tramadol.
DB11556
The risk or severity of CNS depression can be increased when Detomidine is combined with Tramadol.
DB11582
The risk or severity of CNS depression can be increased when Thiocolchicoside is combined with Tramadol.
DB11664
The risk or severity of CNS depression can be increased when Psilocybin is combined with Tramadol.
DB11859
The risk or severity of CNS depression can be increased when Brexanolone is combined with Tramadol.
DB11868
The risk or severity of CNS depression can be increased when Etiracetam is combined with Tramadol.
DB12093
The risk or severity of CNS depression can be increased when Tetrahydropalmatine is combined with Tramadol.
DB12105
The risk or severity of CNS depression can be increased when Imagabalin is combined with Tramadol.
DB12131
The risk or severity of CNS depression can be increased when Vinpocetine is combined with Tramadol.
DB12273
The risk or severity of CNS depression can be increased when Ecopipam is combined with Tramadol.
DB12308
The risk or severity of CNS depression can be increased when Eltanolone is combined with Tramadol.
DB12327
The risk or severity of CNS depression can be increased when Salvinorin A is combined with Tramadol.
DB12338
The risk or severity of CNS depression can be increased when Carisbamate is combined with Tramadol.
DB12518
The risk or severity of CNS depression can be increased when Raclopride is combined with Tramadol.
DB12576
The risk or severity of CNS depression can be increased when AZD-3043 is combined with Tramadol.
DB12590
The risk or severity of CNS depression can be increased when Indiplon is combined with Tramadol.
DB12867
The risk or severity of CNS depression can be increased when Benperidol is combined with Tramadol.
DB12958
The risk or severity of CNS depression can be increased when Prothipendyl is combined with Tramadol.
DB12989
The risk or severity of CNS depression can be increased when Neosaxitoxin is combined with Tramadol.
DB13014
The risk or severity of CNS depression can be increased when Hypericin is combined with Tramadol.
DB13025
The risk or severity of CNS depression can be increased when Tiapride is combined with Tramadol.
DB13082
The risk or severity of CNS depression can be increased when Nefiracetam is combined with Tramadol.
DB13099
The risk or severity of CNS depression can be increased when Valnoctamide is combined with Tramadol.
DB13221
The risk or severity of CNS depression can be increased when Apronalide is combined with Tramadol.
DB13234
The risk or severity of CNS depression can be increased when Propanidid is combined with Tramadol.
DB13253
The risk or severity of CNS depression can be increased when Proxibarbal is combined with Tramadol.
DB13256
The risk or severity of CNS depression can be increased when Clothiapine is combined with Tramadol.
DB13273
The risk or severity of CNS depression can be increased when Sultopride is combined with Tramadol.
DB13295
The risk or severity of CNS depression can be increased when Atracurium is combined with Tramadol.
DB13303
The risk or severity of CNS depression can be increased when Febarbamate is combined with Tramadol.
DB13323
The risk or severity of CNS depression can be increased when Trichloroethylene is combined with Tramadol.
DB13324
The risk or severity of CNS depression can be increased when Tetrazepam is combined with Tramadol.
DB13331
The risk or severity of CNS depression can be increased when Pyrithyldione is combined with Tramadol.
DB13352
The risk or severity of CNS depression can be increased when Deanol is combined with Tramadol.
DB13354
The risk or severity of CNS depression can be increased when Phenprobamate is combined with Tramadol.
DB13357
The risk or severity of CNS depression can be increased when Styramate is combined with Tramadol.
DB13362
The risk or severity of CNS depression can be increased when Pheneturide is combined with Tramadol.
DB13370
The risk or severity of CNS depression can be increased when Bromisoval is combined with Tramadol.
DB13377
The risk or severity of CNS depression can be increased when Vinbarbital is combined with Tramadol.
DB13396
The risk or severity of CNS depression can be increased when Neocitrullamon is combined with Tramadol.
DB13402
The risk or severity of CNS depression can be increased when Acetylglycinamide chloral hydrate is combined with Tramadol.
DB13403
The risk or severity of CNS depression can be increased when Oxypertine is combined with Tramadol.
DB13414
The risk or severity of CNS depression can be increased when Fenyramidol is combined with Tramadol.
DB13455
The risk or severity of CNS depression can be increased when Phenibut is combined with Tramadol.
DB13522
The risk or severity of CNS depression can be increased when Mebicar is combined with Tramadol.
DB13523
The risk or severity of CNS depression can be increased when Veralipride is combined with Tramadol.
DB13534
The risk or severity of CNS depression can be increased when Gedocarnil is combined with Tramadol.
DB13552
The risk or severity of CNS depression can be increased when Trifluperidol is combined with Tramadol.
DB13554
The risk or severity of CNS depression can be increased when Moperone is combined with Tramadol.
DB13557
The risk or severity of CNS depression can be increased when Thiopropazate is combined with Tramadol.
DB13572
The risk or severity of CNS depression can be increased when Emylcamate is combined with Tramadol.
DB13577
The risk or severity of CNS depression can be increased when Allobarbital is combined with Tramadol.
DB13584
The risk or severity of CNS depression can be increased when Gallamine is combined with Tramadol.
DB13601
The risk or severity of CNS depression can be increased when Oxiracetam is combined with Tramadol.
DB13623
The risk or severity of CNS depression can be increased when Fabomotizole is combined with Tramadol.
DB13642
The risk or severity of CNS depression can be increased when Pridinol is combined with Tramadol.
DB13648
The risk or severity of CNS depression can be increased when Alcuronium is combined with Tramadol.
DB13662
The risk or severity of CNS depression can be increased when Hexapropymate is combined with Tramadol.
DB13665
The risk or severity of CNS depression can be increased when Fluanisone is combined with Tramadol.
DB13676
The risk or severity of CNS depression can be increased when Mosapramine is combined with Tramadol.
DB13687
The risk or severity of CNS depression can be increased when Niaprazine is combined with Tramadol.
DB13690
The risk or severity of CNS depression can be increased when Vinyl ether is combined with Tramadol.
DB13733
The risk or severity of CNS depression can be increased when Methylpentynol is combined with Tramadol.
DB13737
The risk or severity of CNS depression can be increased when Cyclobarbital is combined with Tramadol.
DB13745
The risk or severity of CNS depression can be increased when Fazadinium bromide is combined with Tramadol.
DB13754
The risk or severity of CNS depression can be increased when Mephenoxalone is combined with Tramadol.
DB13770
The risk or severity of CNS depression can be increased when Vinylbital is combined with Tramadol.
DB13791
The risk or severity of CNS depression can be increased when Penfluridol is combined with Tramadol.
DB13799
The risk or severity of CNS depression can be increased when Ethadione is combined with Tramadol.
DB13805
The risk or severity of CNS depression can be increased when Reposal is combined with Tramadol.
DB13817
The risk or severity of CNS depression can be increased when Carbromal is combined with Tramadol.
DB13841
The risk or severity of CNS depression can be increased when Clopenthixol is combined with Tramadol.
DB13984
The risk or severity of CNS depression can be increased when Cyclopropane is combined with Tramadol.
DB13993
The risk or severity of CNS depression can be increased when MRK-409 is combined with Tramadol.
DB14050
The risk or severity of CNS depression can be increased when Cannabidivarin is combined with Tramadol.
DB14718
The risk or severity of CNS depression can be increased when Pyrazolam is combined with Tramadol.
DB08927
The risk or severity of CNS depression can be increased when Tramadol is combined with Amperozide.
DB00289
The risk or severity of CNS depression can be increased when Tramadol is combined with Atomoxetine.
DB00866
The risk or severity of CNS depression can be increased when Tramadol is combined with Alprenolol.
DB01616
The risk or severity of CNS depression can be increased when Tramadol is combined with Alverine.
DB04821
The risk or severity of CNS depression can be increased when Tramadol is combined with Nomifensine.
DB04885
The risk or severity of CNS depression can be increased when Tramadol is combined with Cilansetron.
DB04917
The risk or severity of CNS depression can be increased when Tramadol is combined with Renzapride.
DB05227
The risk or severity of CNS depression can be increased when Tramadol is combined with APD791.
DB05542
The risk or severity of CNS depression can be increased when Tramadol is combined with Naronapride.
DB05562
The risk or severity of CNS depression can be increased when Tramadol is combined with Naluzotan.
DB05607
The risk or severity of CNS depression can be increased when Tramadol is combined with PRX-08066.
DB06446
The risk or severity of CNS depression can be increased when Tramadol is combined with Dotarizine.
DB06594
The risk or severity of CNS depression can be increased when Tramadol is combined with Agomelatine.
DB06660
The risk or severity of CNS depression can be increased when Tramadol is combined with Saredutant.
DB08059
The risk or severity of CNS depression can be increased when Tramadol is combined with Wortmannin.
DB09014
The risk or severity of CNS depression can be increased when Tramadol is combined with Captodiame.
DB09184
The risk or severity of CNS depression can be increased when Tramadol is combined with Edivoxetine.
DB09186
The risk or severity of CNS depression can be increased when Tramadol is combined with Nisoxetine.
DB09187
The risk or severity of CNS depression can be increased when Tramadol is combined with Lortalamine.
DB09190
The risk or severity of CNS depression can be increased when Tramadol is combined with Talopram.
DB09247
The risk or severity of CNS depression can be increased when Tramadol is combined with Iproclozide.
DB11686
The risk or severity of CNS depression can be increased when Tramadol is combined with Iferanserin.
DB11755
The risk or severity of CNS depression can be increased when Tramadol is combined with Tetrahydrocannabivarin.
DB11889
The risk or severity of CNS depression can be increased when Tramadol is combined with Lanicemine.
DB11957
The risk or severity of CNS depression can be increased when Tramadol is combined with Idalopirdine.
DB12163
The risk or severity of CNS depression can be increased when Tramadol is combined with Sarpogrelate.
DB12177
The risk or severity of CNS depression can be increased when Tramadol is combined with Eplivanserin.
DB12229
The risk or severity of CNS depression can be increased when Tramadol is combined with Cerlapirdine.
DB12361
The risk or severity of CNS depression can be increased when Tramadol is combined with Piclozotan.
DB12395
The risk or severity of CNS depression can be increased when Tramadol is combined with Esreboxetine.
DB12427
The risk or severity of CNS depression can be increased when Tramadol is combined with Orvepitant.
DB12661
The risk or severity of CNS depression can be increased when Tramadol is combined with Urapidil.
DB12951
The risk or severity of CNS depression can be increased when Tramadol is combined with Pivagabine.
DB13219
The risk or severity of CNS depression can be increased when Tramadol is combined with Medifoxamine.
DB13457
The risk or severity of CNS depression can be increased when Tramadol is combined with Oxaflozane.
DB13520
The risk or severity of CNS depression can be increased when Tramadol is combined with Metergoline.
DB13541
The risk or severity of CNS depression can be increased when Tramadol is combined with Iprazochrome.
DB13588
The risk or severity of CNS depression can be increased when Tramadol is combined with Naftidrofuryl.
DB15203
The risk or severity of CNS depression can be increased when Tramadol is combined with JNJ-26489112.
DB00753
The risk or severity of CNS depression can be increased when Isoflurane is combined with Tramadol.
DB03575
The risk or severity of CNS depression can be increased when Phencyclidine is combined with Tramadol.
DB00470
The risk or severity of CNS depression can be increased when Dronabinol is combined with Tramadol.
DB00486
The risk or severity of CNS depression can be increased when Nabilone is combined with Tramadol.
DB00967
The risk or severity of CNS depression can be increased when Tramadol is combined with Desloratadine.
DB00186
The risk or severity of CNS depression can be increased when Tramadol is combined with Lorazepam.
DB00231
The risk or severity of CNS depression can be increased when Tramadol is combined with Temazepam.
DB00404
The risk or severity of CNS depression can be increased when Tramadol is combined with Alprazolam.
DB00475
The risk or severity of CNS depression can be increased when Tramadol is combined with Chlordiazepoxide.
DB00546
The risk or severity of CNS depression can be increased when Tramadol is combined with Adinazolam.
DB00628
The risk or severity of CNS depression can be increased when Tramadol is combined with Clorazepic acid.
DB00690
The risk or severity of CNS depression can be increased when Tramadol is combined with Flurazepam.
DB00801
The risk or severity of CNS depression can be increased when Tramadol is combined with Halazepam.
DB00842
The risk or severity of CNS depression can be increased when Tramadol is combined with Oxazepam.
DB00897
The risk or severity of CNS depression can be increased when Tramadol is combined with Triazolam.
DB01068
The risk or severity of CNS depression can be increased when Tramadol is combined with Clonazepam.
DB01215
The risk or severity of CNS depression can be increased when Tramadol is combined with Estazolam.
DB01489
The risk or severity of CNS depression can be increased when Tramadol is combined with Camazepam.
DB01511
The risk or severity of CNS depression can be increased when Tramadol is combined with Delorazepam.
DB01544
The risk or severity of CNS depression can be increased when Tramadol is combined with Flunitrazepam.
DB01545
The risk or severity of CNS depression can be increased when Tramadol is combined with Ethyl loflazepate.
DB01553
The risk or severity of CNS depression can be increased when Tramadol is combined with Cloxazolam.
DB01558
The risk or severity of CNS depression can be increased when Tramadol is combined with Bromazepam.
DB01559
The risk or severity of CNS depression can be increased when Tramadol is combined with Clotiazepam.
DB01567
The risk or severity of CNS depression can be increased when Tramadol is combined with Fludiazepam.
DB01588
The risk or severity of CNS depression can be increased when Tramadol is combined with Prazepam.
DB01589
The risk or severity of CNS depression can be increased when Tramadol is combined with Quazepam.
DB01594
The risk or severity of CNS depression can be increased when Tramadol is combined with Cinolazepam.
DB01595
The risk or severity of CNS depression can be increased when Tramadol is combined with Nitrazepam.
DB09017
The risk or severity of CNS depression can be increased when Tramadol is combined with Brotizolam.
DB09166
The risk or severity of CNS depression can be increased when Tramadol is combined with Etizolam.
DB12537
The risk or severity of CNS depression can be increased when Tramadol is combined with Benzodiazepine.
DB13335
The risk or severity of CNS depression can be increased when Tramadol is combined with Pinazepam.
DB13437
The risk or severity of CNS depression can be increased when Tramadol is combined with Medazepam.
DB13643
The risk or severity of CNS depression can be increased when Tramadol is combined with Loprazolam.
DB13837
The risk or severity of CNS depression can be increased when Tramadol is combined with Doxefazepam.
DB13872
The risk or severity of CNS depression can be increased when Tramadol is combined with Lormetazepam.
DB14028
The risk or severity of CNS depression can be increased when Tramadol is combined with Nordazepam.
DB14672
The risk or severity of CNS depression can be increased when Tramadol is combined with Oxazepam acetate.
DB14715
The risk or severity of CNS depression can be increased when Tramadol is combined with Cinazepam.
DB14719
The risk or severity of CNS depression can be increased when Tramadol is combined with Bentazepam.
DB00206
The risk or severity of CNS depression can be increased when Reserpine is combined with Tramadol.
DB00747
The risk or severity of CNS depression can be increased when Scopolamine is combined with Tramadol.
DB01239
The risk or severity of CNS depression can be increased when Chlorprothixene is combined with Tramadol.
DB06770
The risk or severity of CNS depression can be increased when Benzyl alcohol is combined with Tramadol.
DB13598
The risk or severity of CNS depression can be increased when Diethyl ether is combined with Tramadol.
DB01202
The risk or severity of CNS depression can be increased when Tramadol is combined with Levetiracetam.
DB01339
The risk or severity of CNS depression can be increased when Tramadol is combined with Vecuronium.
DB08910
The risk or severity of CNS depression can be increased when Tramadol is combined with Pomalidomide.
DB12401
The risk or severity of CNS depression can be increased when Tramadol is combined with Bromperidol.
DB00555
The risk or severity of CNS depression can be increased when Lamotrigine is combined with Tramadol.
DB01359
The risk or severity of CNS depression can be increased when Tramadol is combined with Penbutolol.
DB09185
The risk or severity of CNS depression can be increased when Tramadol is combined with Viloxazine.
DB14509
The risk or severity of CNS depression can be increased when Tramadol is combined with Lithium carbonate.
DB00532
The risk or severity of CNS depression can be increased when Tramadol is combined with Mephenytoin.
DB00247
The risk or severity of CNS depression can be increased when Methysergide is combined with Tramadol.
DB00593
The risk or severity of CNS depression can be increased when Ethosuximide is combined with Tramadol.
DB00856
The risk or severity of CNS depression can be increased when Chlorphenesin is combined with Tramadol.
DB13259
The risk or severity of CNS depression can be increased when Ethyl chloride is combined with Tramadol.
DB13583
The risk or severity of CNS depression can be increased when Mephenesin is combined with Tramadol.
DB00751
The risk or severity of CNS depression can be increased when Epinastine is combined with Tramadol.
DB00921
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Buprenorphine.
DB01403
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Methotrimeprazine.
DB05271
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Rotigotine.
DB06204
The risk or severity of serotonin syndrome can be increased when Tapentadol is combined with Tramadol.
DB01233
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Metoclopramide.
DB00295
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Morphine.
DB00318
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Codeine.
DB00327
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Hydromorphone.
DB00497
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Oxycodone.
DB00611
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Butorphanol.
DB00647
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dextropropoxyphene.
DB00652
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Pentazocine.
DB00704
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Naltrexone.
DB00708
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Sufentanil.
DB00844
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Nalbuphine.
DB00854
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Levorphanol.
DB00899
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Remifentanil.
DB01081
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Diphenoxylate.
DB01192
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Oxymorphone.
DB01209
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dezocine.
DB01433
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Methadyl acetate.
DB01450
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dihydroetorphine.
DB01459
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Bezitramide.
DB01466
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ethylmorphine.
DB01497
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Etorphine.
DB01529
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dextromoramide.
DB01535
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Carfentanil.
DB01551
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dihydrocodeine.
DB01555
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Alphacetylmethadol.
DB01565
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dihydromorphine.
DB06738
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ketobemidone.
DB08861
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with DPDPE.
DB09174
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Lofentanil.
DB11130
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Opium.
DB11609
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Normethadone.
DB12492
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Piritramide.
DB13160
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Alphaprodine.
DB13454
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Nicomorphine.
DB13478
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Meptazinol.
DB13605
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Phenoperidine.
DB13606
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Phenazocine.
DB13787
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Tilidine.
DB06148
The risk or severity of serotonin syndrome can be increased when Mianserin is combined with Tramadol.
DB00321
The risk or severity of serotonin syndrome can be increased when Amitriptyline is combined with Tramadol.
DB00344
The risk or severity of serotonin syndrome can be increased when Protriptyline is combined with Tramadol.
DB00458
The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Tramadol.
DB00540
The risk or severity of serotonin syndrome can be increased when Nortriptyline is combined with Tramadol.
DB00543
The risk or severity of serotonin syndrome can be increased when Amoxapine is combined with Tramadol.
DB00726
The risk or severity of serotonin syndrome can be increased when Trimipramine is combined with Tramadol.
DB01142
The risk or severity of serotonin syndrome can be increased when Doxepin is combined with Tramadol.
DB01151
The risk or severity of serotonin syndrome can be increased when Desipramine is combined with Tramadol.
DB01242
The risk or severity of serotonin syndrome can be increased when Clomipramine is combined with Tramadol.
DB04836
The risk or severity of serotonin syndrome can be increased when Amineptine is combined with Tramadol.
DB08996
The risk or severity of serotonin syndrome can be increased when Dimetacrine is combined with Tramadol.
DB09016
The risk or severity of serotonin syndrome can be increased when Butriptyline is combined with Tramadol.
DB09167
The risk or severity of serotonin syndrome can be increased when Dosulepin is combined with Tramadol.
DB09289
The risk or severity of serotonin syndrome can be increased when Tianeptine is combined with Tramadol.
DB09307
The risk or severity of serotonin syndrome can be increased when Oxaprotiline is combined with Tramadol.
DB12930
The risk or severity of serotonin syndrome can be increased when Opipramol is combined with Tramadol.
DB13114
The risk or severity of serotonin syndrome can be increased when Amitriptylinoxide is combined with Tramadol.
DB13225
The risk or severity of serotonin syndrome can be increased when Dibenzepin is combined with Tramadol.
DB13246
The risk or severity of serotonin syndrome can be increased when Quinupramine is combined with Tramadol.
DB13384
The risk or severity of serotonin syndrome can be increased when Melitracen is combined with Tramadol.
DB13411
The risk or severity of serotonin syndrome can be increased when Lofepramine is combined with Tramadol.
DB13496
The risk or severity of serotonin syndrome can be increased when Iprindole is combined with Tramadol.
DB13782
The risk or severity of serotonin syndrome can be increased when Imipramine oxide is combined with Tramadol.
DB00377
The risk or severity of serotonin syndrome can be increased when Palonosetron is combined with Tramadol.
DB00757
The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Tramadol.
DB00889
The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Tramadol.
DB09068
The risk or severity of serotonin syndrome can be increased when Vortioxetine is combined with Tramadol.
DB00176
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Fluvoxamine.
DB00215
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Citalopram.
DB00476
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Duloxetine.
DB01105
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Sibutramine.
DB01175
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Escitalopram.
DB04832
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Zimelidine.
DB04884
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dapoxetine.
DB04896
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Milnacipran.
DB06700
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Desvenlafaxine.
DB08918
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Levomilnacipran.
DB08953
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Indalpine.
DB12693
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ritanserin.
DB13233
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Alaproclate.
DB00191
The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Tramadol.
DB00852
The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Tramadol.
DB00865
The risk or severity of serotonin syndrome can be increased when Benzphetamine is combined with Tramadol.
DB00937
The risk or severity of serotonin syndrome can be increased when Diethylpropion is combined with Tramadol.
DB01255
The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Tramadol.
DB01365
The risk or severity of serotonin syndrome can be increased when Mephentermine is combined with Tramadol.
DB01442
The risk or severity of serotonin syndrome can be increased when MMDA is combined with Tramadol.
DB01454
The risk or severity of serotonin syndrome can be increased when Midomafetamine is combined with Tramadol.
DB01467
The risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Tramadol.
DB01484
The risk or severity of serotonin syndrome can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Tramadol.
DB01509
The risk or severity of serotonin syndrome can be increased when Tenamfetamine is combined with Tramadol.
DB01556
The risk or severity of serotonin syndrome can be increased when Chlorphentermine is combined with Tramadol.
DB01576
The risk or severity of serotonin syndrome can be increased when Dextroamphetamine is combined with Tramadol.
DB01577
The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Tramadol.
DB09480
The risk or severity of serotonin syndrome can be increased when Iofetamine I-123 is combined with Tramadol.
DB12080
The risk or severity of serotonin syndrome can be increased when Ritobegron is combined with Tramadol.
DB13108
The risk or severity of serotonin syndrome can be increased when Mephedrone is combined with Tramadol.
DB13624
The risk or severity of serotonin syndrome can be increased when Methoxyphenamine is combined with Tramadol.
DB13703
The risk or severity of serotonin syndrome can be increased when Gepefrine is combined with Tramadol.
DB13940
The risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Tramadol.
DB00420
The risk or severity of serotonin syndrome can be increased when Promazine is combined with Tramadol.
DB01069
The risk or severity of serotonin syndrome can be increased when Promethazine is combined with Tramadol.
DB00477
The risk or severity of serotonin syndrome can be increased when Chlorpromazine is combined with Tramadol.
DB00721
The risk or severity of serotonin syndrome can be increased when Procaine is combined with Tramadol.
DB00285
The risk or severity of serotonin syndrome can be increased when Venlafaxine is combined with Tramadol.
DB00150
The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Tramadol.
DB00246
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ziprasidone.
DB00315
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Zolmitriptan.
DB00514
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dextromethorphan.
DB00574
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Fenfluramine.
DB00579
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Mazindol.
DB00589
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Lisuride.
DB00714
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Apomorphine.
DB00904
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ondansetron.
DB00952
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Naratriptan.
DB00998
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Frovatriptan.
DB01049
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ergoloid mesylate.
DB01075
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Diphenhydramine.
DB01114
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Chlorpheniramine.
DB01186
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Pergolide.
DB01238
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Aripiprazole.
DB01488
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dimethyltryptamine.
DB01624
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Zuclopenthixol.
DB04829
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Lysergic acid diethylamide.
DB04842
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Fluspirilene.
DB04946
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Iloperidone.
DB05316
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Pimavanserin.
DB06016
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Cariprazine.
DB06109
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with YKP-1358.
DB06144
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Sertindole.
DB06153
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Pizotifen.
DB06216
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Asenapine.
DB06684
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Vilazodone.
DB06701
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dexmethylphenidate.
DB08810
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Cinitapride.
DB08839
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Serotonin.
DB09128
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Brexpiprazole.
DB09225
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Zotepine.
DB09286
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Pipamperone.
DB11675
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Mosapride.
DB11732
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Lasmiditan.
DB12071
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Vabicaserin.
DB12110
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with m-Chlorophenylpiperazine.
DB12111
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with MK-212.
DB12184
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Gepirone.
DB12465
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ketanserin.
DB12725
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with TD-8954.
DB12833
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Tandospirone.
DB12883
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Eltoprazine.
DB13550
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Bifemelane.
DB13948
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DB14010
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14185
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Aripiprazole lauroxil.
DB04948
The risk or severity of serotonin syndrome can be increased when Lofexidine is combined with Tramadol.
DB01104
The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Tramadol.
DB00454
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Meperidine.
DB09061
The risk or severity of serotonin syndrome can be increased when Cannabidiol is combined with Tramadol.
DB01191
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dexfenfluramine.
DB08167
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Methylthioninium.
DB13910
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Valproate bismuth.
DB01235
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Levodopa.
DB00334
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Olanzapine.
DB01392
The risk or severity of serotonin syndrome can be increased when Yohimbine is combined with Tramadol.
DB08815
The risk or severity of serotonin syndrome can be increased when Lurasidone is combined with Tramadol.
DB00660
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Metaxalone.
DB00956
The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Tramadol.
DB00656
The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Tramadol.
DB00408
The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Tramadol.
DB00875
The risk or severity of serotonin syndrome can be increased when Flupentixol is combined with Tramadol.
DB01253
The risk or severity of serotonin syndrome can be increased when Ergometrine is combined with Tramadol.
DB01267
The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Tramadol.
DB04908
The risk or severity of serotonin syndrome can be increased when Flibanserin is combined with Tramadol.
DB00248
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Cabergoline.
DB00669
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Sumatriptan.
DB00734
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Risperidone.
DB01079
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Tegaserod.
DB00915
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Amantadine.
DB00918
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Almotriptan.
DB00934
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Maprotiline.
DB00951
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Isoniazid.
DB00953
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Rizatriptan.
DB00960
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Pindolol.
DB09194
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Etoperidone.
DB09223
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Blonanserin.
DB01356
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Lithium cation.
DB00313
The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Tramadol.
DB01149
The risk or severity of serotonin syndrome can be increased when Nefazodone is combined with Tramadol.
DB00472
The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Tramadol.
DB00679
The risk or severity of serotonin syndrome can be increased when Thioridazine is combined with Tramadol.
DB00715
The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Tramadol.
DB00320
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Dihydroergotamine.
DB00490
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Buspirone.
DB00696
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Ergotamine.
DB00802
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Alfentanil.
DB00813
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Fentanyl.
DB00907
The risk or severity of serotonin syndrome can be increased when Cocaine is combined with Tramadol.
DB04871
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Lorcaserin.
DB00216
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Eletriptan.
DB01224
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Quetiapine.
DB01227
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Levacetylmethadol.
DB00604
The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Cisapride.
DB01323
The risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with Tramadol.
DB09352
The risk or severity of serotonin syndrome can be increased when Hydroxyamphetamine is combined with Tramadol.
DB00390
The risk or severity of adverse effects can be increased when Tramadol is combined with Digoxin.
DB13401
The risk or severity of adverse effects can be increased when Tramadol is combined with Metildigoxin.
DB13691
The risk or severity of adverse effects can be increased when Tramadol is combined with Acetyldigoxin.
DB00682
The therapeutic efficacy of Warfarin can be increased when used in combination with Tramadol.
DB01418
The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Tramadol.
DB08496
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Tramadol.
DB14055
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Tramadol.
DB08735
The therapeutic efficacy of R,S-Warfarin alcohol can be increased when used in combination with Tramadol.
DB08736
The therapeutic efficacy of S,R-Warfarin alcohol can be increased when used in combination with Tramadol.
DB00503
The serum concentration of Tramadol can be increased when it is combined with Ritonavir.
DB11652
The metabolism of Tucatinib can be decreased when combined with Tramadol.
DB08816
Tramadol can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12404
The risk or severity of sedation can be increased when Remimazolam is combined with Tramadol.
DB11932
The serum concentration of Tramadol can be increased when it is combined with Abametapir.
DB14881
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Tramadol is combined with Oliceridine.
DB15762
The serum concentration of Tramadol can be decreased when it is combined with Satralizumab.
序列
实验性质
Water Solubility
Soluble
'MSDS'
Melting Point
178-181 °C
'MSDS'
Boiling Point
406.6 ºC
Chemical Book
logP
1.34
'MSDS'
pKa
9.41
'FDA label'
外部标识符
resource:Drugs Product Database (DPD)
identifier:13904
resource:ChEBI
identifier:75725
resource:PubChem Compound
identifier:33741
resource:PubChem Substance
identifier:46506256
resource:KEGG Compound
identifier:C07153
resource:KEGG Drug
identifier:D08623
resource:ChemSpider
identifier:31105
resource:BindingDB
identifier:50176259
resource:PharmGKB
identifier:PA451735
resource:Therapeutic Targets Database
identifier:DAP000140
resource:Wikipedia
identifier:Tramadol
resource:ChEMBL
identifier:CHEMBL1066
resource:ZINC
identifier:ZINC000000000853
resource:RxCUI
identifier:10689
外部链接
RxList
http://www.rxlist.com/cgi/generic/tramadol.htm
Drugs.com
http://www.drugs.com/tramadol.html
路径
smpdb-id:SMP0000671
name:Tramadol Action Action Pathway
category:drug_action
drugbank-id:DB00171
name:ATP
drugbank-id:DB00193
name:Tramadol
drugbank-id:DB00368
name:Norepinephrine
drugbank-id:DB00988
name:Dopamine
drugbank-id:DB01345
name:Potassium cation
drugbank-id:DB01373
name:Calcium
enzymes_uniprot-id:P35372
enzymes_uniprot-id:P17787
enzymes_uniprot-id:P43681
enzymes_uniprot-id:O00555
enzymes_uniprot-id:Q02641
enzymes_uniprot-id:Q9NY47
enzymes_uniprot-id:Q9Y5Y9
enzymes_uniprot-id:Q07699
enzymes_uniprot-id:Q9NZV8
enzymes_uniprot-id:Q9NS61
enzymes_uniprot-id:P05023
enzymes_uniprot-id:P50993
enzymes_uniprot-id:P13637
enzymes_uniprot-id:Q13733
enzymes_uniprot-id:P05026
enzymes_uniprot-id:P14415
enzymes_uniprot-id:P54709
enzymes_uniprot-id:B7ZKV8
enzymes_uniprot-id:P54710
enzymes_uniprot-id:P01189
enzymes_uniprot-id:P01203
enzymes_uniprot-id:P16519
enzymes_uniprot-id:Q05586
enzymes_uniprot-id:Q12879
enzymes_uniprot-id:Q8TCU5
enzymes_uniprot-id:P35348
enzymes_uniprot-id:P08908
enzymes_uniprot-id:P23975
enzymes_uniprot-id:P31645
enzymes_uniprot-id:Q01959
enzymes_uniprot-id:P21728
smpdb-id:SMP0000637
name:Tramadol Metabolism Pathway
category:drug_metabolism
drugbank-id:DB00157
name:NADH
drugbank-id:DB00171
name:ATP
drugbank-id:DB00193
name:Tramadol
drugbank-id:DB02577
name:Mesoheme
drugbank-id:DB03435
name:Uridine-5'-Diphosphate
drugbank-id:DB03843
name:Formaldehyde
enzymes_uniprot-id:P20813
enzymes_uniprot-id:P08684
enzymes_uniprot-id:P10635
enzymes_uniprot-id:P16662
enzymes_uniprot-id:Q9HAW9
enzymes_uniprot-id:O15245
enzymes_uniprot-id:Q92887
目标
id:BE0000770
name:Mu-type opioid receptor
organism:Humans
action:agonist
Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21.
Potschka H, Friderichs E, Loscher W: Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12.
Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan;260(1):275-85.
Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology. 2006 Sep;51(3):651-8. Epub 2006 Jun 21.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007 Mar;103(3):253-60.
Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:yes
name:Mu-type opioid receptor
general-function:Voltage-gated calcium channel activity
specific-function:Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.
gene-name:OPRM1
locus:6q24-q25
cellular-location:Cell membrane
transmembrane-regions:69-93 107-131 143-165 186-207 231-255 284-307 315-338
signal-regions:
theoretical-pi:8.29
molecular-weight:44778.855
chromosome-location:6
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:8156GenAtlasOPRM1GenBank Gene DatabaseL25119GenBank Protein Database452073IUPHAR319Guide to Pharmacology319UniProtKBP35372UniProt AccessionOPRM_HUMAN
synonyms:hMOPM-OR-1MOPMOR1Mu opiate receptorMu opioid receptor
amino-acid-sequence:>lcl|BSEQ0001536|Mu-type opioid receptor MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP
gene-sequence:>lcl|BSEQ0021649|Mu-type opioid receptor (OPRM1) ATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA AGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC CTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCT CCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG TGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG ATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC AGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC CTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC TGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC CGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT GGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA CTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTGCTGAAGATCTGTGTTTTCATC TTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC CTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC ACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT TACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG CACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT CTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT GAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT ACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC TAA
pfams:PF000017tm_1
go-classifiers:componentcytosolcomponentendoplasmic reticulumcomponentGolgi apparatuscomponentintegral component of plasma membranecomponentneuron projectioncomponentplasma membranefunctionbeta-endorphin receptor activityfunctionG-protein alpha-subunit bindingfunctionG-protein beta-subunit bindingfunctionG-protein coupled receptor activityfunctionmorphine receptor activityfunctionneuropeptide bindingfunctionvoltage-gated calcium channel activityprocessadenylate cyclase-activating dopamine receptor signaling pathwayprocessadenylate cyclase-inhibiting G-protein coupled receptor signaling pathwayprocessbehavioral response to ethanolprocesscalcium ion transmembrane transportprocesscellular response to morphineprocesscellular response to stressprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocesslocomotory behaviorprocessnegative regulation of adenylate cyclase activityprocessnegative regulation of cAMP-mediated signalingprocessnegative regulation of cell proliferationprocessnegative regulation of cytosolic calcium ion concentrationprocessnegative regulation of nitric oxide biosynthetic processprocessnegative regulation of Wnt protein secretionprocessneuropeptide signaling pathwayprocessopioid receptor signaling pathwayprocessphospholipase C-activating G-protein coupled receptor signaling pathwayprocesspositive regulation of cAMP-mediated signalingprocesspositive regulation of cytosolic calcium ion concentrationprocesspositive regulation of ERK1 and ERK2 cascadeprocesspositive regulation of neurogenesisprocesspositive regulation of nitric oxide biosynthetic processprocessregulation of N-methyl-D-aspartate selective glutamate receptor activityprocesssensory perceptionprocesssensory perception of painprocesssynaptic transmission
id:BE0000486
name:Sodium-dependent noradrenaline transporter
organism:Humans
action:inhibitor
Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, Shigematsu A: Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002 Apr;94(4):901-6, table of contents.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Berrocoso E, Mico JA: Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol. 2009 Sep;12(8):1033-44. doi: 10.1017/S1461145709000236. Epub 2009 Apr 3.
Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:yes
name:Sodium-dependent noradrenaline transporter
general-function:Norepinephrine:sodium symporter activity
specific-function:Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
gene-name:SLC6A2
locus:16q12.2
cellular-location:Membrane
transmembrane-regions:65-85 93-112 136-156 235-253 262-279 315-332 344-365 398-417 444-462 478-498 519-538 557-575
signal-regions:
theoretical-pi:7.53
molecular-weight:69331.42
chromosome-location:16
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:11048GenAtlasSLC6A2GenBank Gene DatabaseM65105GenBank Protein Database189258Guide to Pharmacology926UniProtKBP23975UniProt AccessionSC6A2_HUMAN
synonyms:NAT1NETNET1Norepinephrine transporterSLC6A5Solute carrier family 6 member 2
amino-acid-sequence:>lcl|BSEQ0000970|Sodium-dependent noradrenaline transporter MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL VAQRDIRQFQLQHWLAI
gene-sequence:>lcl|BSEQ0010343|Sodium-dependent noradrenaline transporter (SLC6A2) ATGCTTCTGGCGCGGATGAACCCGCAGGTGCAGCCCGAGAACAACGGGGCGGACACGGGT CCAGAGCAGCCCCTTCGGGCGCGCAAAACTGCGGAGCTGCTGGTGGTGAAGGAGCGCAAC GGCGTCCAGTGCCTGCTGGCGCCCCGCGACGGCGACGCGCAGCCCCGGGAGACCTGGGGC AAGAAGATCGACTTCCTGCTGTCCGTAGTCGGCTTCGCAGTGGACCTGGCCAACGTGTGG CGCTTCCCCTACCTCTGCTACAAGAACGGCGGCGGTGCCTTCTTGATCCCGTACACACTG TTCCTTATCATCGCGGGGATGCCCCTGTTCTACATGGAGCTGGCTCTGGGACAGTACAAC CGGGAGGGGGCTGCCACCGTTTGGAAAATCTGCCCATTCTTCAAAGGCGTTGGCTATGCT GTCATCCTGATCGCCCTGTACGTTGGCTTCTACTACAACGTCATCATCGCCTGGTCACTC TACTACCTCTTCTCCTCCTTCACCCTCAACCTGCCCTGGACCGACTGTGGCCACACCTGG AACAGCCCCAACTGTACCGACCCCAAGCTCCTCAATGGCTCCGTGCTTGGCAACCACACC AAGTACTCCAAGTACAAGTTCACGCCGGCAGCCGAGTTTTATGAGCGTGGTGTCCTGCAC CTTCACGAGAGCAGCGGGATTCATGACATCGGCCTGCCCCAGTGGCAGCTCTTGCTCTGT CTGATGGTCGTCGTCATCGTCTTGTATTTTAGCCTCTGGAAAGGGGTGAAGACATCAGGA AAGGTGGTGTGGATCACAGCCACGCTGCCTTACTTCGTGCTGTTCGTGCTCCTGGTCCAT GGCGTCACGCTGCCCGGAGCCTCCAATGGCATCAATGCCTACCTGCACATCGACTTCTAC CGCTTGAAAGAGGCCACGGTATGGATTGATGCCGCAACTCAGATATTTTTTTCCTTGGGG GCTGGATTTGGAGTATTGATTGCATTTGCCAGTTACAACAAATTTGACAACAACTGTTAC AGGGATGCCCTGCTGACCAGCAGCATCAACTGTATCACCAGCTTCGTCTCTGGGTTCGCC ATCTTCTCCATCCTTGGTTACATGGCCCATGAACACAAGGTCAACATTGAGGATGTGGCC ACAGAAGGAGCTGGCCTAGTGTTCATCCTGTATCCAGAGGCCATTTCTACCCTGTCTGGA TCTACATTCTGGGCTGTTGTGTTTTTCGTCATGCTCCTGGCGCTGGGCCTTGACAGCTCA ATGGGAGGCATGGAGGCTGTCATCACGGGCCTGGCAGATGACTTCCAGGTCCTGAAGCGA CACCGGAAACTCTTCACATTTGGCGTCACCTTCAGCACTTTCCTTCTCGCCCTGTTCTGC ATAACCAAGGGTGGAATTTACGTCTTGACCCTCCTGGACACCTTTGCTGCGGGCACCTCC ATCCTTTTTGCTGTCCTCATGGAAGCCATCGGAGTTTCCTGGTTTTATGGAGTGGACAGG TTCAGCAACGACATCCAGCAGATGATGGGGTTCAGGCCGGGTCTATACTGGAGACTGTGC TGGAAGTTCGTCAGTCCTGCCTTCCTCCTGTTCGTGGTTGTGGTCAGCATCATCAACTTC AAGCCACTCACCTACGACGACTACATCTTCCCGCCCTGGGCCAACTGGGTGGGGTGGGGC ATCGCCCTGTCCTCCATGGTCCTGGTGCCCATCTACGTCATCTATAAGTTCCTCAGCACG CAGGGCTCTCTTTGGGAGAGACTGGCCTATGGCATCACGCCAGAGAACGAGCACCACCTG GTGGCTCAGAGGGACATCAGACAGTTCCAGTTGCAACACTGGCTGGCCATCTGA
pfams:PF00209SNF
go-classifiers:componentintegral component of plasma membranecomponentmembranecomponentneuron projectioncomponentplasma membranefunctionmonoamine transmembrane transporter activityfunctionnorepinephrineprocessmonoamine transportprocessnorepinephrine transportprocessresponse to painprocesssynaptic transmissionprocesstransmembrane transportprocesstransport
id:BE0000749
name:Sodium-dependent serotonin transporter
organism:Humans
action:inhibitor
Barann M, Urban B, Stamer U, Dorner Z, Bonisch H, Bruss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol. 2006 Feb 15;531(1-3):54-8. Epub 2006 Jan 19.
Driessen B, Reimann W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol. 1992 Jan;105(1):147-51.
Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:yes
name:Sodium-dependent serotonin transporter
general-function:Serotonin:sodium symporter activity
specific-function:Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.
gene-name:SLC6A4
locus:17q11.1-q12
cellular-location:Cell membrane
transmembrane-regions:88-108 116-135 160-180 253-271 280-297 333-350 362-383 417-436 464-482 498-518 539-558 577-595
signal-regions:
theoretical-pi:6.17
molecular-weight:70324.165
chromosome-location:17
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:11050GenAtlasSLC6A4GenBank Gene DatabaseX70697GenBank Protein Database36433Guide to Pharmacology928UniProtKBP31645UniProt AccessionSC6A4_HUMAN
synonyms:5HT transporter5HTTHTTSERTSolute carrier family 6 member 4
amino-acid-sequence:>lcl|BSEQ0001494|Sodium-dependent serotonin transporter METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTR HSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLP YTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIM AWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIH RSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGA TLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQD ALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPAS TFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVT LTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRIC WVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIIT PGTFKERIIKSITPETPTEIPCGDIRLNAV
gene-sequence:>lcl|BSEQ0021275|Sodium-dependent serotonin transporter (SLC6A4) ATGGAGACGACGCCCTTGAATTCTCAGAAGCAGCTATCAGCGTGTGAAGATGGAGAAGAT TGTCAGGAAAACGGAGTTCTACAGAAGGTTGTTCCCACCCCAGGGGACAAAGTGGAGTCC GGGCAAATATCCAATGGGTACTCAGCAGTTCCAAGTCCTGGTGCGGGAGATGACACACGG CACTCTATCCCAGCGACCACCACCACCCTAGTGGCTGAGCTTCATCAAGGGGAACGGGAG ACCTGGGGCAAGAAGGTGGATTTCCTTCTCTCAGTGATTGGCTATGCTGTGGACCTGGGC AATGTCTGGCGCTTCCCCTACATATGTTACCAGAATGGAGGGGGGGCATTCCTCCTCCCC TACACCATCATGGCCATTTTTGGGGGAATCCCGCTCTTTTACATGGAGCTCGCACTGGGA CAGTACCACCGAAATGGATGCATTTCAATATGGAGGAAAATCTGCCCGATTTTCAAAGGG ATTGGTTATGCCATCTGCATCATTGCCTTTTACATTGCTTCCTACTACAACACCATCATG GCCTGGGCGCTATACTACCTCATCTCCTCCTTCACGGACCAGCTGCCCTGGACCAGCTGC AAGAACTCCTGGAACACTGGCAACTGCACCAATTACTTCTCCGAGGACAACATCACCTGG ACCCTCCATTCCACGTCCCCTGCTGAAGAATTTTACACGCGCCACGTCCTGCAGATCCAC CGGTCTAAGGGGCTCCAGGACCTGGGGGGCATCAGCTGGCAGCTGGCCCTCTGCATCATG CTGATCTTCACTGTTATCTACTTCAGCATCTGGAAAGGCGTCAAGACCTCTGGCAAGGTG GTGTGGGTGACAGCCACCTTCCCTTATATCATCCTTTCTGTCCTGCTGGTGAGGGGTGCC ACCCTCCCTGGAGCCTGGAGGGGTGTTCTCTTCTACTTGAAACCCAATTGGCAGAAACTC CTGGAGACAGGGGTGTGGATAGATGCAGCCGCTCAGATCTTCTTCTCTCTTGGTCCGGGC TTTGGGGTCCTGCTGGCTTTTGCTAGCTACAACAAGTTCAACAACAACTGCTACCAAGAT GCCCTGGTGACCAGCGTGGTGAACTGCATGACGAGCTTCGTTTCGGGATTTGTCATCTTC ACAGTGCTCGGTTACATGGCTGAGATGAGGAATGAAGATGTGTCTGAGGTGGCCAAAGAC GCAGGTCCCAGCCTCCTCTTCATCACGTATGCAGAAGCGATAGCCAACATGCCAGCGTCC ACTTTCTTTGCCATCATCTTCTTTCTGATGTTAATCACGCTGGGCTTGGACAGCACGTTT GCAGGCTTGGAGGGGGTGATCACGGCTGTGCTGGATGAGTTCCCACACGTCTGGGCCAAG CGCCGGGAGCGGTTCGTGCTCGCCGTGGTCATCACCTGCTTCTTTGGATCCCTGGTCACC CTGACTTTTGGAGGGGCCTACGTGGTGAAGCTGCTGGAGGAGTATGCCACGGGGCCCGCA GTGCTCACTGTCGCGCTGATCGAAGCAGTCGCTGTGTCTTGGTTCTATGGCATCACTCAG TTCTGCAGGGACGTGAAGGAAATGCTCGGCTTCAGCCCGGGGTGGTTCTGGAGGATCTGC TGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTCATCATTTGCAGTTTTCTGATGAGCCCG CCACAACTACGACTTTTCCAATATAATTATCCTTACTGGAGTATCATCTTGGGTTACTGC ATAGGAACCTCATCTTTCATTTGCATCCCCACATATATAGCTTATCGGTTGATCATCACT CCAGGGACATTTAAAGAGCGTATTATTAAAAGTATTACCCCAGAAACACCAACAGAAATT CCTTGTGGGGACATCCGCTTGAATGCTGTGTAA
pfams:PF00209SNFPF034915HT_transport_N
go-classifiers:componentcytosolcomponentendomembrane systemcomponentendosome membranecomponentintegral component of plasma membranecomponentmembrane raftcomponentneuron projectioncomponentplasma membranefunctionactin filament bindingfunctioncocaine bindingfunctionmonoamine transmembrane transporter activityfunctionRab GTPase bindingfunctionserotoninfunctionserotonin transmembrane transporter activityprocessbrain morphogenesisprocesscellular response to cGMPprocesscellular response to retinoic acidprocesscircadian rhythmprocessmemoryprocessmonoamine transportprocessnegative regulation of cerebellar granule cell precursor proliferationprocessnegative regulation of neuron differentiationprocessnegative regulation of organ growthprocessnegative regulation of synaptic transmission, dopaminergicprocesspositive regulation of cell cycleprocesspositive regulation of gene expressionprocessprotein homooligomerizationprocessprotein oligomerizationprocessresponse to drugprocessresponse to estradiolprocessresponse to hypoxiaprocessresponse to nutrientprocessresponse to toxic substanceprocessserotonin transportprocessserotonin uptakeprocesssocial behaviorprocesssperm ejaculationprocesssynaptic transmissionprocessthalamus developmentprocessvasoconstriction
id:BE0000533
name:5-hydroxytryptamine receptor 2C
organism:Humans
action:antagonist
Ogata J, Minami K, Uezono Y, Okamoto T, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
Horishita T, Minami K, Uezono Y, Shiraishi M, Ogata J, Okamoto T, Shigematsu A: The tramadol metabolite, O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in Xenopus Oocytes. Pharmacology. 2006;77(2):93-9. Epub 2006 May 5.
known-action:unknown
name:5-hydroxytryptamine receptor 2C
general-function:Serotonin receptor activity
specific-function:G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.
gene-name:HTR2C
locus:Xq24
cellular-location:Cell membrane
transmembrane-regions:53-78 90-110 128-150 171-193 214-235 312-333 349-371
signal-regions:1-32
theoretical-pi:9.11
molecular-weight:51820.705
chromosome-location:X
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:5295GenAtlasHTR2CGenBank Gene DatabaseM81778GenBank Protein Database338028IUPHAR8Guide to Pharmacology8UniProtKBP28335UniProt Accession5HT2C_HUMAN
synonyms:5-HT-1C5-HT-2C5-HT1C5-hydroxytryptamine receptor 1CHTR1CSerotonin receptor 2C
amino-acid-sequence:>lcl|BSEQ0001064|5-hydroxytryptamine receptor 2C MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV
gene-sequence:>lcl|BSEQ0010373|5-hydroxytryptamine receptor 2C (HTR2C) ATGGTGAACCTGAGGAATGCGGTGCATTCATTCCTTGTGCACCTAATTGGCCTATTGGTT TGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACC TCCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATC GTCATCATAATAATCATGACAATAGGTGGCAACATCCTTGTGATCATGGCAGTAAGCATG GAAAAGAAACTGCACAATGCCACCAATTACTTCTTAATGTCCCTAGCCATTGCTGATATG CTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCTGGCAATCCTTTATGATTATGTCTGG CCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTTTATTTTCAACAGCG TCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAGCAATACGTAATCCTATT GAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCA ATTTCTATAGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTG TTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTC GTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTT CTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGT CTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCT AACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATG CAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTT CTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCC TGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGT TCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCC AACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGA GTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAAT GAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAAT TTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGA
pfams:PF000017tm_1
go-classifiers:componentcytosolcomponentintegral component of plasma membranecomponentplasma membranefunction1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine bindingfunctiondrug bindingfunctionGq/11-coupled serotonin receptor activityfunctionserotonin bindingfunctionserotonin receptor activityprocessbehavioral fear responseprocesscellular calcium ion homeostasisprocesscGMP biosynthetic processprocessfeeding behaviorprocesslocomotory behaviorprocessphospholipase C-activating G-protein coupled receptor signaling pathwayprocessphospholipase C-activating serotonin receptor signaling pathwayprocesspositive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathwayprocesspositive regulation of ERK1 and ERK2 cascadeprocesspositive regulation of fat cell differentiationprocesspositive regulation of phosphatidylinositol biosynthetic processprocessregulation of appetiteprocessregulation of corticotropin-releasing hormone secretionprocessregulation of neurological system processprocessrelease of sequestered calcium ion into cytosolprocessresponse to drugprocessserotonin receptor signaling pathwayprocesssynaptic transmission
id:BE0000632
name:Kappa-type opioid receptor
organism:Humans
action:agonist
Sun HL, Zheng JW, Wang K, Liu RK, Liang JH: Tramadol reduces the 5-HTP-induced head-twitch response in mice via the activation of mu and kappa opioid receptors. Life Sci. 2003 Jan 31;72(11):1221-30.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:unknown
name:Kappa-type opioid receptor
general-function:Opioid receptor activity
specific-function:G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.
gene-name:OPRK1
locus:8q11.2
cellular-location:Cell membrane
transmembrane-regions:58-85 96-119 133-154 174-196 223-247 275-296 312-333
signal-regions:
theoretical-pi:7.79
molecular-weight:42644.665
chromosome-location:8
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:8154GenAtlasOPRK1GenBank Gene DatabaseU11053GenBank Protein Database532060IUPHAR318Guide to Pharmacology318UniProtKBP41145UniProt AccessionOPRK_HUMAN
synonyms:K-OR-1OPRK
amino-acid-sequence:>lcl|BSEQ0001260|Kappa-type opioid receptor MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPV IITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYL MNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINI CIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVL IIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALG STSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRV RNTVQDPAYLRDIDGMNKPV
gene-sequence:>lcl|BSEQ0021645|Kappa-type opioid receptor (OPRK1) ATGGACTCCCCGATCCAGATCTTCCGCGGGGAGCCGGGCCCTACCTGCGCCCCGAGCGCC TGCCTGCCCCCCAACAGCAGCGCCTGGTTTCCCGGCTGGGCCGAGCCCGACAGCAACGGC AGCGCCGGCTCGGAGGACGCGCAGCTGGAGCCCGCGCACATCTCCCCGGCCATCCCGGTC ATCATCACGGCGGTCTACTCCGTAGTGTTCGTCGTGGGCTTGGTGGGCAACTCGCTGGTC ATGTTCGTGATCATCCGATACACAAAGATGAAGACAGCAACCAACATTTACATATTTAAC CTGGCTTTGGCAGATGCTTTAGTTACTACAACCATGCCCTTTCAGAGTACGGTCTACTTG ATGAATTCCTGGCCTTTTGGGGATGTGCTGTGCAAGATAGTAATTTCCATTGATTACTAC AACATGTTCACCAGCATCTTCACCTTGACCATGATGAGCGTGGACCGCTACATTGCCGTG TGCCACCCCGTGAAGGCTTTGGACTTCCGCACACCCTTGAAGGCAAAGATCATCAATATC TGCATCTGGCTGCTGTCGTCATCTGTTGGCATCTCTGCAATAGTCCTTGGAGGCACCAAA GTCAGGGAAGACGTCGATGTCATTGAGTGCTCCTTGCAGTTCCCAGATGATGACTACTCC TGGTGGGACCTCTTCATGAAGATCTGCGTCTTCATCTTTGCCTTCGTGATCCCTGTCCTC ATCATCATCGTCTGCTACACCCTGATGATCCTGCGTCTCAAGAGCGTCCGGCTCCTTTCT GGCTCCCGAGAGAAAGATCGCAACCTGCGTAGGATCACCAGACTGGTCCTGGTGGTGGTG GCAGTCTTCGTCGTCTGCTGGACTCCCATTCACATATTCATCCTGGTGGAGGCTCTGGGG AGCACCTCCCACAGCACAGCTGCTCTCTCCAGCTATTACTTCTGCATCGCCTTAGGCTAT ACCAACAGTAGCCTGAATCCCATTCTCTACGCCTTTCTTGATGAAAACTTCAAGCGGTGT TTCCGGGACTTCTGCTTTCCACTGAAGATGAGGATGGAGCGGCAGAGCACTAGCAGAGTC CGAAATACAGTTCAGGATCCTGCTTACCTGAGGGACATCGATGGGATGAATAAACCAGTA TGA
pfams:PF000017tm_1
go-classifiers:componentaxon terminuscomponentdendritecomponentintegral component of membranecomponentintegral component of plasma membranecomponentneuron projectioncomponentperikaryoncomponentplasma membranecomponentsynapsefunctiondynorphin receptor activityfunctionneuropeptide bindingfunctionopioid receptor activityprocessadenylate cyclase-inhibiting G-protein coupled receptor signaling pathwayprocessadenylate cyclase-inhibiting opioid receptor signaling pathwayprocessbehaviorprocessbehavioral response to cocaineprocesscellular response to lipopolysaccharideprocessdefense response to virusprocesseating behaviorprocessestrous cycleprocessimmune responseprocesslocomotory behaviorprocessmaternal behaviorprocessnegative regulation of luteinizing hormone secretionprocessneuropeptide signaling pathwayprocessopioid receptor signaling pathwayprocessphospholipase C-activating G-protein coupled receptor signaling pathwayprocesspositive regulation of dopamine secretionprocesspositive regulation of locomotionprocesspositive regulation of p38MAPK cascadeprocesspositive regulation of potassium ion transmembrane transportprocessregulation of aerobic respirationprocessregulation of energy homeostasisprocessregulation of saliva secretionprocessregulation of sensory perception of painprocessresponse to acrylamideprocessresponse to estrogenprocessresponse to ethanolprocessresponse to insulinprocessresponse to morphineprocessresponse to radiationprocesssensory perceptionprocesssensory perception of painprocesssensory perception of temperature stimulusprocesssynaptic transmission
id:BE0000420
name:Delta-type opioid receptor
organism:Humans
action:agonist
Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM: Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. doi: 10.1016/j.bmcl.2008.10.134. Epub 2008 Nov 7.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:unknown
name:Delta-type opioid receptor
general-function:Opioid receptor activity
specific-function:G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.
gene-name:OPRD1
locus:1p36.1-p34.3
cellular-location:Cell membrane
transmembrane-regions:48-75 86-110 123-144 164-186 207-238 262-284 300-321
signal-regions:
theoretical-pi:9.17
molecular-weight:40368.235
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:8153GenAtlasOPRD1GenBank Gene DatabaseU07882GenBank Protein Database27545517IUPHAR317Guide to Pharmacology317UniProtKBP41143UniProt AccessionOPRD_HUMAN
synonyms:D-OR-1OPRD
amino-acid-sequence:>lcl|BSEQ0010290|Delta-type opioid receptor MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAIAITALYSAVC AVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELL CKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVG VPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRL RSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAAL HLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTAC TPSDGPGGGAAA
gene-sequence:>lcl|BSEQ0010291|Delta-type opioid receptor (OPRD1) ATGGAACCGGCCCCCTCCGCCGGCGCCGAGCTGCAGCCCCCGCTCTTCGCCAACGCCTCG GACGCCTACCCTAGCGCCTGCCCCAGCGCTGGCGCCAATGCGTCGGGGCCGCCAGGCGCG CGGAGCGCCTCGTCCCTCGCCCTGGCAATCGCCATCACCGCGCTCTACTCGGCCGTGTGC GCCGTGGGGCTGCTGGGCAACGTGCTTGTCATGTTCGGCATCGTCCGGTACACTAAGATG AAGACGGCCACCAACATCTACATCTTCAACCTGGCCTTAGCCGATGCGCTGGCCACCAGC ACGCTGCCTTTCCAGAGTGCCAAGTACCTGATGGAGACGTGGCCCTTCGGCGAGCTGCTC TGCAAGGCTGTGCTCTCCATCGACTACTACAATATGTTCACCAGCATCTTCACGCTCACC ATGATGAGTGTTGACCGCTACATCGCTGTCTGCCACCCTGTCAAGGCCCTGGACTTCCGC ACGCCTGCCAAGGCCAAGCTGATCAACATCTGTATCTGGGTCCTGGCCTCAGGCGTTGGC GTGCCCATCATGGTCATGGCTGTGACCCGTCCCCGGGACGGGGCAGTGGTGTGCATGCTC CAGTTCCCCAGCCCCAGCTGGTACTGGGACACGGTGACCAAGATCTGCGTGTTCCTCTTC GCCTTCGTGGTGCCCATCCTCATCATCACCGTGTGCTATGGCCTCATGCTGCTGCGCCTG CGCAGTGTGCGCCTGCTGTCGGGCTCCAAGGAGAAGGACCGCAGCCTGCGGCGCATCACG CGCATGGTGCTGGTGGTTGTGGGCGCCTTCGTGGTGTGTTGGGCGCCCATCCACATCTTC GTCATCGTCTGGACGCTGGTGGACATCGACCGGCGCGACCCGCTGGTGGTGGCTGCGCTG CACCTGTGCATCGCGCTGGGCTACGCCAATAGCAGCCTCAACCCCGTGCTCTACGCTTTC CTCGACGAGAACTTCAAGCGCTGCTTCCGCCAGCTCTGCCGCAAGCCCTGCGGCCGCCCA GACCCCAGCAGCTTCAGCCGCGCCCGCGAAGCCACGGCCCGCGAGCGTGTCACCGCCTGC ACCCCGTCCGATGGTCCCGGCGGTGGCGCTGCCGCCTGA
pfams:PF000017tm_1
go-classifiers:componentaxon terminuscomponentcytoplasmcomponentdendrite membranecomponentintegral component of plasma membranecomponentintrinsic component of plasma membranecomponentmembrane raftcomponentneuron projectioncomponentplasma membranecomponentpostsynaptic membranecomponentvesiclefunctionenkephalin receptor activityfunctionneuropeptide bindingfunctionopioid receptor activityprocessadenylate cyclase-inhibiting G-protein coupled receptor signaling pathwayprocessadult locomotory behaviorprocesscellular response to growth factor stimulusprocesscellular response to hypoxiaprocesscellular response to toxic substanceprocesseating behaviorprocessG-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessimmune responseprocessnegative regulation of gene expressionprocessnegative regulation of protein oligomerizationprocessneuropeptide signaling pathwayprocessopioid receptor signaling pathwayprocessphospholipase C-activating G-protein coupled receptor signaling pathwayprocesspositive regulation of CREB transcription factor activityprocesspositive regulation of peptidyl-serine phosphorylationprocessprotein import into nucleus, translocationprocessregulation of calcium ion transportprocessregulation of mitochondrial membrane potentialprocessregulation of sensory perception of painprocesssynaptic transmission
id:BE0003438
name:Alpha-7 nicotinic cholinergic receptor subunit
organism:Humans
action:antagonist
Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A, Shibuya I: Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha 7 receptors. Br J Pharmacol. 2002 May;136(2):207-16.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:unknown
name:Alpha-7 nicotinic cholinergic receptor subunit
general-function:
specific-function:
gene-name:CHRNA7
locus:
cellular-location:
transmembrane-regions:
signal-regions:1-22
theoretical-pi:3.55
molecular-weight:2987.635
chromosome-location:
organism:Humans
external-identifiers:GenAtlasCHRFAM7AGenBank Gene DatabaseAY641831UniProtKBQ693P7UniProt AccessionQ693P7_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0022322|Alpha-7 nicotinic cholinergic receptor subunit ITVLLSLTVFMLLVAEIMPATSDSVPLI
gene-sequence:>lcl|BSEQ0006706|87 bp GGATAACAGTCTTACTCTCTCTTACCGTCTTCATGCTGCTCGTGGCTGAGATCATGCCCG CAACATCCGATTCGGTACCATTGATAG
pfams:PF02932Neur_chan_memb
go-classifiers:componentintegral component of membraneprocession transport
id:BE0000045
name:Muscarinic acetylcholine receptor M3
organism:Humans
action:antagonist
Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A: Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther. 2001 Oct;299(1):255-60.
Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, Shigematsu A: The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg. 2002 Nov;95(5):1269-73, table of contents.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:unknown
name:Muscarinic acetylcholine receptor M3
general-function:Receptor activity
specific-function:The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
gene-name:CHRM3
locus:1q43
cellular-location:Cell membrane
transmembrane-regions:68-91 105-130 143-164 185-206 230-252 492-514 527-546
signal-regions:
theoretical-pi:9.62
molecular-weight:66127.445
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1952GenAtlasCHRM3GenBank Gene DatabaseX15266GenBank Protein Database32324IUPHAR15Guide to Pharmacology15UniProtKBP20309UniProt AccessionACM3_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0009898|Muscarinic acetylcholine receptor M3 MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL
gene-sequence:>lcl|BSEQ0009899|Muscarinic acetylcholine receptor M3 (CHRM3) ATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG ATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC AATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG GGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG GTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG ACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT TCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC TGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG GTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA ACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG GCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG TGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT TATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG CGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT GTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG AAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG AAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT GATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG ACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC ACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC TTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT CCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT TCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA GCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG ATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC ATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC ATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC CCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG TGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT TTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG
pfams:PF000017tm_1
go-classifiers:componentasymmetric synapsecomponentaxon terminuscomponentbasolateral plasma membranecomponentcell junctioncomponentdendritecomponentintegral component of plasma membranecomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionacetylcholine bindingfunctiondrug bindingfunctionG-protein coupled acetylcholine receptor activityfunctionphosphatidylinositol phospholipase C activityfunctionreceptor activityprocessadenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathwayprocesscell proliferationprocesscellular protein modification processprocessenergy reserve metabolic processprocessG-protein coupled acetylcholine receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessnervous system developmentprocessphospholipase C-activating G-protein coupled acetylcholine receptor signaling pathwayprocesspositive regulation of smooth muscle contractionprocessregulation of insulin secretionprocessregulation of vascular smooth muscle contractionprocesssaliva secretionprocesssensory perception of chemical stimulusprocesssignal transductionprocesssmall molecule metabolic processprocesssmooth muscle contractionprocesssynaptic transmission, cholinergic
id:BE0000092
name:Muscarinic acetylcholine receptor M1
organism:Humans
action:antagonist
Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A: Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther. 2001 Oct;299(1):255-60.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:unknown
name:Muscarinic acetylcholine receptor M1
general-function:Phosphatidylinositol phospholipase c activity
specific-function:The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
gene-name:CHRM1
locus:11q13
cellular-location:Cell membrane
transmembrane-regions:25-47 62-82 100-121 142-164 187-209 367-387 402-421
signal-regions:
theoretical-pi:9.67
molecular-weight:51420.375
chromosome-location:11
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1950GenAtlasCHRM1GenBank Gene DatabaseX52068GenBank Protein Database34451IUPHAR13Guide to Pharmacology13UniProtKBP11229UniProt AccessionACM1_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0000184|Muscarinic acetylcholine receptor M1 MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVN NYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLIS FDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYI QFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSS SERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEV VIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKE KKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYAL CNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC
gene-sequence:>lcl|BSEQ0009929|Muscarinic acetylcholine receptor M1 (CHRM1) ATGAACACTTCAGCCCCACCTGCTGTCAGCCCCAACATCACCGTCCTGGCACCAGGAAAG GGTCCCTGGCAAGTGGCCTTCATTGGGATCACCACGGGCCTCCTGTCGCTAGCCACAGTG ACAGGCAACCTGCTGGTACTCATCTCTTTCAAGGTCAACACGGAGCTCAAGACAGTCAAT AACTACTTCCTGCTGAGCCTGGCCTGTGCTGACCTCATCATCGGTACCTTCTCCATGAAC CTCTATACCACGTACCTGCTCATGGGCCACTGGGCTCTGGGCACGCTGGCTTGTGACCTC TGGCTGGCCCTGGACTATGTGGCCAGCAATGCCTCCGTCATGAATCTGCTGCTCATCAGC TTTGACCGCTACTTCTCCGTGACTCGGCCCCTGAGCTACCGTGCCAAGCGCACACCCCGC CGGGCAGCTCTGATGATCGGCCTGGCCTGGCTGGTTTCCTTTGTGCTCTGGGCCCCAGCC ATCCTCTTCTGGCAGTACCTGGTAGGGGAGCGGACAGTGCTAGCTGGGCAGTGCTACATC CAGTTCCTCTCCCAGCCCATCATCACCTTTGGCACAGCCATGGCTGCCTTCTACCTCCCT GTCACAGTCATGTGCACGCTCTACTGGCGCATCTACCGGGAGACAGAGAACCGAGCACGG GAGCTGGCAGCCCTTCAGGGCTCCGAGACGCCAGGCAAAGGGGGTGGCAGCAGCAGCAGC TCAGAGAGGTCTCAGCCAGGGGCTGAGGGCTCACCAGAGACTCCTCCAGGCCGCTGCTGT CGCTGCTGCCGGGCCCCCAGGCTGCTGCAGGCCTACAGCTGGAAGGAAGAAGAGGAAGAG GACGAAGGCTCCATGGAGTCCCTCACATCCTCAGAGGGAGAGGAGCCTGGCTCCGAAGTG GTGATCAAGATGCCAATGGTGGACCCCGAGGCACAGGCCCCCACCAAGCAGCCCCCACGG AGCTCCCCAAATACAGTCAAGAGGCCGACTAAGAAAGGGCGTGATCGAGCTGGCAAGGGC CAGAAGCCCCGTGGAAAGGAGCAGCTGGCCAAGCGGAAGACCTTCTCGCTGGTCAAGGAG AAGAAGGCGGCTCGGACCCTGAGTGCCATCCTCCTGGCCTTCATCCTCACCTGGACACCG TACAACATCATGGTGCTGGTGTCCACCTTCTGCAAGGACTGTGTTCCCGAGACCCTGTGG GAGCTGGGCTACTGGCTGTGCTACGTCAACAGCACCATCAACCCCATGTGCTACGCACTC TGCAACAAAGCCTTCCGGGACACCTTTCGCCTGCTGCTGCTTTGCCGCTGGGACAAGAGA CGCTGGCGCAAGATCCCCAAGCGCCCTGGCTCCGTGCACCGCACTCCCTCCCGCCAATGC TGA
pfams:PF000017tm_1
go-classifiers:componentasymmetric synapsecomponentaxon terminuscomponentcell junctioncomponentdendritecomponentintegral component of plasma membranecomponentmembranecomponentplasma membranecomponentpostsynaptic densitycomponentpostsynaptic membranecomponentsynapsefunctiondrug bindingfunctionG-protein coupled acetylcholine receptor activityfunctionphosphatidylinositol phospholipase C activityprocessadenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathwayprocesscell proliferationprocesscellular protein modification processprocesscognitionprocessentrainment of circadian clockprocessG-protein coupled acetylcholine receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessnervous system developmentprocessneuromuscular synaptic transmissionprocessphospholipase C-activating G-protein coupled acetylcholine receptor signaling pathwayprocessphototransduction, visible lightprocesspositive regulation of cell proliferationprocesspositive regulation of intracellular protein transportprocesspositive regulation of ion transportprocessprotein kinase C-activating G-protein coupled receptor signaling pathwayprocessregulation of locomotionprocesssaliva secretionprocesssensory perception of chemical stimulusprocesssignal transductionprocesssynaptic transmission, cholinergic
id:BE0000384
name:Neurokinin 1 receptor
organism:Humans
action:inhibitor
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:no
name:Substance-P receptor
general-function:Tachykinin receptor activity
specific-function:This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.
gene-name:TACR1
locus:2p13.1
cellular-location:Cell membrane
transmembrane-regions:32-54 65-86 107-128 149-169 195-219 249-270 284-308
signal-regions:
theoretical-pi:7.22
molecular-weight:46250.5
chromosome-location:2
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:11526GenAtlasTACR1GenBank Gene DatabaseS62045GenBank Protein Database8176544IUPHAR360Guide to Pharmacology360UniProtKBP25103UniProt AccessionNK1R_HUMAN
synonyms:NK-1 receptorNK-1RNK1RSPRTAC1RTachykinin receptor 1
amino-acid-sequence:>lcl|BSEQ0000765|Substance-P receptor MDNVLPVDSDLSPNISTNTSEPNQFVQPAWQIVLWAAAYTVIVVTSVVGNVVVMWIILAH KRMRTVTNYFLVNLAFAEASMAAFNTVVNFTYAVHNEWYYGLFYCKFHNFFPIAAVFASI YSMTAVAFDRYMAIIHPLQPRLSATATKVVICVIWVLALLLAFPQGYYSTTETMPSRVVC MIEWPEHPNKIYEKVYHICVTVLIYFLPLLVIGYAYTVVGITLWASEIPGDSSDRYHEQV SAKRKVVKMMIVVVCTFAICWLPFHIFFLLPYINPDLYLKKFIQQVYLAIMWLAMSSTMY NPIIYCCLNDRFRLGFKHAFRCCPFISAGDYEGLEMKSTRYLQTQGSVYKVSRLETTIST VVGAHEEEPEDGPKATPSSLDLTSNCSSRSDSKTMTESFSFSSNVLS
gene-sequence:>lcl|BSEQ0010126|Substance-P receptor (TACR1) ATGGATAACGTCCTCCCGGTGGACTCAGACCTCTCCCCAAACATCTCCACTAACACCTCG GAACCCAATCAGTTCGTGCAACCAGCCTGGCAAATTGTCCTTTGGGCAGCTGCCTACACG GTCATTGTGGTGACCTCTGTGGTGGGCAACGTGGTAGTGATGTGGATCATCTTAGCCCAC AAAAGAATGAGGACAGTGACGAACTATTTTCTGGTGAACCTGGCCTTCGCGGAGGCCTCC ATGGCTGCATTCAATACAGTGGTGAACTTCACCTATGCTGTCCACAACGAATGGTACTAC GGCCTGTTCTACTGCAAGTTCCACAACTTCTTTCCCATCGCCGCTGTCTTCGCCAGTATC TACTCCATGACGGCTGTGGCCTTTGATAGGTACATGGCCATCATACATCCCCTCCAGCCC CGGCTGTCAGCCACAGCCACCAAAGTGGTCATCTGTGTCATCTGGGTCCTGGCTCTCCTG CTGGCCTTCCCCCAGGGCTACTACTCAACCACAGAGACCATGCCCAGCAGAGTCGTGTGC ATGATCGAATGGCCAGAGCATCCGAACAAGATTTATGAGAAAGTGTACCACATCTGTGTG ACTGTGCTGATCTACTTCCTCCCCCTGCTGGTGATTGGCTATGCATACACCGTAGTGGGA ATCACACTATGGGCCAGTGAGATCCCCGGGGACTCCTCTGACCGCTACCACGAGCAAGTC TCTGCCAAGCGCAAGGTGGTCAAAATGATGATTGTCGTGGTGTGCACCTTCGCCATCTGC TGGCTGCCCTTCCACATCTTCTTCCTCCTGCCCTACATCAACCCAGATCTCTACCTGAAG AAGTTTATCCAGCAGGTCTACCTGGCCATCATGTGGCTGGCCATGAGCTCCACCATGTAC AACCCCATCATCTACTGCTGCCTCAATGACAGGTTCCGTCTGGGCTTCAAGCATGCCTTC CGGTGCTGCCCCTTCATCAGCGCCGGCGACTATGAGGGGCTGGAAATGAAATCCACCCGG TATCTCCAGACCCAGGGCAGTGTGTACAAAGTCAGCCGCCTGGAGACCACCATCTCCACA GTGGTGGGGGCCCACGAGGAGGAGCCAGAGGACGGCCCCAAGGCCACACCCTCGTCCCTG GACCTGACCTCCAACTGCTCTTCACGAAGTGACTCCAAGACCATGACAGAGAGCTTCAGC TTCTCCTCCAATGTGCTCTCCTAG
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentplasma membranefunctionsubstance P receptor activityfunctiontachykinin receptor activityprocesscell surface receptor signaling pathwayprocessdetection of abiotic stimulusprocessinflammatory responseprocessneuropeptide signaling pathwayprocessphospholipase C-activating G-protein coupled receptor signaling pathwayprocesspositive regulation of smooth muscle contractionprocessregulation of uterine smooth muscle contractionprocessresponse to painprocesssynaptic transmissionprocesstachykinin receptor signaling pathway
id:BE0002081
name:Sodium channel protein type 2 subunit alpha
organism:Humans
action:inhibitor
Haeseler G, Foadi N, Ahrens J, Dengler R, Hecker H, Leuwer M: Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels. Pain. 2006 Dec 15;126(1-3):234-44. doi: 10.1016/j.pain.2006.07.003. Epub 2006 Sep 1.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:yes
name:Sodium channel protein type 2 subunit alpha
general-function:Voltage-gated sodium channel activity
specific-function:Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
gene-name:SCN2A
locus:2q23-q24
cellular-location:Cell membrane
transmembrane-regions:125-148 157-176 190-208 215-234 251-274 402-427 754-778 790-813 822-841 848-867 884-904 958-983 1204-1227 1241-1266 1273-1294 1299-1320 1340-1367 1447-1473 1527-1550 1562-1585 1592-1615 1626-1647 1663-1685 1752-1776
signal-regions:
theoretical-pi:5.42
molecular-weight:227972.64
chromosome-location:2
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:10588GenAtlasSCN2AGenBank Gene DatabaseM94055GenBank Protein Database457879IUPHAR579Guide to Pharmacology579UniProtKBQ99250UniProt AccessionSCN2A_HUMAN
synonyms:HBSC IINAC2SCN2A1SCN2A2Sodium channel protein brain II subunit alphaSodium channel protein type II subunit alphaVoltage-gated sodium channel subunit alpha Nav1.2
amino-acid-sequence:>lcl|BSEQ0004080|Sodium channel protein type 2 subunit alpha MAQSVLVPPGPDSFRFFTRESLAAIEQRIAEEKAKRPKQERKDEDDENGPKPNSDLEAGK SLPFIYGDIPPEMVSVPLEDLDPYYINKKTFIVLNKGKAISRFSATPALYILTPFNPIRK LAIKILVHSLFNMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKILARGFC LEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGLKTIVGA LIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCLQWPPDNSSFEINITSFFNNSL DGNGTTFNRTVSIFNWDEYIEDKSHFYFLEGQNDALLCGNSSDAGQCPEGYICVKAGRNP NYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLINLI LAVVAMAYEEQNQATLEEAEQKEAEFQQMLEQLKKQQEEAQAAAAAASAESRDFSGAGGI GVFSESSSVASKLSSKSEKELKNRRKKKKQKEQSGEEEKNDRVRKSESEDSIRRKGFRFS LEGSRLTYEKRFSSPHQSLLSIRGSLFSPRRNSRASLFSFRGRAKDIGSENDFADDEHST FEDNDSRRDSLFVPHRHGERRHSNVSQASRASRVLPILPMNGKMHSAVDCNGVVSLVGGP STLTSAGQLLPEGTTTETEIRKRRSSSYHVSMDLLEDPTSRQRAMSIASILTNTMEELEE SRQKCPPCWYKFANMCLIWDCCKPWLKVKHLVNLVVMDPFVDLAITICIVLNTLFMAMEH YPMTEQFSSVLSVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVSLSLMELGL ANVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGM QLFGKSYKECVCKISNDCELPRWHMHDFFHSFLIVFRVLCGEWIETMWDCMEVAGQTMCL TVFMMVMVIGNLVVLNLFLALLLSSFSSDNLAATDDDNEMNNLQIAVGRMQKGIDFVKRK IREFIQKAFVRKQKALDEIKPLEDLNNKKDSCISNHTTIEIGKDLNYLKDGNGTTSGIGS SVEKYVVDESDYMSFINNPSLTVTVPIAVGESDFENLNTEEFSSESDMEESKEKLNATSS SEGSTVDIGAPAEGEQPEVEPEESLEPEACFTEDCVRKFKCCQISIEEGKGKLWWNLRKT CYKIVEHNWFETFIVFMILLSSGALAFEDIYIEQRKTIKTMLEYADKVFTYIFILEMLLK WVAYGFQVYFTNAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRF EGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCINYTTGEMFDVSVV NNYSECKALIESNQTARWKNVKVNFDNVGLGYLSLLQVATFKGWMDIMYAAVDSRNVELQ PKYEDNLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNA MKKLGSKKPQKPIPRPANKFQGMVFDFVTKQVFDISIMILICLNMVTMMVETDDQSQEMT NILYWINLVFIVLFTGECVLKLISLRYYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFV SPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMS NFAYVKREVGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSGPPDCDPDKDHPGS SVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYE VWEKFDPDATQFIEFAKLSDFADALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFA FTKRVLGESGEMDALRIQMEERFMASNPSKVSYEPITTTLKRKQEEVSAIIIQRAYRRYL LKQKVKKVSSIYKKDKGKECDGTPIKEDTLIDKLNENSTPEKTDMTPSTTSPPSYDSVTK PEKEKFEKDKSEKEDKGKDIRESKK
gene-sequence:>lcl|BSEQ0021675|Sodium channel protein type 2 subunit alpha (SCN2A) ATGGCACAGTCAGTGCTGGTACCGCCAGGACCTGACAGCTTCCGCTTCTTTACCAGGGAA TCCCTTGCTGCTATTGAACAACGCATTGCAGAAGAGAAAGCTAAGAGACCCAAACAGGAA CGCAAGGATGAGGATGATGAAAATGGCCCAAAGCCAAACAGTGACTTGGAAGCAGGAAAA TCTCTTCCATTTATTTATGGAGACATTCCTCCAGAGATGGTGTCAGTGCCCCTGGAGGAT CTGGACCCCTACTATATCAATAAGAAAACGTTTATAGTATTGAATAAAGGGAAAGCAATC TCTCGATTCAGTGCCACCCCTGCCCTTTACATTTTAACTCCCTTCAACCCTATTAGAAAA TTAGCTATTAAGATTTTGGTACATTCTTTATTCAATATGCTCATTATGTGCACGATTCTT ACCAACTGTGTATTTATGACCATGAGTAACCCTCCAGACTGGACAAAGAATGTGGAGTAT ACCTTTACAGGAATTTATACTTTTGAATCACTTATTAAAATACTTGCAAGGGGCTTTTGT TTAGAAGATTTCACATTTTTACGGGATCCATGGAATTGGTTGGATTTCACAGTCATTACT TTTGCATATGTGACAGAGTTTGTGGACCTGGGCAATGTCTCAGCGTTGAGAACATTCAGA GTTCTCCGAGCATTGAAAACAATTTCAGTCATTCCAGGCCTGAAGACCATTGTGGGGGCC CTGATCCAGTCAGTGAAGAAGCTTTCTGATGTCATGATCTTGACTGTGTTCTGTCTAAGC GTGTTTGCGCTAATAGGATTGCAGTTGTTCATGGGCAACCTACGAAATAAATGTTTGCAA TGGCCTCCAGATAATTCTTCCTTTGAAATAAATATCACTTCCTTCTTTAACAATTCATTG GATGGGAATGGTACTACTTTCAATAGGACAGTGAGCATATTTAACTGGGATGAATATATT GAGGATAAAAGTCACTTTTATTTTTTAGAGGGGCAAAATGATGCTCTGCTTTGTGGCAAC AGCTCAGATGCAGGCCAGTGTCCTGAAGGATACATCTGTGTGAAGGCTGGTAGAAACCCC AACTATGGCTACACGAGCTTTGACACCTTTAGTTGGGCCTTTTTGTCCTTATTTCGTCTC ATGACTCAAGACTTCTGGGAAAACCTTTATCAACTGACACTACGTGCTGCTGGGAAAACG TACATGATATTTTTTGTGCTGGTCATTTTCTTGGGCTCATTCTATCTAATAAATTTGATC TTGGCTGTGGTGGCCATGGCCTATGAGGAACAGAATCAGGCCACATTGGAAGAGGCTGAA CAGAAGGAAGCTGAATTTCAGCAGATGCTCGAACAGTTGAAAAAGCAACAAGAAGAAGCT CAGGCGGCAGCTGCAGCCGCATCTGCTGAATCAAGAGACTTCAGTGGTGCTGGTGGGATA GGAGTTTTTTCAGAGAGTTCTTCAGTAGCATCTAAGTTGAGCTCCAAAAGTGAAAAAGAG CTGAAAAACAGAAGAAAGAAAAAGAAACAGAAAGAACAGTCTGGAGAAGAAGAGAAAAAT GACAGAGTCCGAAAATCGGAATCTGAAGACAGCATAAGAAGAAAAGGTTTCCGTTTTTCC TTGGAAGGAAGTAGGCTGACATATGAAAAGAGATTTTCTTCTCCACACCAGTCCTTACTG AGCATCCGTGGCTCCCTTTTCTCTCCAAGACGCAACAGTAGGGCGAGCCTTTTCAGCTTC AGAGGTCGAGCAAAGGACATTGGCTCTGAGAATGACTTTGCTGATGATGAGCACAGCACC TTTGAGGACAATGACAGCCGAAGAGACTCTCTGTTCGTGCCGCACAGACATGGAGAACGG CGCCACAGCAATGTCAGCCAGGCCAGCCGTGCCTCCAGGGTGCTCCCCATCCTGCCCATG AATGGGAAGATGCATAGCGCTGTGGACTGCAATGGTGTGGTCTCCCTGGTCGGGGGCCCT TCTACCCTCACATCTGCTGGGCAGCTCCTACCAGAGGGCACAACTACTGAAACAGAAATA AGAAAGAGACGGTCCAGTTCTTATCATGTTTCCATGGATTTATTGGAAGATCCTACATCA AGGCAAAGAGCAATGAGTATAGCCAGTATTTTGACCAACACCATGGAAGAACTTGAAGAA TCCAGACAGAAATGCCCACCATGCTGGTATAAATTTGCTAATATGTGTTTGATTTGGGAC TGTTGTAAACCATGGTTAAAGGTGAAACACCTTGTCAACCTGGTTGTAATGGACCCATTT GTTGACCTGGCCATCACCATCTGCATTGTCTTAAATACACTCTTCATGGCTATGGAGCAC TATCCCATGACGGAGCAGTTCAGCAGTGTACTGTCTGTTGGAAACCTGGTCTTCACAGGG ATCTTCACAGCAGAAATGTTTCTCAAGATAATTGCCATGGATCCATATTATTACTTTCAA GAAGGCTGGAATATTTTTGATGGTTTTATTGTGAGCCTTAGTTTAATGGAACTTGGTTTG GCAAATGTGGAAGGATTGTCAGTTCTCCGATCATTCCGGCTGCTCCGAGTTTTCAAGTTG GCAAAATCTTGGCCAACTCTAAATATGCTAATTAAGATCATTGGCAATTCTGTGGGGGCT CTAGGAAACCTCACCTTGGTATTGGCCATCATCGTCTTCATTTTTGCTGTGGTCGGCATG CAGCTCTTTGGTAAGAGCTACAAAGAATGTGTCTGCAAGATTTCCAATGATTGTGAACTC CCACGCTGGCACATGCATGACTTTTTCCACTCCTTCCTGATCGTGTTCCGCGTGCTGTGT GGAGAGTGGATAGAGACCATGTGGGACTGTATGGAGGTCGCTGGCCAAACCATGTGCCTT ACTGTCTTCATGATGGTCATGGTGATTGGAAATCTAGTGGTTCTGAACCTCTTCTTGGCC TTGCTTTTGAGTTCCTTCAGTTCTGACAATCTTGCTGCCACTGATGATGATAACGAAATG AATAATCTCCAGATTGCTGTGGGAAGGATGCAGAAAGGAATCGATTTTGTTAAAAGAAAA ATACGTGAATTTATTCAGAAAGCCTTTGTTAGGAAGCAGAAAGCTTTAGATGAAATTAAA CCGCTTGAAGATCTAAATAATAAAAAAGACAGCTGTATTTCCAACCATACCACCATAGAA ATAGGCAAAGACCTCAATTATCTCAAAGACGGAAATGGAACTACTAGTGGCATAGGCAGC AGTGTAGAAAAATATGTCGTGGATGAAAGTGATTACATGTCATTTATAAACAACCCTAGC CTCACTGTGACAGTACCAATTGCTGTTGGAGAATCTGACTTTGAAAATTTAAATACTGAA GAATTCAGCAGCGAGTCAGATATGGAGGAAAGCAAAGAGAAGCTAAATGCAACTAGTTCA TCTGAAGGCAGCACGGTTGATATTGGAGCTCCCGCCGAGGGAGAACAGCCTGAGGTTGAA CCTGAGGAATCCCTTGAACCTGAAGCCTGTTTTACAGAAGACTGTGTACGGAAGTTCAAG TGTTGTCAGATAAGCATAGAAGAAGGCAAAGGGAAACTCTGGTGGAATTTGAGGAAAACA TGCTATAAGATAGTGGAGCACAATTGGTTCGAAACCTTCATTGTCTTCATGATTCTGCTG AGCAGTGGGGCTCTGGCCTTTGAAGATATATACATTGAGCAGCGAAAAACCATTAAGACC ATGTTAGAATATGCTGACAAGGTTTTCACTTACATATTCATTCTGGAAATGCTGCTAAAG TGGGTTGCATATGGTTTTCAAGTGTATTTTACCAATGCCTGGTGCTGGCTAGACTTCCTG ATTGTTGATGTCTCACTGGTTAGCTTAACTGCAAATGCCTTGGGTTACTCAGAACTTGGT GCCATCAAATCCCTCAGAACACTAAGAGCTCTGAGGCCACTGAGAGCTTTGTCCCGGTTT GAAGGAATGAGGGTTGTTGTAAATGCTCTTTTAGGAGCCATTCCATCTATCATGAATGTA CTTCTGGTTTGTCTGATCTTTTGGCTAATATTCAGTATCATGGGAGTGAATCTCTTTGCT GGCAAGTTTTACCATTGTATTAATTACACCACTGGAGAGATGTTTGATGTAAGCGTGGTC AACAACTACAGTGAGTGCAAAGCTCTCATTGAGAGCAATCAAACTGCCAGGTGGAAAAAT GTGAAAGTAAACTTTGATAACGTAGGACTTGGATATCTGTCTCTACTTCAAGTAGCCACG TTTAAGGGATGGATGGATATTATGTATGCAGCTGTTGATTCACGAAATGTAGAATTACAA CCCAAGTATGAAGACAACCTGTACATGTATCTTTATTTTGTCATCTTTATTATTTTTGGT TCATTCTTTACCTTGAATCTTTTCATTGGTGTCATCATAGATAACTTCAACCAACAGAAA AAGAAGTTTGGAGGTCAAGACATTTTTATGACAGAAGAACAGAAGAAATACTACAATGCA ATGAAAAAACTGGGTTCAAAGAAACCACAAAAACCCATACCTCGACCTGCTAACAAATTC CAAGGAATGGTCTTTGATTTTGTAACCAAACAAGTCTTTGATATCAGCATCATGATCCTC ATCTGCCTTAACATGGTCACCATGATGGTGGAAACCGATGACCAGAGTCAAGAAATGACA AACATTCTGTACTGGATTAATCTGGTGTTTATTGTTCTGTTCACTGGAGAATGTGTGCTG AAACTGATCTCTCTTCGTTACTACTATTTCACTATTGGATGGAATATTTTTGATTTTGTG GTGGTCATTCTCTCCATTGTAGGAATGTTTCTGGCTGAACTGATAGAAAAGTATTTTGTG TCCCCTACCCTGTTCCGAGTGATCCGTCTTGCCAGGATTGGCCGAATCCTACGTCTGATC AAAGGAGCAAAGGGGATCCGCACGCTGCTCTTTGCTTTGATGATGTCCCTTCCTGCGTTG TTTAACATCGGCCTCCTTCTTTTCCTGGTCATGTTCATCTACGCCATCTTTGGGATGTCC AATTTTGCCTATGTTAAGAGGGAAGTTGGGATCGATGACATGTTCAACTTTGAGACCTTT GGCAACAGCATGATCTGCCTGTTCCAAATTACAACCTCTGCTGGCTGGGATGGATTGCTA GCACCTATTCTTAATAGTGGACCTCCAGACTGTGACCCTGACAAAGATCACCCTGGAAGC TCAGTTAAAGGAGACTGTGGGAACCCATCTGTTGGGATTTTCTTTTTTGTCAGTTACATC ATCATATCCTTCCTGGTTGTGGTGAACATGTACATCGCGGTCATCCTGGAGAACTTCAGT GTTGCTACTGAAGAAAGTGCAGAGCCTCTGAGTGAGGATGACTTTGAGATGTTCTATGAG GTTTGGGAGAAGTTTGATCCCGATGCGACCCAGTTTATAGAGTTTGCCAAACTTTCTGAT TTTGCAGATGCCCTGGATCCTCCTCTTCTCATAGCAAAACCCAACAAAGTCCAGCTCATT GCCATGGATCTGCCCATGGTGAGTGGTGACCGGATCCACTGTCTTGACATCTTATTTGCT TTTACAAAGCGTGTTTTGGGTGAGAGTGGAGAGATGGATGCCCTTCGAATACAGATGGAA GAGCGATTCATGGCATCAAACCCCTCCAAAGTCTCTTATGAGCCCATTACGACCACGTTG AAACGCAAACAAGAGGAGGTGTCTGCTATTATTATCCAGAGGGCTTACAGACGCTACCTC TTGAAGCAAAAAGTTAAAAAGGTATCAAGTATATACAAGAAAGACAAAGGCAAAGAATGT GATGGAACACCCATCAAAGAAGATACTCTCATTGATAAACTGAATGAGAATTCAACTCCA GAGAAAACCGATATGACGCCTTCCACCACGTCTCCACCCTCGTATGATAGTGTGACCAAA CCAGAAAAAGAAAAATTTGAAAAAGACAAATCAGAAAAGGAAGACAAAGGGAAAGATATC AGGGAAAGTAAAAAGTAA
pfams:PF00520Ion_transPF06512Na_trans_assocPF11933Na_trans_cytopl
go-classifiers:componentaxoncomponentintegral component of plasma membranecomponentintercalated disccomponentintracellularcomponentintrinsic component of plasma membranecomponentnode of Ranviercomponentparanode region of axoncomponentplasma membranecomponentsodium channel complexcomponentT-tubulecomponentvoltage-gated sodium channel complexfunctionvoltage-gated sodium channel activityprocessintrinsic apoptotic signaling pathway in response to osmotic stressprocessmembrane depolarization during action potentialprocessmyelinationprocessneuron apoptotic processprocessneuronal action potentialprocesssodium ion transmembrane transportprocesssodium ion transport
id:BE0001023
name:Transient receptor potential cation channel subfamily V member 1
organism:Humans
action:agonist
Marincsak R, Toth BI, Czifra G, Szabo T, Kovacs L, Biro T: The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1. Anesth Analg. 2008 Jun;106(6):1890-6. doi: 10.1213/ane.0b013e318172fefc.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:no
name:Transient receptor potential cation channel subfamily V member 1
general-function:Transmembrane signaling receptor activity
specific-function:Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis (By similarity). Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel.
gene-name:TRPV1
locus:17p13.3
cellular-location:Cell junction
transmembrane-regions:434-454 472-497 511-531 536-556 572-599 659-687
signal-regions:
theoretical-pi:7.26
molecular-weight:94955.33
chromosome-location:17
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:12716GenAtlasTRPV1GenBank Gene DatabaseAJ277028GenBank Protein Database8977866IUPHAR507Guide to Pharmacology507UniProtKBQ8NER1UniProt AccessionTRPV1_HUMAN
synonyms:Capsaicin receptorOsm-9-like TRP channel 1OTRPC1TrpV1Vanilloid receptor 1VR1
amino-acid-sequence:>lcl|BSEQ0037113|Transient receptor potential cation channel subfamily V member 1 MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFP VDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFE AVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEI ARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKT KGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTA DNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQE PECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLN RLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEIL SVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVAS MVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIE DGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVF IILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKA FRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRS SRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK
gene-sequence:>lcl|BSEQ0020500|Transient receptor potential cation channel subfamily V member 1 (TRPV1) ATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTCCAAAAGGACACC TGCCCAGACCCCCTGGATGGAGACCCTAACTCCAGGCCACCTCCAGCCAAGCCCCAGCTC TCCACGGCCAAGAGCCGCACCCGGCTCTTTGGGAAGGGTGACTCGGAGGAGGCTTTCCCG GTGGATTGCCCTCACGAGGAAGGTGAGCTGGACTCCTGCCCGACCATCACAGTCAGCCCT GTTATCACCATCCAGAGGCCAGGAGACGGCCCCACCGGTGCCAGGCTGCTGTCCCAGGAC TCTGTCGCCGCCAGCACCGAGAAGACCCTCAGGCTCTATGATCGCAGGAGTATCTTTGAA GCCGTTGCTCAGAATAACTGCCAGGATCTGGAGAGCCTGCTGCTCTTCCTGCAGAAGAGC AAGAAGCACCTCACAGACAACGAGTTCAAAGACCCTGAGACAGGGAAGACCTGTCTGCTG AAAGCCATGCTCAACCTGCACGACGGACAGAACACCACCATCCCCCTGCTCCTGGAGATC GCGCGGCAAACGGACAGCCTGAAGGAGCTTGTCAACGCCAGCTACACGGACAGCTACTAC AAGGGCCAGACAGCACTGCACATCGCCATCGAGAGACGCAACATGGCCCTGGTGACCCTC CTGGTGGAGAACGGAGCAGACGTCCAGGCTGCGGCCCATGGGGACTTCTTTAAGAAAACC AAAGGGCGGCCTGGATTCTACTTCGGTGAACTGCCCCTGTCCCTGGCCGCGTGCACCAAC CAGCTGGGCATCGTGAAGTTCCTGCTGCAGAACTCCTGGCAGACGGCCGACATCAGCGCC AGGGACTCGGTGGGCAACACGGTGCTGCACGCCCTGGTGGAGGTGGCCGACAACACGGCC GACAACACGAAGTTTGTGACGAGCATGTACAATGAGATTCTGATGCTGGGGGCCAAACTG CACCCGACGCTGAAGCTGGAGGAGCTCACCAACAAGAAGGGAATGACGCCGCTGGCTCTG GCAGCTGGGACCGGGAAGATCGGGGTCTTGGCCTATATTCTCCAGCGGGAGATCCAGGAG CCCGAGTGCAGGCACCTGTCCAGGAAGTTCACCGAGTGGGCCTACGGGCCCGTGCACTCC TCGCTGTACGACCTGTCCTGCATCGACACCTGCGAGAAGAACTCGGTGCTGGAGGTGATC GCCTACAGCAGCAGCGAGACCCCTAATCGCCACGACATGCTCTTGGTGGAGCCGCTGAAC CGACTCCTGCAGGACAAGTGGGACAGATTCGTCAAGCGCATCTTCTACTTCAACTTCCTG GTCTACTGCCTGTACATGATCATCTTCACCATGGCTGCCTACTACAGGCCCGTGGATGGC TTGCCTCCCTTTAAGATGGAAAAAACTGGAGACTATTTCCGAGTTACTGGAGAGATCCTG TCTGTGTTAGGAGGAGTCTACTTCTTTTTCCGAGGGATTCAGTATTTCCTGCAGAGGCGG CCGTCGATGAAGACCCTGTTTGTGGACAGCTACAGTGAGATGCTTTTCTTTCTGCAGTCA CTGTTCATGCTGGCCACCGTGGTGCTGTACTTCAGCCACCTCAAGGAGTATGTGGCTTCC ATGGTATTCTCCCTGGCCTTGGGCTGGACCAACATGCTCTACTACACCCGCGGTTTCCAG CAGATGGGCATCTATGCCGTCATGATAGAGAAGATGATCCTGAGAGACCTGTGCCGTTTC ATGTTTGTCTACATCGTCTTCTTGTTCGGGTTTTCCACAGCGGTGGTGACGCTGATTGAA GACGGGAAGAATGACTCCCTGCCGTCTGAGTCCACGTCGCACAGGTGGCGGGGGCCTGCC TGCAGGCCCCCCGATAGCTCCTACAACAGCCTGTACTCCACCTGCCTGGAGCTGTTCAAG TTCACCATCGGCATGGGCGACCTGGAGTTCACTGAGAACTATGACTTCAAGGCTGTCTTC ATCATCCTGCTGCTGGCCTATGTAATTCTCACCTACATCCTCCTGCTCAACATGCTCATC GCCCTCATGGGTGAGACTGTCAACAAGATCGCACAGGAGAGCAAGAACATCTGGAAGCTG CAGAGAGCCATCACCATCCTGGACACGGAGAAGAGCTTCCTTAAGTGCATGAGGAAGGCC TTCCGCTCAGGCAAGCTGCTGCAGGTGGGGTACACACCTGATGGCAAGGACGACTACCGG TGGTGCTTCAGGGTGGACGAGGTGAACTGGACCACCTGGAACACCAACGTGGGCATCATC AACGAAGACCCGGGCAACTGTGAGGGCGTCAAGCGCACCCTGAGCTTCTCCCTGCGGTCA AGCAGAGTTTCAGGCAGACACTGGAAGAACTTTGCCCTGGTCCCCCTTTTAAGAGAGGCA AGTGCTCGAGATAGGCAGTCTGCTCAGCCCGAGGAAGTTTATCTGCGACAGTTTTCAGGG TCTCTGAAGCCAGAGGACGCTGAGGTCTTCAAGAGTCCTGCCGCTTCCGGGGAGAAGTGA
pfams:PF00520Ion_transPF12796Ank_2
go-classifiers:componentcell junctioncomponentdendritic spine membranecomponentintegral component of membranecomponentintegral component of plasma membranecomponentintrinsic component of plasma membranecomponentplasma membranecomponentpostsynaptic membranefunctionATP bindingfunctioncalcium channel activityfunctioncalcium-release channel activityfunctionexcitatory extracellular ligand-gated ion channel activityfunctionphosphoprotein bindingfunctiontransmembrane signaling receptor activityprocesscalcium ion transmembrane transportprocesscell surface receptor signaling pathwayprocesscellular response to alkaloidprocesscellular response to ATPprocesschemosensory behaviorprocession transmembrane transportprocessthermoceptionprocesstransmembrane transportprocesstransport
id:BE0004956
name:NMDA receptor
organism:Humans
action:inhibitor
Hara K, Minami K, Sata T: The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg. 2005 May;100(5):1400-5, table of contents.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:yes
name:Glutamate receptor ionotropic, NMDA 1
general-function:Voltage-gated cation channel activity
specific-function:NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
gene-name:GRIN1
locus:9q34.3
cellular-location:Cell membrane
transmembrane-regions:560-580 637-657 813-833
signal-regions:1-18
theoretical-pi:9.2
molecular-weight:105371.945
chromosome-location:9
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4584GenAtlasGRIN1GenBank Gene DatabaseD13515GenBank Protein Database219920IUPHAR455UniProtKBQ05586UniProt AccessionNMDZ1_HUMAN
synonyms:GluN1Glutamate [NMDA] receptor subunit zeta-1N-methyl-D-aspartate receptor subunit NR1NMD-R1NMDAR1
amino-acid-sequence:>lcl|BSEQ0000727|Glutamate receptor ionotropic, NMDA 1 MSTMRLLTLALLFSCSVARAACDPKIVNIGAVLSTRKHEQMFREAVNQANKRHGSWKIQL NATSVTHKPNAIQMALSVCEDLISSQVYAILVSHPPTPNDHFTPTPVSYTAGFYRIPVLG LTTRMSIYSDKSIHLSFLRTVPPYSHQSSVWFEMMRVYSWNHIILLVSDDHEGRAAQKRL ETLLEERESKAEKVLQFDPGTKNVTALLMEAKELEARVIILSASEDDAATVYRAAAMLNM TGSGYVWLVGEREISGNALRYAPDGILGLQLINGKNESAHISDAVGVVAQAVHELLEKEN ITDPPRGCVGNTNIWKTGPLFKRVLMSSKYADGVTGRVEFNEDGDRKFANYSIMNLQNRK LVQVGIYNGTHVIPNDRKIIWPGGETEKPRGYQMSTRLKIVTIHQEPFVYVKPTLSDGTC KEEFTVNGDPVKKVICTGPNDTSPGSPRHTVPQCCYGFCIDLLIKLARTMNFTYEVHLVA DGKFGTQERVNNSNKKEWNGMMGELLSGQADMIVAPLTINNERAQYIEFSKPFKYQGLTI LVKKEIPRSTLDSFMQPFQSTLWLLVGLSVHVVAVMLYLLDRFSPFGRFKVNSEEEEEDA LTLSSAMWFSWGVLLNSGIGEGAPRSFSARILGMVWAGFAMIIVASYTANLAAFLVLDRP EERITGINDPRLRNPSDKFIYATVKQSSVDIYFRRQVELSTMYRHMEKHNYESAAEAIQA VRDNKLHAFIWDSAVLEFEASQKCDLVTTGELFFRSGFGIGMRKDSPWKQNVSLSILKSH ENGFMEDLDKTWVRYQECDSRSNAPATLTFENMAGVFMLVAGGIVAGIFLIFIEIAYKRH KDARRKQMQLAFAAVNVWRKNLQDRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDT STGGGRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES
gene-sequence:>lcl|BSEQ0016071|Glutamate receptor ionotropic, NMDA 1 (GRIN1) ATGAGCACCATGCGCCTGCTGACGCTCGCCCTGCTGTTCTCCTGCTCCGTCGCCCGTGCC GCGTGCGACCCCAAGATCGTCAACATTGGCGCGGTGCTGAGCACGCGGAAGCACGAGCAG ATGTTCCGCGAGGCCGTGAACCAGGCCAACAAGCGGCACGGCTCCTGGAAGATTCAGCTC AATGCCACCTCCGTCACGCACAAGCCCAACGCCATCCAGATGGCTCTGTCGGTGTGCGAG GACCTCATCTCCAGCCAGGTCTACGCCATCCTAGTTAGCCATCCACCTACCCCCAACGAC CACTTCACTCCCACCCCTGTCTCCTACACAGCCGGCTTCTACCGCATACCCGTGCTGGGG CTGACCACCCGCATGTCCATCTACTCGGACAAGAGCATCCACCTGAGCTTCCTGCGCACC GTGCCGCCCTACTCCCACCAGTCCAGCGTGTGGTTTGAGATGATGCGTGTCTACAGCTGG AACCACATCATCCTGCTGGTCAGCGACGACCACGAGGGCCGGGCGGCTCAGAAACGCCTG GAGACGCTGCTGGAGGAGCGTGAGTCCAAGGCAGAGAAGGTGCTGCAGTTTGACCCAGGG ACCAAGAACGTGACGGCCCTGCTGATGGAGGCGAAAGAGCTGGAGGCCCGGGTCATCATC CTTTCTGCCAGCGAGGACGATGCTGCCACTGTATACCGCGCAGCCGCGATGCTGAACATG ACGGGCTCCGGGTACGTGTGGCTGGTCGGCGAGCGCGAGATCTCGGGGAACGCCCTGCGC TACGCCCCAGACGGCATCCTCGGGCTGCAGCTCATCAACGGCAAGAACGAGTCGGCCCAC ATCAGCGACGCCGTGGGCGTGGTGGCCCAGGCCGTGCACGAGCTCCTCGAGAAGGAGAAC ATCACCGACCCGCCGCGGGGCTGCGTGGGCAACACCAACATCTGGAAGACCGGGCCGCTC TTCAAGAGAGTGCTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTGGAGTTC AATGAGGATGGGGACCGGAAGTTCGCCAACTACAGCATCATGAACCTGCAGAACCGCAAG CTGGTGCAAGTGGGCATCTACAATGGCACCCACGTCATCCCTAATGACAGGAAGATCATC TGGCCAGGCGGAGAGACAGAGAAGCCTCGAGGGTACCAGATGTCCACCAGACTGAAGATT GTGACGATCCACCAGGAGCCCTTCGTGTACGTCAAGCCCACGCTGAGTGATGGGACATGC AAGGAGGAGTTCACAGTCAACGGCGACCCAGTCAAGAAGGTGATCTGCACCGGGCCCAAC GACACGTCGCCGGGCAGCCCCCGCCACACGGTGCCTCAGTGTTGCTACGGCTTTTGCATC GACCTGCTCATCAAGCTGGCACGGACCATGAACTTCACCTACGAGGTGCACCTGGTGGCA GATGGCAAGTTCGGCACACAGGAGCGGGTGAACAACAGCAACAAGAAGGAGTGGAATGGG ATGATGGGCGAGCTGCTCAGCGGGCAGGCAGACATGATCGTGGCGCCGCTAACCATAAAC AACGAGCGCGCGCAGTACATCGAGTTTTCCAAGCCCTTCAAGTACCAGGGCCTGACTATT CTGGTCAAGAAGGAGATTCCCCGGAGCACGCTGGACTCGTTCATGCAGCCGTTCCAGAGC ACACTGTGGCTGCTGGTGGGGCTGTCGGTGCACGTGGTGGCCGTGATGCTGTACCTGCTG GACCGCTTCAGCCCCTTCGGCCGGTTCAAGGTGAACAGCGAGGAGGAGGAGGAGGACGCA CTGACCCTGTCCTCGGCCATGTGGTTCTCCTGGGGCGTCCTGCTCAACTCCGGCATCGGG GAAGGCGCCCCCAGAAGCTTCTCAGCGCGCATCCTGGGCATGGTGTGGGCCGGCTTTGCC ATGATCATCGTGGCCTCCTACACCGCCAACCTGGCGGCCTTCCTGGTGCTGGACCGGCCG GAGGAGCGCATCACGGGCATCAACGACCCTCGGCTGAGGAACCCCTCGGACAAGTTTATC TACGCCACGGTGAAGCAGAGCTCCGTGGATATCTACTTCCGGCGCCAGGTGGAGCTGAGC ACCATGTACCGGCATATGGAGAAGCACAACTACGAGAGTGCGGCGGAGGCCATCCAGGCC GTGAGAGACAACAAGCTGCATGCCTTCATCTGGGACTCGGCGGTGCTGGAGTTCGAGGCC TCGCAGAAGTGCGACCTGGTGACGACTGGAGAGCTGTTTTTCCGCTCGGGCTTCGGCATA GGCATGCGCAAAGACAGCCCCTGGAAGCAGAACGTCTCCCTGTCCATCCTCAAGTCCCAC GAGAATGGCTTCATGGAAGACCTGGACAAGACGTGGGTTCGGTATCAGGAATGTGACTCG CGCAGCAACGCCCCTGCGACCCTTACTTTTGAGAACATGGCCGGGGTCTTCATGCTGGTA GCTGGGGGCATCGTGGCCGGGATCTTCCTGATTTTCATCGAGATTGCCTACAAGCGGCAC AAGGATGCTCGCCGGAAGCAGATGCAGCTGGCCTTTGCCGCCGTTAACGTGTGGCGGAAG AACCTGCAGCAGTACCATCCCACTGATATCACGGGCCCGCTCAACCTCTCAGATCCCTCG GTCAGCACCGTGGTGTGA
pfams:PF01094ANF_receptorPF00060Lig_chanPF10613Lig_chan-Glu_bdPF10562CaM_bdg_C0
go-classifiers:componentcell junctioncomponentcell surfacecomponentdendritecomponentdendrite membranecomponentdendritic branchcomponentdendritic spinecomponentendoplasmic reticulumcomponentexcitatory synapsecomponentintegral component of plasma membranecomponentneuron projectioncomponentneuronal cell bodycomponentneuronal postsynaptic densitycomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic densitycomponentpostsynaptic membranecomponentsynapsecomponentsynaptic cleftcomponentsynaptic vesiclecomponentterminal boutonfunctioncalcium channel activityfunctioncalcium ion bindingfunctioncalmodulin bindingfunctionextracellular-glutamate-gated ion channel activityfunctionglutamate bindingfunctionglycine bindingfunctionneurotransmitter bindingfunctionNMDA glutamate receptor activityfunctionvoltage-gated cation channel activityprocessactivation of MAPKK activityprocessadult locomotory behaviorprocessaxon guidanceprocesscalcium ion homeostasisprocesscalcium ion transmembrane transportprocesscation transportprocesscellular calcium ion homeostasisprocesscellular response to manganese ionprocesscerebral cortex developmentprocessconditioned taste aversionprocessephrin receptor signaling pathwayprocessepidermal growth factor receptor signaling pathwayprocessexcitatory postsynaptic potentialprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessinnate immune responseprocessinsulin receptor signaling pathwayprocession transmembrane transportprocessionotropic glutamate receptor signaling pathwayprocesslong-term memoryprocessmale mating behaviorprocessMAPK cascadeprocessnegative regulation of neuron apoptotic processprocessneurotrophin TRK receptor signaling pathwayprocessolfactory learningprocesspons maturationprocesspositive regulation of apoptotic processprocesspositive regulation of excitatory postsynaptic potentialprocesspositive regulation of transcription from RNA polymerase II promoterprocessprepulse inhibitionprocesspropylene metabolic processprocessprotein tetramerizationprocessRas protein signal transductionprocessregulation of axonogenesisprocessregulation of dendrite morphogenesisprocessregulation of long-term neuronal synaptic plasticityprocessregulation of membrane potentialprocessregulation of respiratory gaseous exchangeprocessregulation of synapse assemblyprocessrespiratory gaseous exchangeprocessresponse to amphetamineprocessresponse to calcium ionprocessresponse to ethanolprocessresponse to fungicideprocessresponse to morphineprocessrhythmic processprocesssensory perception of painprocesssmall GTPase mediated signal transductionprocesssocial behaviorprocesssuckling behaviorprocesssynaptic transmissionprocesssynaptic transmission, glutamatergicprocessvascular endothelial growth factor receptor signaling pathwayprocessvisual learning
name:Glutamate receptor ionotropic, NMDA 2A
general-function:Zinc ion binding
specific-function:NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.
gene-name:GRIN2A
locus:16p13.2
cellular-location:Cell membrane
transmembrane-regions:556-576 634-654 817-837
signal-regions:1-22
theoretical-pi:7.11
molecular-weight:165281.215
chromosome-location:16
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4585GenAtlasGRIN2AGenBank Gene DatabaseU09002GenBank Protein Database558749IUPHAR456Guide to Pharmacology456UniProtKBQ12879UniProt AccessionNMDE1_HUMAN
synonyms:GluN2AGlutamate [NMDA] receptor subunit epsilon-1hNR2AN-methyl D-aspartate receptor subtype 2ANMDAR2ANR2A
amino-acid-sequence:>lcl|BSEQ0001516|Glutamate receptor ionotropic, NMDA 2A MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQA AGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHT FVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGY REFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLIL SEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILT TAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPR LVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVE DIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLV TNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRS NGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFT IGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVD QVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSL KTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALL QFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHL FYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRS AKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNM NELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDS IRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNH KTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVT LPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPH SETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNP ATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLL EGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIG RCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYS TPRVLNSCSNRRVYKKMPSIESDV
gene-sequence:>lcl|BSEQ0016199|Glutamate receptor ionotropic, NMDA 2A (GRIN2A) ATGGGCAGAGTGGGCTATTGGACCCTGCTGGTGCTGCCGGCCCTTCTGGTCTGGCGCGGT CCGGCGCCGAGCGCGGCGGCGGAGAAGGGTCCCCCCGCGCTAAATATTGCGGTGATGCTG GGTCACAGCCACGACGTGACAGAGCGCGAACTTCGAACACTGTGGGGCCCCGAGCAGGCG GCGGGGCTGCCCCTGGACGTGAACGTGGTAGCTCTGCTGATGAACCGCACCGACCCCAAG AGCCTCATCACGCACGTGTGCGACCTCATGTCCGGGGCACGCATCCACGGCCTCGTGTTT GGGGACGACACGGACCAGGAGGCCGTAGCCCAGATGCTGGATTTTATCTCCTCCCACACC TTCGTCCCCATCTTGGGCATTCATGGGGGCGCATCTATGATCATGGCTGACAAGGATCCG ACGTCTACCTTCTTCCAGTTTGGAGCGTCCATCCAGCAGCAAGCCACGGTCATGCTGAAG ATCATGCAGGATTATGACTGGCATGTCTTCTCCCTGGTGACCACTATCTTCCCTGGCTAC AGGGAATTCATCAGCTTCGTCAAGACCACAGTGGACAACAGCTTTGTGGGCTGGGACATG CAGAATGTGATCACACTGGACACTTCCTTTGAGGATGCAAAGACACAAGTCCAGCTGAAG AAGATCCACTCTTCTGTCATCTTGCTCTACTGTTCCAAAGACGAGGCTGTTCTCATTCTG AGTGAGGCCCGCTCCCTTGGCCTCACCGGGTATGATTTCTTCTGGATTGTCCCCAGCTTG GTCTCTGGGAACACGGAGCTCATCCCAAAAGAGTTTCCATCGGGACTCATTTCTGTCTCC TACGATGACTGGGACTACAGCCTGGAGGCGAGAGTGAGGGACGGCATTGGCATCCTAACC ACCGCTGCATCTTCTATGCTGGAGAAGTTCTCCTACATCCCCGAGGCCAAGGCCAGCTGC TACGGGCAGATGGAGAGGCCAGAGGTCCCGATGCACACCTTGCACCCATTTATGGTCAAT GTTACATGGGATGGCAAAGACTTATCCTTCACTGAGGAAGGCTACCAGGTGCACCCCAGG CTGGTGGTGATTGTGCTGAACAAAGACCGGGAATGGGAAAAGGTGGGCAAGTGGGAGAAC CATACGCTGAGCCTGAGGCACGCCGTGTGGCCCAGGTACAAGTCCTTCTCCGACTGTGAG CCGGATGACAACCATCTCAGCATCGTCACCCTGGAGGAGGCCCCATTCGTCATCGTGGAA GACATAGACCCCCTGACCGAGACGTGTGTGAGGAACACCGTGCCATGTCGGAAGTTCGTC AAAATCAACAATTCAACCAATGAGGGGATGAATGTGAAGAAATGCTGCAAGGGGTTCTGC ATTGATATTCTGAAGAAGCTTTCCAGAACTGTGAAGTTTACTTACGACCTCTATCTGGTG ACCAATGGGAAGCATGGCAAGAAAGTTAACAATGTGTGGAATGGAATGATCGGTGAAGTG GTCTATCAACGGGCAGTCATGGCAGTTGGCTCGCTCACCATCAATGAGGAACGTTCTGAA GTGGTGGACTTCTCTGTGCCCTTTGTGGAAACGGGAATCAGTGTCATGGTTTCAAGAAGT AATGGCACCGTCTCACCTTCTGCTTTTCTAGAACCATTCAGCGCCTCTGTCTGGGTGATG ATGTTTGTGATGCTGCTCATTGTTTCTGCCATAGCTGTTTTTGTCTTTGAATACTTCAGC CCTGTTGGATACAACAGAAACTTAGCCAAAGGGAAAGCACCCCATGGGCCTTCTTTTACA ATTGGAAAAGCTATATGGCTTCTTTGGGGCCTGGTGTTCAATAACTCCGTGCCTGTCCAG AATCCTAAAGGGACCACCAGCAAGATCATGGTATCTGTATGGGCCTTCTTCGCTGTCATA TTCCTGGCTAGCTACACAGCCAATCTGGCTGCCTTCATGATCCAAGAGGAATTTGTGGAC CAAGTGACCGGCCTCAGTGACAAAAAGTTTCAGAGACCTCATGACTATTCCCCACCTTTT CGATTTGGGACAGTGCCTAATGGAAGCACGGAGAGAAACATTCGGAATAACTATCCCTAC ATGCATCAGTACATGACCAAATTTAATCAGAAAGGAGTAGAGGACGCCTTGGTCAGCCTG AAAACGGGGAAGCTGGACGCTTTCATCTACGATGCCGCAGTCTTGAATTACAAGGCTGGG AGGGATGAAGGCTGCAAGCTGGTGACCATCGGGAGTGGGTACATCTTTGCCACCACCGGT TATGGAATTGCCCTTCAGAAAGGCTCTCCTTGGAAGAGGCAGATCGACCTGGCCTTGCTT CAGTTTGTGGGTGATGGTGAGATGGAGGAGCTGGAGACCCTGTGGCTCACTGGGATCTGC CACAACGAGAAGAACGAGGTGATGAGCAGCCAGCTGGACATTGACAACATGGCGGGCGTA TTCTACATGCTGGCTGCCGCCATGGCCCTTAGCCTCATCACCTTCATCTGGGAGCACCTC TTCTACTGGAAGCTGCGCTTCTGTTTCACGGGCGTGTGCTCCGACCGGCCTGGGTTGCTC TTCTCCATCAGCAGGGGCATCTACAGCTGCATTCATGGAGTGCACATTGAAGAAAAGAAG AAGTCTCCAGACTTCAATCTGACGGGATCCCAGAGCAACATGTTAAAACTCCTCCGGTCA GCCAAAAACATTTCCAGCATGTCCAACATGAACTCCTCAAGAATGGACTCACCCAAAAGA GCTGCTGACTTCATCCAAAGAGGTTCCCTCATCATGGACATGGTTTCAGATAAGGGGAAT TTGATGTACTCAGACAACAGGTCCTTTCAGGGGAAAGAGAGCATTTTTGGAGACAACATG AACGAACTCCAAACATTTGTGGCCAACCGGCAGAAGGATAACCTCAATAACTATGTATTC CAGGGACAACATCCTCTTACTCTCAATGAGTCCAACCCTAACACGGTGGAGGTGGCCGTG AGCACAGAATCCAAAGCGAACTCTAGACCCCGGCAGCTGTGGAAGAAATCCGTGGATTCC ATACGCCAGGATTCACTATCCCAGAATCCAGTCTCCCAGAGGGATGAGGCAACAGCAGAG AATAGGACCCACTCCCTAAAGAGCCCTAGGTATCTTCCAGAAGAGATGGCCCACTCTGAC ATTTCAGAAACGTCAAATCGGGCCACGTGCCACAGGGAACCTGACAACAGTAAGAACCAC AAAACCAAGGACAACTTTAAAAGGTCAGTGGCCTCCAAATACCCCAAGGACTGTAGTGAG GTCGAGCGCACCTACCTGAAAACCAAATCAAGCTCCCCTAGAGACAAGATCTACACTATA GATGGTGAGAAGGAGCCTGGTTTCCACTTAGATCCACCCCAGTTTGTTGAAAATGTGACC CTGCCCGAGAACGTGGACTTCCCGGACCCCTACCAGGATCCCAGTGAAAACTTCCGCAAG GGGGACTCCACGCTGCCAATGAACCGGAACCCCTTGCATAATGAAGAGGGGCTTTCCAAC AACGACCAGTATAAACTCTACTCCAAGCACTTCACCTTGAAAGACAAGGGTTCCCCGCAC AGTGAGACCAGCGAGCGATACCGGCAGAACTCCACGCACTGCAGAAGCTGCCTTTCCAAC ATGCCCACCTATTCAGGCCACTTCACCATGAGGTCCCCCTTCAAGTGCGATGCCTGCCTG CGGATGGGGAACCTCTATGACATCGATGAAGACCAGATGCTTCAGGAGACAGGTAACCCA GCCACCGGGGAGCAGGTCTACCAGCAGGACTGGGCACAGAACAATGCCCTTCAATTACAA AAGAACAAGCTAAGGATTAGCCGTCAGCATTCCTACGATAACATTGTCGACAAACCTAGG GAGCTAGACCTTAGCAGGCCCTCCCGGAGCATAAGCCTCAAGGACAGGGAACGGCTTCTG GAGGGAAATTTTTACGGCAGCCTGTTTAGTGTCCCCTCAAGCAAACTCTCGGGGAAAAAA AGCTCCCTTTTCCCCCAAGGTCTGGAGGACAGCAAGAGGAGCAAGTCTCTCTTGCCAGAC CACACCTCCGATAACCCTTTCCTCCACTCCCACAGGGATGACCAACGCTTGGTTATTGGG AGATGCCCCTCGGACCCTTACAAACACTCGTTGCCATCCCAGGCGGTGAATGACAGCTAT CTTCGGTCGTCCTTGAGGTCAACGGCATCGTACTGTTCCAGGGACAGTCGGGGCCACAAT GATGTGTATATTTCGGAGCATGTTATGCCTTATGCTGCAAATAAGAATAATATGTACTCT ACCCCCAGGGTTTTAAATTCCTGCAGCAATAGACGCGTGTACAAGAAAATGCCTAGTATC GAATCTGATGTTTAA
pfams:PF01094ANF_receptorPF00060Lig_chanPF10613Lig_chan-Glu_bdPF10565NMDAR2_C
go-classifiers:componentcell junctioncomponentcell surfacecomponentdendritecomponentendoplasmic reticulumcomponentintegral component of plasma membranecomponentneuronal postsynaptic densitycomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic membranecomponentpresynaptic membranecomponentsynaptic vesiclecomponentterminal boutonfunctioncalcium channel activityfunctionextracellular-glutamate-gated ion channel activityfunctionglutamate bindingfunctionneurotransmitter bindingfunctionNMDA glutamate receptor activityfunctionvoltage-gated cation channel activityfunctionzinc ion bindingprocessaction potentialprocessactivation of MAPKK activityprocessaxon guidanceprocesscellular response to amino acid stimulusprocesscellular response to dsRNAprocesscellular response to lipidprocesscellular response to magnesium ionprocesscellular response to manganese ionprocesscellular response to zinc ionprocesscerebral cortex developmentprocessdirectional locomotionprocessdopamine metabolic processprocessepidermal growth factor receptor signaling pathwayprocessexcitatory postsynaptic potentialprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessglutamate receptor signaling pathwayprocesshippocampus developmentprocessinnate immune responseprocessinsulin receptor signaling pathwayprocession transmembrane transportprocessionotropic glutamate receptor signaling pathwayprocesslearning or memoryprocesslong-term synaptic potentiationprocessMAPK cascadeprocessmemoryprocessnegative regulation of protein catabolic processprocessneurotrophin TRK receptor signaling pathwayprocesspositive regulation of apoptotic processprocessprotein localizationprocessprotein tetramerizationprocessRas protein signal transductionprocessregulation of long-term neuronal synaptic plasticityprocessregulation of sensory perception of painprocessresponse to amphetamineprocessresponse to calcium ionprocessresponse to carbohydrateprocessresponse to cocaineprocessresponse to drugprocessresponse to ethanolprocessresponse to fungicideprocessresponse to methylmercuryprocessresponse to other organismprocessresponse to woundingprocessrhythmic processprocesssensory perception of painprocessserotonin metabolic processprocesssleepprocesssmall GTPase mediated signal transductionprocessspinal cord developmentprocessstartle responseprocesssynaptic transmissionprocesssynaptic transmission, glutamatergicprocesstransportprocessvascular endothelial growth factor receptor signaling pathwayprocessvisual learning
name:Glutamate receptor ionotropic, NMDA 2B
general-function:Zinc ion binding
specific-function:NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity).
gene-name:GRIN2B
locus:12p12
cellular-location:Cell membrane
transmembrane-regions:558-578 635-655 818-838
signal-regions:1-26
theoretical-pi:6.92
molecular-weight:166365.885
chromosome-location:12
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4586GenAtlasGRIN2BGenBank Gene DatabaseU90278GenBank Protein Database1899202IUPHAR457UniProtKBQ13224UniProt AccessionNMDE2_HUMAN
synonyms:GluN2BGlutamate [NMDA] receptor subunit epsilon-2hNR3N-methyl D-aspartate receptor subtype 2BN-methyl-D-aspartate receptor subunit 3NMDAR2BNR2BNR3
amino-acid-sequence:>lcl|BSEQ0010288|Glutamate receptor ionotropic, NMDA 2B MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFH HLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTL TPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQ DFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYI FEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAII TTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHP KLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVE SVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYL VTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSR SNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSF TIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYV DQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLS LKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAI LQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH LFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILR LLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFS DYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISK KPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKR RKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTK ENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKN LTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSL QELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPR SVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPD RVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPA RFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV
gene-sequence:>lcl|BSEQ0010289|Glutamate receptor ionotropic, NMDA 2B (GRIN2B) ATGAAGCCCAGAGCGGAGTGCTGTTCTCCCAAGTTCTGGTTGGTGTTGGCCGTCCTGGCC GTGTCAGGCAGCAGAGCTCGTTCTCAGAAGAGCCCCCCCAGCATTGGCATTGCTGTCATC CTCGTGGGCACTTCCGACGAGGTGGCCATCAAGGATGCCCACGAGAAAGATGATTTCCAC CATCTCTCCGTGGTACCCCGGGTGGAACTGGTAGCCATGAATGAGACCGACCCAAAGAGC ATCATCACCCGCATCTGTGATCTCATGTCTGACCGGAAGATCCAGGGGGTGGTGTTTGCT GATGACACAGACCAGGAAGCCATCGCCCAGATCCTCGATTTCATTTCAGCACAGACTCTC ACCCCCATCCTGGGCATCCACGGGGGCTCCTCTATGATAATGGCAGATAAGGATGAATCC TCCATGTTCTTCCAGTTTGGCCCATCAATTGAACAGCAAGCTTCCGTAATGCTCAACATC ATGGAAGAATATGACTGGTACATCTTTTCTATCGTCACCACCTATTTCCCTGGCTACCAG GACTTTGTAAACAAGATCCGCAGCACCATTGAGAATAGCTTTGTGGGCTGGGAGCTAGAG GAGGTCCTCCTACTGGACATGTCCCTGGACGATGGAGATTCTAAGATCCAGAATCAGCTC AAGAAACTTCAAAGCCCCATCATTCTTCTTTACTGTACCAAGGAAGAAGCCACCTACATC TTTGAAGTGGCCAACTCAGTAGGGCTGACTGGCTATGGCTACACGTGGATCGTGCCCAGT CTGGTGGCAGGGGATACAGACACAGTGCCTGCGGAGTTCCCCACTGGGCTCATCTCTGTA TCATATGATGAATGGGACTATGGCCTCCCCGCCAGAGTGAGAGATGGAATTGCCATAATC ACCACTGCTGCTTCTGACATGCTGTCTGAGCACAGCTTCATCCCTGAGCCCAAAAGCAGT TGTTACAACACCCACGAGAAGAGAATCTACCAGTCCAATATGCTAAATAGGTATCTGATC AATGTCACTTTTGAGGGGAGGAATTTGTCCTTCAGTGAAGATGGCTACCAGATGCACCCG AAACTGGTGATAATTCTTCTGAACAAGGAGAGGAAGTGGGAAAGGGTGGGGAAGTGGAAA GACAAGTCCCTGCAGATGAAGTACTATGTGTGGCCCCGAATGTGTCCAGAGACTGAAGAG CAGGAGGATGACCATCTGAGCATTGTGACCCTGGAGGAGGCACCATTTGTCATTGTGGAA AGTGTGGACCCTCTGAGTGGAACCTGCATGAGGAACACAGTCCCCTGCCAAAAACGCATA GTCACTGAGAATAAAACAGACGAGGAGCCGGGTTACATCAAAAAATGCTGCAAGGGGTTC TGTATTGACATCCTTAAGAAAATTTCTAAATCTGTGAAGTTCACCTATGACCTTTACCTG GTTACCAATGGCAAGCATGGGAAGAAAATCAATGGAACCTGGAATGGTATGATTGGAGAG GTGGTCATGAAGAGGGCCTACATGGCAGTGGGCTCACTCACCATCAATGAGGAACGATCG GAGGTGGTCGACTTCTCTGTGCCCTTCATAGAGACAGGCATCAGTGTCATGGTGTCACGC AGCAATGGGACTGTCTCACCTTCTGCCTTCTTAGAGCCATTCAGCGCTGACGTATGGGTG ATGATGTTTGTGATGCTGCTCATCGTCTCAGCCGTGGCTGTCTTTGTCTTTGAGTACTTC AGCCCTGTGGGTTATAACAGGTGCCTCGCTGATGGCAGAGAGCCTGGTGGACCCTCTTTC ACCATCGGCAAAGCTATTTGGTTGCTCTGGGGTCTGGTGTTTAACAACTCCGTACCTGTG CAGAACCCAAAGGGGACCACCTCCAAGATCATGGTGTCAGTGTGGGCCTTCTTTGCTGTC ATCTTCCTGGCCAGCTACACTGCCAACTTAGCTGCCTTCATGATCCAAGAGGAATATGTG GACCAGGTTTCTGGCCTGAGCGACAAAAAGTTCCAGAGACCTAATGACTTCTCACCCCCT TTCCGCTTTGGGACCGTGCCCAACGGCAGCACAGAGAGAAATATTCGCAATAACTATGCA GAAATGCATGCCTACATGGGAAAGTTCAACCAGAGGGGTGTAGATGATGCATTGCTCTCC CTGAAAACAGGGAAACTGGATGCCTTCATCTATGATGCAGCAGTGCTGAACTATATGGCA GGCAGAGATGAAGGCTGCAAGCTGGTGACCATTGGCAGTGGGAAGGTCTTTGCTTCCACT GGCTATGGCATTGCCATCCAAAAAGATTCTGGGTGGAAGCGCCAGGTGGACCTTGCTATC CTGCAGCTCTTTGGAGATGGGGAGATGGAAGAACTGGAAGCTCTCTGGCTCACTGGCATT TGTCACAATGAGAAGAATGAGGTCATGAGCAGCCAGCTGGACATTGACAACATGGCAGGG GTCTTCTACATGTTGGGGGCGGCCATGGCTCTCAGCCTCATCACCTTCATCTGCGAACAC CTTTTCTATTGGCAGTTCCGACATTGCTTTATGGGTGTCTGTTCTGGCAAGCCTGGCATG GTCTTCTCCATCAGCAGAGGTATCTACAGCTGCATCCATGGGGTGGCGATCGAGGAGCGC CAGTCTGTAATGAACTCCCCCACCGCAACCATGAACAACACACACTCCAACATCCTGCGC CTGCTGCGCACGGCCAAGAACATGGCTAACCTGTCTGGTGTGAATGGCTCACCGCAGAGC GCCCTGGACTTCATCCGACGGGAGTCATCCGTCTATGACATCTCAGAGCACCGCCGCAGC TTCACGCATTCTGACTGCAAATCCTACAACAACCCGCCCTGTGAGGAGAACCTCTTCAGT GACTACATCAGTGAGGTAGAGAGAACGTTCGGGAACCTGCAGCTGAAGGACAGCAACGTG TACCAAGATCACTACCACCATCACCACCGGCCCCATAGTATTGGCAGTGCCAGCTCCATC GATGGGCTCTACGACTGTGACAACCCACCCTTCACCACCCAGTCCAGGTCCATCAGCAAG AAGCCCCTGGACATCGGCCTCCCCTCCTCCAAGCACAGCCAGCTCAGTGACCTGTACGGC AAATTCTCCTTCAAGAGCGACCGCTACAGTGGCCACGACGACTTGATCCGCTCCGATGTC TCTGACATCTCAACCCACACCGTCACCTATGGGAACATCGAGGGCAATGCCGCCAAGAGG CGTAAGCAGCAATATAAGGACAGCCTGAAGAAGCGGCCTGCCTCGGCCAAGTCCCGCAGG GAGTTTGACGAGATCGAGCTGGCCTACCGTCGCCGACCGCCCCGCTCCCCTGACCACAAG CGCTACTTCAGGGACAAGGAAGGGCTACGGGACTTCTACCTGGACCAGTTCCGAACAAAG GAGAACTCACCCCACTGGGAGCACGTAGACCTGACCGACATCTACAAGGAGCGGAGTGAT GACTTTAAGCGCGACTCCGTCAGCGGAGGAGGGCCCTGTACCAACAGGTCTCACATCAAG CACGGGACGGGCGACAAACACGGCGTGGTCAGCGGGGTACCTGCACCTTGGGAGAAGAAC CTGACCAACGTGGAGTGGGAGGACCGGTCCGGGGGCAACTTCTGCCGCAGCTGTCCCTCC AAGCTGCACAACTACTCCACGACGGTGACGGGTCAGAACTCGGGCAGGCAGGCGTGCATC CGGTGTGAGGCTTGCAAGAAAGCAGGCAACCTGTATGACATCAGTGAGGACAACTCCCTG CAGGAACTGGACCAGCCGGCTGCCCCAGTGGCGGTGACGTCAAACGCCTCCACCACTAAG TACCCTCAGAGCCCGACTAATTCCAAGGCCCAGAAGAAGAACCGGAACAAACTGCGCCGG CAGCACTCCTACGACACCTTCGTGGACCTGCAGAAGGAAGAAGCCGCCCTGGCCCCGCGC AGCGTAAGCCTGAAAGACAAGGGCCGATTCATGGATGGGAGCCCCTACGCCCACATGTTT GAGATGTCAGCTGGCGAGAGCACCTTTGCCAACAACAAGTCCTCAGTGCCCACTGCCGGA CATCACCACCACAACAACCCCGGCGGCGGGTACATGCTCAGCAAGTCGCTCTACCCTGAC CGGGTCACGCAAAACCCTTTCATCCCCACTTTTGGGGACGACCAGTGCTTGCTCCATGGC AGCAAATCCTACTTCTTCAGGCAGCCCACGGTGGCGGGGGCGTCGAAAGCCAGGCCGGAC TTCCGGGCCCTTGTCACCAACAAGCCGGTGGTCTCGGCCCTTCATGGGGCCGTGCCAGCC CGTTTCCAGAAGGACATCTGTATAGGGAACCAGTCCAACCCCTGTGTGCCTAACAACAAA AACCCCAGGGCTTTCAATGGCTCCAGCAATGGGCATGTTTATGAGAAACTTTCTAGTATT GAGTCTGATGTCTGA
pfams:PF01094ANF_receptorPF00060Lig_chanPF10613Lig_chan-Glu_bdPF10565NMDAR2_C
go-classifiers:componentcell junctioncomponentcell surfacecomponentintegral component of plasma membranecomponentneuron projectioncomponentneuronal postsynaptic densitycomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic membranecomponentsynaptic vesiclefunctioncalcium channel activityfunctionextracellular-glutamate-gated ion channel activityfunctionglycine bindingfunctionNMDA glutamate receptor activityfunctionzinc ion bindingprocessactivation of MAPKK activityprocessaxon guidanceprocessbehavioral fear responseprocessbehavioral response to painprocessdetection of mechanical stimulus involved in sensory perception of painprocessephrin receptor signaling pathwayprocessepidermal growth factor receptor signaling pathwayprocessexcitatory postsynaptic potentialprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessglutamate receptor signaling pathwayprocessin utero embryonic developmentprocessinnate immune responseprocessinsulin receptor signaling pathwayprocessionotropic glutamate receptor signaling pathwayprocesslearningprocesslearning or memoryprocesslong-term synaptic potentiationprocessMAPK cascadeprocessmemoryprocessneurotrophin TRK receptor signaling pathwayprocessRas protein signal transductionprocessregulation of protein kinase A signalingprocessresponse to ethanolprocesssensory organ developmentprocesssmall GTPase mediated signal transductionprocessstartle responseprocesssuckling behaviorprocesssynaptic transmissionprocesstransportprocessvascular endothelial growth factor receptor signaling pathway
name:Glutamate receptor ionotropic, NMDA 2C
general-function:Nmda glutamate receptor activity
specific-function:NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
gene-name:GRIN2C
locus:17q25
cellular-location:Cell membrane
transmembrane-regions:554-574 627-647 815-835
signal-regions:1-19
theoretical-pi:8.61
molecular-weight:134207.77
chromosome-location:17
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4587GenAtlasGRIN2CGenBank Gene DatabaseL76224GenBank Protein Database1196449IUPHAR458UniProtKBQ14957UniProt AccessionNMDE3_HUMAN
synonyms:GluN2CGlutamate [NMDA] receptor subunit epsilon-3N-methyl D-aspartate receptor subtype 2CNMDAR2CNR2C
amino-acid-sequence:>lcl|BSEQ0010317|Glutamate receptor ionotropic, NMDA 2C MGGALGPALLLTSLFGAWAGLGPGQGEQGMTVAVVFSSSGPPQAQFRARLTPQSFLDLPL EIQPLTVGVNTTNPSSLLTQICGLLGAAHVHGIVFEDNVDTEAVAQILDFISSQTHVPIL SISGGSAVVLTPKEPGSAFLQLGVSLEQQLQVLFKVLEEYDWSAFAVITSLHPGHALFLE GVRAVADASHVSWRLLDVVTLELGPGGPRARTQRLLRQLDAPVFVAYCSREEAEVLFAEA AQAGLVGPGHVWLVPNLALGSTDAPPATFPVGLISVVTESWRLSLRQKVRDGVAILALGA HSYWRQHGTLPAPAGDCRVHPGPVSPAREAFYRHLLNVTWEGRDFSFSPGGYLVQPTMVV IALNRHRLWEMVGRWEHGVLYMKYPVWPRYSASLQPVVDSRHLTVATLEERPFVIVESPD PGTGGCVPNTVPCRRQSNHTFSSGDVAPYTKLCCKGFCIDILKKLARVVKFSYDLYLVTN GKHGKRVRGVWNGMIGEVYYKRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNG TVSPSAFLEPYSPAVWVMMFVMCLTVVAITVFMFEYFSPVSYNQNLTRGKKSGGPAFTIG KSVWLLWALVFNNSVPIENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEQYIDTV SGLSDKKFQRPQDQYPPFRFGTVPNGSTERNIRSNYRDMHTHMVKFNQRSVEDALTSLKM GKLDAFIYDAAVLNYMAGKDEGCKLVTIGSGKVFATTGYGIAMQKDSHWKRAIDLALLQF LGDGETQKLETVWLSGICQNEKNEVMSSKLDIDNMAGVFYMLLVAMGLALLVFAWEHLVY WKLRHSVPNSSQLDFLLAFSRGIYSCFSGVQSLASPPRQASPDLTASSAQASVLKMLQAA RDMVTTAGVSSSLDRATRTIENWGGGRRAPPPSPCPTPRSGPSPCLPTPDPPPEPSPTGW GPPDGGRAALVRRAPQPPGRPPTPGPPLSDVSRVSRRPAWEARWPVRTGHCGRHLSASER PLSPARCHYSSFPRADRSGRPFLPLFPELEDLPLLGPEQLARREALLHAAWARGSRPRHA SLPSSVAEAFARPSSLPAGCTGPACARPDGHSACRRLAQAQSMCLPIYREACQEGEQAGA PAWQHRQHVCLHAHAHLPFCWGAVCPHLPPCASHGSWLSGAWGPLGHRGRTLGLGTGYRD SGGLDEISRVARGTQGFPGPCTWRRISSLESEV
gene-sequence:>lcl|BSEQ0010318|Glutamate receptor ionotropic, NMDA 2C (GRIN2C) ATGGGTGGGGCCCTGGGGCCGGCCCTGTTGCTCACCTCGCTCTTCGGTGCCTGGGCAGGG CTGGGTCCGGGGCAGGGCGAGCAGGGCATGACGGTGGCCGTGGTGTTTAGCAGCTCAGGG CCGCCCCAGGCCCAGTTCCGTGCCCGCCTCACCCCCCAGAGCTTCCTGGACCTACCCCTG GAGATCCAGCCGCTCACAGTTGGGGTCAACACCACCAACCCCAGCAGCCTCCTCACCCAG ATCTGCGGCCTCCTGGGTGCTGCCCACGTCCACGGCATTGTCTTTGAGGACAACGTGGAC ACCGAGGCGGTGGCCCAGATCCTTGACTTCATCTCCTCCCAGACCCATGTGCCCATCCTC AGCATCAGCGGAGGCTCTGCTGTGGTCCTCACCCCCAAGGAGCCGGGCTCCGCCTTCCTG CAGCTGGGCGTGTCCCTGGAGCAGCAGCTGCAGGTGCTGTTCAAGGTGCTGGAAGAGTAC GACTGGAGCGCCTTCGCCGTCATCACCAGCCTGCACCCGGGCCACGCGCTCTTCCTGGAG GGCGTGCGCGCCGTCGCCGACGCCAGCCACGTGAGTTGGCGGCTGCTGGACGTGGTCACG CTGGAGCTGGGCCCGGGAGGGCCGCGCGCGCGCACGCAGCGCCTGCTGCGCCAGCTCGAC GCGCCCGTGTTTGTGGCCTACTGCTCGCGCGAGGAGGCCGAGGTGCTCTTCGCCGAGGCG GCGCAGGCCGGTCTGGTGGGGCCCGGCCACGTGTGGCTGGTGCCCAACCTGGCGCTGGGC AGCACCGATGCGCCCCCCGCCACCTTCCCCGTGGGCCTCATCAGCGTCGTCACCGAGAGC TGGCGCCTCAGCCTGCGCCAGAAGGTGCGCGACGGCGTGGCCATTCTGGCCCTGGGCGCC CACAGCTACTGGCGCCAGCATGGAACCCTGCCAGCCCCGGCCGGGGACTGCCGTGTTCAC CCTGGGCCCGTCAGCCCTGCCCGGGAGGCCTTCTACAGGCACCTACTGAATGTCACCTGG GAGGGCCGAGACTTCTCCTTCAGCCCTGGTGGGTACCTGGTCCAGCCCACCATGGTGGTG ATCGCCCTCAACCGGCACCGCCTCTGGGAGATGGTGGGGCGCTGGGAGCATGGCGTCCTA TACATGAAGTACCCCGTGTGGCCTCGCTACAGTGCCTCTCTGCAGCCTGTGGTGGACAGT CGGCACCTGACGGTGGCCACGCTGGAAGAGCGGCCCTTTGTCATCGTGGAGAGCCCTGAC CCTGGCACAGGAGGCTGTGTCCCCAACACCGTGCCCTGCCGCAGGCAGAGCAACCACACC TTCAGCAGCGGGGACGTGGCCCCCTACACCAAGCTCTGCTGTAAGGGATTCTGCATCGAC ATCCTCAAGAAGCTGGCCAGAGTGGTCAAATTCTCCTACGACCTGTACCTGGTGACCAAC GGCAAGCATGGCAAGCGGGTGCGCGGCGTATGGAACGGCATGATTGGGGAGGTGTACTAC AAGCGGGCAGACATGGCCATCGGCTCCCTCACCATCAATGAGGAACGCTCCGAGATCGTA GACTTCTCTGTACCCTTTGTGGAGACGGGCATCAGTGTGATGGTGGCTCGCAGCAATGGC ACCGTCTCCCCCTCGGCCTTCTTGGAGCCATATAGCCCTGCAGTGTGGGTGATGATGTTT GTCATGTGCCTCACTGTGGTGGCCATCACCGTCTTCATGTTCGAGTACTTCAGCCCTGTC AGCTACAACCAGAACCTCACCAGAGGCAAGAAGTCCGGGGGCCCAGCTTTCACTATCGGC AAGTCCGTGTGGCTGCTGTGGGCGCTGGTCTTCAACAACTCAGTGCCCATCGAGAACCCG CGGGGCACCACCAGCAAGATCATGGTTCTGGTCTGGGCCTTCTTTGCTGTCATCTTCCTC GCCAGCTACACGGCCAACCTGGCCGCCTTCATGATCCAAGAGCAATACATCGACACTGTG TCGGGCCTCAGTGACAAGAAGTTTCAGCGGCCTCAAGATCAGTACCCACCTTTCCGCTTC GGCACGGTGCCCAACGGCAGCACGGAGCGGAACATCCGCAGTAACTACCGTGACATGCAC ACCCACATGGTCAAGTTCAACCAGCGCTCGGTGGAGGACGCGCTCACCAGCCTCAAGATG GGGAAGCTGGATGCCTTCATCTATGATGCTGCTGTCCTCAACTACATGGCAGGCAAGGAC GAGGGCTGCAAGCTGGTCACCATTGGGTCTGGCAAGGTCTTTGCTACCACTGGCTACGGC ATCGCCATGCAGAAGGACTCCCACTGGAAGCGGGCCATAGACCTGGCGCTCTTGCAGTTC CTGGGGGACGGAGAGACACAGAAACTGGAGACAGTGTGGCTCTCAGGGATCTGCCAGAAT GAGAAGAACGAGGTGATGAGCAGCAAGCTGGACATCGACAACATGGCAGGCGTCTTCTAC ATGCTGCTGGTGGCCATGGGGCTGGCCCTGCTGGTCTTCGCCTGGGAGCACCTGGTCTAC TGGAAGCTGCGCCACTCGGTGCCCAACTCATCCCAGCTGGACTTCCTGCTGGCTTTCAGC AGGGGCATCTACAGCTGCTTCAGCGGGGTGCAGAGCCTCGCCAGCCCACCGCGGCAGGCC AGCCCGGACCTCACGGCCAGCTCGGCCCAGGCCAGCGTGCTCAAGATGCTGCAGGCAGCC CGCGACATGGTGACCACGGCGGGCGTAAGCAGCTCCCTGGACCGCGCCACTCGCACCATC GAGAATTGGGGTGGCGGCCGCCGTGCGCCCCCACCGTCCCCCTGCCCGACCCCGCGGTCT GGCCCCAGCCCATGCCTGCCCACCCCCGACCCGCCCCCAGAGCCGAGCCCCACGGGCTGG GGACCGCCAGACGGGGGTCGCGCGGCGCTTGTGCGCAGGGCTCCGCAGCCCCCGGGCCGC CCCCCGACGCCGGGGCCGCCCCTGTCCGACGTCTCCCGAGTGTCGCGCCGCCCAGCCTGG GAGGCGCGGTGGCCGGTGCGGACCGGGCACTGCGGGAGGCACCTCTCGGCCTCCGAGCGG CCCCTGTCGCCCGCGCGCTGTCACTACAGCTCCTTTCCTCGAGCCGACCGATCCGGCCGC CCCTTCCTCCCGCTCTTCCCGGAGCTGGAGGACCTGCCGCTGCTCGGTCCGGAGCAGCTG GCCCGGCGGGAGGCCCTGCTGCACGCGGCCTGGGCCCGGGGCTCGCGCCCGCGTCACGCT TCCCTGCCCAGCTCCGTGGCCGAGGCCTTCGCTCGGCCCAGCTCGCTGCCCGCTGGGTGC ACCGGCCCCGCCTGCGCCCGCCCCGACGGCCACTCGGCCTGCAGGCGCTTGGCGCAGGCG CAGTCGATGTGCTTGCCGATCTACCGGGAGGCCTGCCAGGAGGGCGAGCAGGCAGGGGCC CCCGCCTGGCAGCACAGACAGCACGTCTGCCTGCACGCCCACGCCCACCTGCCATTTTGC TGGGGGGCTGTCTGTCCTCACCTTCCACCCTGTGCCAGCCACGGCTCCTGGCTCTCCGGG GCCTGGGGGCCTCTGGGGCACAGGGGCAGGACTCTGGGGCTGGGCACAGGCTACAGAGAC AGTGGGGGACTGGACGAGATCAGCAGGGTAGCCCGTGGGACGCAAGGCTTCCCGGGACCC TGCACCTGGAGACGGATCTCCAGTCTGGAGTCAGAAGTGTGA
pfams:PF01094ANF_receptorPF00060Lig_chanPF10613Lig_chan-Glu_bdPF10565NMDAR2_C
go-classifiers:componentcell junctioncomponentdendritecomponentintegral component of plasma membranecomponentintracellularcomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic densitycomponentpostsynaptic membranefunctioncation channel activityfunctionextracellular-glutamate-gated ion channel activityfunctionNMDA glutamate receptor activityprocessactivation of MAPKK activityprocessaxon guidanceprocessdirectional locomotionprocessepidermal growth factor receptor signaling pathwayprocessexcitatory postsynaptic potentialprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessglutamate receptor signaling pathwayprocessinnate immune responseprocessinsulin receptor signaling pathwayprocession transmembrane transportprocessionotropic glutamate receptor signaling pathwayprocessMAPK cascadeprocessnegative regulation of protein catabolic processprocessneuromuscular process controlling balanceprocessneurotrophin TRK receptor signaling pathwayprocessprotein localizationprocessRas protein signal transductionprocessresponse to woundingprocesssmall GTPase mediated signal transductionprocesssynaptic transmissionprocesssynaptic transmission, glutamatergicprocesstransportprocessvascular endothelial growth factor receptor signaling pathway
name:Glutamate receptor ionotropic, NMDA 2D
general-function:Nmda glutamate receptor activity
specific-function:NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
gene-name:GRIN2D
locus:19q13.1-qter
cellular-location:Cell membrane
transmembrane-regions:584-604 657-677 845-865
signal-regions:1-27
theoretical-pi:8.27
molecular-weight:143750.685
chromosome-location:19
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:4588GenAtlasGRIN2DGenBank Gene DatabaseU77783GenBank Protein Database2444026IUPHAR459UniProtKBO15399UniProt AccessionNMDE4_HUMAN
synonyms:EB11GluN2DGlutamate [NMDA] receptor subunit epsilon-4N-methyl D-aspartate receptor subtype 2DNMDAR2DNR2D
amino-acid-sequence:>lcl|BSEQ0016080|Glutamate receptor ionotropic, NMDA 2D MRGAGGPRGPRGPAKMLLLLALACASPFPEEAPGPGGAGGPGGGLGGARPLNVALVFSGP AYAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVVFEDD SRAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIFEVLE EYDWTSFVAVTTRAPGHRAFLSYIEVLTDGSLVGWEHRGALTLDPGAGEAVLSAQLRSVS AQIRLLFCAREEAEPVFRAAEEAGLTGSGYVWFMVGPQLAGGGGSGAPGEPPLLPGGAPL PAGLFAVRSAGWRDDLARRVAAGVAVVARGAQALLRDYGFLPELGHDCRAQNRTHRGESL HRYFMNITWDNRDYSFNEDGFLVNPSLVVISLTRDRTWEVVGSWEQQTLRLKYPLWSRYG RFLQPVDDTQHLTVATLEERPFVIVEPADPISGTCIRDSVPCRSQLNRTHSPPPDAPRPE KRCCKGFCIDILKRLAHTIGFSYDLYLVTNGKHGKKIDGVWNGMIGEVFYQRADMAIGSL TINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAVT VFIFEYLSPVGYNRSLATGKRPGGSTFTIGKSIWLLWALVFNNSVPVENPRGTTSKIMVL VWAFFAVIFLASYTANLAAFMIQEEYVDTVSGLSDRKFQRPQEQYPPLKFGTVPNGSTEK NIRSNYPDMHSYMVRYNQPRVEEALTQLKAGKLDAFIYDAAVLNYMARKDEGCKLVTIGS GKVFATTGYGIALHKGSRWKRPIDLALLQFLGDDEIEMLERLWLSGICHNDKIEVMSSKL DIDNMAGVFYMLLVAMGLSLLVFAWEHLVYWRLRHCLGPTHRMDFLLAFSRGMYSCCSAE AAPPPAKPPPPPQPLPSPAYPAPRPAPGPAPFVPRERASVDRWRRTKGAGPPGGAGLADG FHRYYGPIEPQGLGLGLGEARAAPRGAAGRPLSPPAAQPPQKPPPSYFAIVRDKEPAEPP AGAFPGFPSPPAPPAAAATAVGPPLCRLAFEDESPPAPARWPRSDPESQPLLGPGAGGAG GTGGAGGGAPAAPPPCRAAPPPCPYLDLEPSPSDSEDSESLGGASLGGLEPWWFADFPYP YAERLGPPPGRYWSVDKLGGWRAGSWDYLPPRSGPAAWHCRHCASLELLPPPRHLSCSHD GLDGGWWAPPPPPWAAGPLPRRRARCGCPRSHPHRPRASHRTPAAAAPHHHRHRRAAGGW DLPPPAPTSRSLEDLSSCPRAAPARRLTGPSRHARRCPHAAHWGPPLPTASHRRHRGGDL GTRRGSAHFSSLESEV
gene-sequence:>lcl|BSEQ0016081|Glutamate receptor ionotropic, NMDA 2D (GRIN2D) ATGCGCGGCGCCGGTGGCCCCCGCGGCCCTCGGGGCCCCGCTAAGATGCTGCTGCTGCTG GCGCTGGCCTGCGCCAGCCCGTTCCCGGAGGAGGCGCCGGGGCCGGGCGGGGCCGGTGGG CCCGGCGGCGGCCTCGGCGGGGCGCGGCCGCTCAACGTGGCGCTCGTGTTCTCGGGGCCC GCGTACGCGGCCGAGGCGGCACGCCTGGGCCCGGCCGTGGCGGCGGCGGTGCGCAGCCCG GGCCTAGACGTGCGGCCCGTGGCGCTGGTGCTCAACGGCTCGGACCCGCGCAGCCTCGTG CTGCAGCTCTGCGACCTGCTGTCGGGGTTGCGCGTGCACGGCGTGGTCTTCGAAGACGAC TCGCGCGCGCCCGCCGTCGCGCCCATCCTCGACTTCCTGTCGGCGCAGACCTCGCTGCCC ATCGTGGCCGTGCACGGCGGCGCCGCGCTCGTGCTCACGCCCAAGGAGAAGGGCTCCACC TTCCTGCAGCTGGGCTCTTCCACCGAGCAACAGCTTCAGGTCATCTTTGAGGTGCTGGAG GAGTATGACTGGACGTCCTTTGTAGCCGTGACCACTCGTGCCCCTGGCCACCGGGCCTTC CTGTCCTACATTGAGGTGCTGACTGACGGTAGTCTGGTGGGCTGGGAGCACCGCGGAGCG CTGACGCTGGACCCTGGGGCGGGCGAGGCCGTGCTCAGTGCCCAGCTCCGCAGTGTCAGC GCGCAGATCCGCCTGCTCTTCTGCGCCCGAGAGGAGGCCGAGCCCGTGTTCCGCGCAGCT GAGGAGGCTGGCCTCACTGGATCTGGCTACGTCTGGTTCATGGTGGGGCCCCAGCTGGCT GGAGGCGGGGGCTCTGGGGCCCCTGGTGAGCCCCCTCTTCTGCCAGGAGGCGCCCCCCTG CCTGCCGGGCTGTTTGCAGTGCGCTCGGCTGGCTGGCGGGATGACCTGGCTCGGCGAGTG GCAGCTGGCGTGGCCGTAGTGGCCAGAGGTGCCCAGGCCCTGCTGCGTGATTATGGTTTC CTTCCTGAGCTCGGCCACGACTGTCGCGCCCAGAACCGCACCCACCGCGGCGAGAGTCTG CATAGGTACTTCATGAACATCACGTGGGATAACCGGGATTACTCCTTCAATGAGGACGGC TTCCTAGTGAACCCCTCCCTGGTGGTCATCTCCCTCACCAGAGACAGGACGTGGGAGGTG GTGGGCAGCTGGGAGCAGCAGACGCTCCGCCTCAAGTACCCGCTGTGGTCCCGCTATGGT CGCTTCCTGCAGCCAGTGGACGACACGCAGCACCTCACGGTGGCCACGCTGGAGGAAAGG CCGTTTGTCATCGTGGAGCCTGCAGACCCTATCAGCGGCACCTGCATCCGAGACTCCGTC CCCTGCCGGAGCCAGCTCAACCGAACCCACAGCCCTCCACCGGATGCCCCCCGCCCGGAA AAGCGCTGCTGCAAGGGTTTCTGCATCGACATTCTGAAGCGGCTGGCGCATACCATCGGC TTCAGCTACGACCTCTACCTGGTCACCAATGGCAAGCACGGAAAGAAGATCGATGGCGTC TGGAACGGCATGATCGGGGAGGTGTTCTACCAGCGCGCAGACATGGCCATCGGCTCCCTC ACCATCAACGAGGAGCGCTCCGAGATCGTGGACTTCTCCGTCCCCTTCGTGGAGACCGGC ATCAGCGTCATGGTGGCGCGCAGCAATGGCACGGTGTCCCCCTCGGCCTTCCTCGAGCCC TACAGCCCCGCCGTGTGGGTGATGATGTTCGTCATGTGCCTCACTGTGGTCGCCGTCACT GTTTTCATCTTCGAGTACCTCAGTCCTGTTGGTTACAACCGCAGCCTGGCCACGGGCAAG CGCCCTGGCGGTTCAACCTTCACCATTGGGAAATCCATCTGGCTGCTCTGGGCCCTGGTG TTCAATAATTCGGTGCCCGTGGAGAACCCCCGGGGAACCACCAGCAAAATCATGGTGCTG GTGTGGGCCTTCTTCGCCGTCATCTTCCTCGCCAGCTACACAGCCAACCTGGCCGCCTTC ATGATCCAGGAGGAGTACGTGGATACTGTGTCTGGGCTCAGTGACCGCAAGTTCCAGAGG CCCCAGGAGCAGTACCCGCCCCTGAAGTTTGGGACCGTGCCCAACGGCTCCACGGAGAAG AACATCCGCAGCAACTATCCCGACATGCACAGCTACATGGTGCGCTACAACCAGCCCCGC GTAGAGGAAGCGCTCACTCAGCTCAAGGCAGGGAAGCTGGACGCCTTCATCTACGATGCT GCAGTGCTCAATTACATGGCCCGCAAGGACGAGGGCTGCAAGCTTGTCACCATCGGCTCC GGCAAGGTCTTCGCCACGACAGGCTATGGCATCGCCCTGCACAAGGGCTCCCGCTGGAAG CGGCCCATCGACCTGGCGTTGCTGCAGTTCCTGGGGGATGATGAGATCGAGATGCTGGAG CGGCTGTGGCTCTCTGGGATCTGCCACAATGACAAAATCGAGGTGATGAGCAGCAAGCTG GACATCGACAACATGGCGGGCGTCTTCTACATGCTCCTGGTGGCCATGGGCCTGTCCCTG CTGGTCTTCGCCTGGGAGCACCTGGTGTACTGGCGCCTGCGGCACTGCCTGGGGCCCACC CACCGCATGGACTTCCTGCTGGCCTTCTCCAGGGGCATGTACAGCTGCTGCAGCGCTGAG GCCGCCCCACCGCCCGCCAAGCCCCCGCCGCCGCCACAGCCCCTGCCCAGCCCCGCGTAC CCCGCGCCGCGGCCGGCTCCCGGGCCCGCACCTTTCGTGCCCCGCGAGCGCGCCTCAGTG GACCGCTGGCGCCGGACCAAGGGCGCGGGGCCGCCGGGGGGCGCGGGCCTGGCCGACGGC TTCCACCGCTACTACGGCCCCATCGAGCCGCAGGGCCTAGGCCTCGGCCTGGGCGAAGCG CGCGCGGCACCGCGGGGCGCAGCCGGGCGCCCGCTGTCCCCGCCGGCCGCTCAGCCCCCG CAGAAGCCGCCGCCCTCCTATTTCGCCATCGTACGCGACAAGGAGCCAGCCGAGCCCCCC GCCGGCGCCTTCCCCGGCTTCCCGTCGCCGCCCGCGCCCCCCGCCGCCGCGGCCACCGCC GTCGGGCCGCCACTCTGCCGCTTGGCCTTCGAGGACGAGAGCCCGCCGGCGCCCGCGCGG TGGCCGCGCTCGGACCCCGAGAGCCAACCCCTGCTGGGGCCAGGCGCGGGCGGCGCGGGG GGCACGGGGGGCGCAGGCGGAGGAGCCCCGGCCGCTCCGCCCCCGTGCCGCGCCGCGCCG CCCCCGTGCCCTTACCTCGATCTCGAGCCGTCGCCGTCGGACTCGGAGGACTCGGAGAGC CTGGGCGGCGCGTCGCTGGGCGGCCTGGAGCCCTGGTGGTTCGCCGACTTCCCTTACCCG TATGCCGAGCGCCTCGGGCCGCCGCCCGGCCGCTACTGGTCGGTCGACAAGCTCGGGGGC TGGCGCGCCGGGAGCTGGGACTACCTGCCCCCGCGCAGCGGTCCGGCCGCCTGGCACTGT CGGCACTGCGCCAGCCTGGAGCTGCTGCCGCCGCCGCGCCATCTCAGCTGCTCGCACGAT GGCCTGGACGGCGGCTGGTGGGCGCCACCGCCTCCACCCTGGGCCGCCGGGCCCCTGCCC CGACGCCGGGCCCGCTGCGGGTGCCCGCGGTCGCACCCGCACCGCCCGCGGGCCTCGCAC CGCACGCCCGCCGCCGCCGCGCCCCACCACCACAGGCACCGGCGCGCCGCTGGGGGCTGG GACCTCCCGCCGCCCGCGCCCACCTCGCGCTCGCTCGAGGACCTCAGCTCGTGCCCTCGC GCCGCCCCTGCGCGCAGGCTTACCGGGCCCTCCCGCCACGCTCGCAGGTGTCCGCACGCC GCGCACTGGGGGCCGCCGCTGCCCACAGCTTCCCACCGGAGACACCGGGGCGGGGACCTG GGCACCCGCAGGGGCTCGGCGCACTTCTCTAGCCTCGAGTCCGAGGTATGA
pfams:PF01094ANF_receptorPF00060Lig_chanPF10613Lig_chan-Glu_bd
go-classifiers:componentcell junctioncomponentdendritecomponentintracellularcomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic membranefunctionextracellular-glutamate-gated ion channel activityfunctionNMDA glutamate receptor activityprocessactivation of MAPKK activityprocessadult locomotory behaviorprocessaxon guidanceprocessepidermal growth factor receptor signaling pathwayprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessinnate immune responseprocessinsulin receptor signaling pathwayprocession transmembrane transportprocessionotropic glutamate receptor signaling pathwayprocessMAPK cascadeprocessneurotrophin TRK receptor signaling pathwayprocessRas protein signal transductionprocessregulation of sensory perception of painprocesssignal transductionprocesssmall GTPase mediated signal transductionprocessstartle responseprocesssynaptic transmissionprocesssynaptic transmission, glutamatergicprocessvascular endothelial growth factor receptor signaling pathway
name:Glutamate receptor ionotropic, NMDA 3A
general-function:Protein phosphatase 2a binding
specific-function:NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
gene-name:GRIN3A
locus:9q31.1
cellular-location:Cell membrane
transmembrane-regions:675-695 749-769 931-951
signal-regions:1-23
theoretical-pi:7.81
molecular-weight:125464.07
chromosome-location:9
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:16767GenAtlasGRIN3AGenBank Gene DatabaseAJ416950GenBank Protein Database20372905IUPHAR460UniProtKBQ8TCU5UniProt AccessionNMD3A_HUMAN
synonyms:GluN3AKIAA1973N-methyl-D-aspartate receptor subtype 3ANMDAR-LNMDAR3ANR3A
amino-acid-sequence:>lcl|BSEQ0037055|Glutamate receptor ionotropic, NMDA 3A MRRLSLWWLLSRVCLLLPPPCALVLAGVPSSSSHPQPCQILKRIGHAVRVGAVHLQPWTT APRAASRAPDDSRAGAQRDEPEPGTRRSPAPSPGARWLGSTLHGRGPPGSRKPGEGARAE ALWPRDALLFAVDNLNRVEGLLPYNLSLEVVMAIEAGLGDLPLLPFSSPSSPWSSDPFSF LQSVCHTVVVQGVSALLAFPQSQGEMMELDLVSLVLHIPVISIVRHEFPRESQNPLHLQL SLENSLSSDADVTVSILTMNNWYNFSLLLCQEDWNITDFLLLTQNNSKFHLGSIINITAN LPSTQDLLSFLQIQLESIKNSTPTVVMFGCDMESIRRIFEITTQFGVMPPELRWVLGDSQ NVEELRTEGLPLGLIAHGKTTQSVFEHYVQDAMELVARAVATATMIQPELALIPSTMNCM EVETTNLTSGQYLSRFLANTTFRGLSGSIRVKGSTIVSSENNFFIWNLQHDPMGKPMWTR LGSWQGGKIVMDYGIWPEQAQRHKTHFQHPSKLHLRVVTLIEHPFVFTREVDDEGLCPAG QLCLDPMTNDSSTLDSLFSSLHSSNDTVPIKFKKCCYGYCIDLLEKIAEDMNFDFDLYIV GDGKYGAWKNGHWTGLVGDLLRGTAHMAVTSFSINTARSQVIDFTSPFFSTSLGILVRTR DTAAPIGAFMWPLHWTMWLGIFVALHITAVFLTLYEWKSPFGLTPKGRNRSKVFSFSSAL NICYALLFGRTVAIKPPKCWTGRFLMNLWAIFCMFCLSTYTANLAAVMVGEKIYEELSGI HDPKLHHPSQGFRFGTVRESSAEDYVRQSFPEMHEYMRRYNVPATPDGVEYLKNDPEKLD AFIMDKALLDYEVSIDADCKLLTVGKPFAIEGYGIGLPPNSPLTANISELISQYKSHGFM DMLHDKWYRVVPCGKRSFAVTETLQMGIKHFSGLFVLLCIGFGLSILTTIGEHIVYRLLL PRIKNKSKLQYWLHTSQRLHRAINTSFIEEKQQHFKTKRVEKRSNVGPRQLTVWNTSNLS HDNRRKYIFSDEEGQNQLGIRIHQDIPLPPRRRELPALRTTNGKADSLNVSRNSVMQELS ELEKQIQVIRQELQLAVSRKTELEEYQRTSRTCES
gene-sequence:>lcl|BSEQ0016161|Glutamate receptor ionotropic, NMDA 3A (GRIN3A) ATGAGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGGTCTGTCTGCTGTTGCCGCCGCCC TGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAGCCCTGCCAGATC CTCAAGCGCATCGGGCACGCGGTGAGGGTGGGCGCGGTGCACTTGCAGCCCTGGACCACC GCCCCCCGCGCGGCCAGCCGCGCTCCGGACGACAGCCGAGCAGGAGCCCAGAGGGATGAG CCGGAGCCAGGGACTAGGCGGTCCCCGGCGCCCTCGCCGGGCGCACGCTGGTTGGGGAGC ACCCTGCATGGCCGGGGGCCGCCGGGCTCCCGTAAGCCCGGGGAGGGCGCCAGGGCGGAG GCCCTGTGGCCACGGGACGCCCTCCTATTTGCCGTGGACAACCTGAACCGCGTGGAAGGG CTGCTACCCTACAACCTGTCTTTGGAAGTAGTGATGGCCATCGAGGCAGGCCTGGGCGAT CTGCCACTTTTGCCCTTCTCCTCCCCTAGTTCGCCATGGAGCAGTGACCCTTTCTCCTTC CTGCAAAGTGTGTGCCATACCGTGGTGGTGCAAGGGGTGTCGGCGCTGCTCGCCTTCCCC CAGAGCCAGGGCGAAATGATGGAGCTCGACTTGGTCAGCTTAGTCCTGCACATTCCAGTG ATCAGCATCGTGCGCCACGAGTTTCCACGGGAGAGTCAGAATCCCCTTCACCTACAACTG AGTTTAGAAAATTCATTAAGTTCTGATGCTGATGTCACTGTCTCAATCCTGACCATGAAC AACTGGTACAATTTTAGCTTGTTGCTGTGCCAGGAAGACTGGAACATCACCGACTTCCTC CTCCTTACCCAGAATAATTCCAAGTTCCACCTTGGTTCTATCATCAACATCACCGCTAAC CTCCCCTCCACCCAGGACCTCTTGAGCTTCCTACAGATCCAGCTTGAGAGTATTAAGAAC AGCACACCCACAGTGGTGATGTTTGGCTGCGACATGGAAAGTATCCGGCGGATTTTCGAA ATTACAACCCAGTTTGGGGTCATGCCCCCTGAACTTCGTTGGGTGCTGGGAGATTCCCAG AATGTGGAGGAACTGAGGACAGAGGGTCTGCCCTTAGGGCTCATTGCTCATGGAAAAACA ACACAGTCTGTCTTTGAGCACTACGTACAAGATGCTATGGAGCTGGTCGCAAGAGCTGTA GCCACAGCCACCATGATCCAACCAGAACTTGCTCTCATTCCCAGCACGATGAACTGCATG GAGGTGGAAACTACAAATCTCACTTCAGGACAATATTTATCAAGGTTTCTAGCCAATACC ACTTTCAGAGGCCTCAGTGGTTCCATCAGAGTAAAAGGTTCCACCATCGTCAGCTCAGAA AACAACTTTTTCATCTGGAATCTTCAACATGACCCCATGGGAAAGCCAATGTGGACCCGC TTGGGCAGCTGGCAGGGGGGAAAGATTGTCATGGACTATGGAATATGGCCAGAGCAGGCC CAGAGACACAAAACCCACTTCCAACATCCAAGTAAGCTACACTTGAGAGTGGTTACCCTG ATTGAGCATCCTTTTGTCTTCACAAGGGAGGTAGATGATGAAGGCTTGTGCCCTGCTGGC CAACTCTGTCTAGACCCCATGACTAATGACTCTTCCACATTGGACAGCCTTTTTAGCAGC CTCCATAGCAGTAATGATACAGTGCCCATTAAATTCAAGAAGTGCTGCTATGGATATTGC ATTGATCTGCTGGAAAAGATAGCAGAAGACATGAACTTTGACTTCGACCTCTATATTGTA GGGGATGGAAAGTATGGAGCATGGAAAAATGGGCACTGGACTGGGCTAGTGGGTGATCTC CTGAGAGGGACTGCCCACATGGCAGTCACTTCCTTTAGCATCAATACTGCACGGAGCCAG GTGATAGATTTCACCAGCCCTTTCTTCTCCACCAGCTTGGGCATCTTAGTGAGGACCCGA GATACAGCAGCTCCCATTGGAGCCTTCATGTGGCCACTCCACTGGACAATGTGGCTGGGG ATTTTTGTGGCTCTGCACATCACTGCCGTCTTCCTCACTCTGTATGAATGGAAGAGTCCA TTTGGTTTGACTCCCAAGGGGCGAAATAGAAGTAAAGTCTTCTCCTTTTCTTCAGCCTTG AACATCTGTTATGCCCTCTTGTTTGGCAGAACAGTGGCCATCAAACCTCCAAAATGTTGG ACTGGAAGGTTTCTAATGAACCTTTGGGCCATTTTCTGTATGTTTTGCCTTTCCACATAC ACGGCAAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATA CATGACCCCAAGTTACATCATCCTTCCCAAGGATTCCGCTTTGGAACTGTCCGAGAAAGC AGTGCTGAAGATTATGTGAGACAAAGTTTCCCAGAGATGCATGAATATATGAGAAGGTAC AATGTTCCAGCCACCCCTGATGGAGTGGAGTATCTGAAGAATGATCCAGAGAAACTAGAC GCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAA CTTCTCACTGTGGGGAAGCCATTTGCCATAGAAGGATACGGCATTGGCCTCCCACCCAAC TCTCCATTGACCGCCAACATATCCGAGCTAATCAGTCAATACAAGTCACATGGGTTTATG GATATGCTCCATGACAAGTGGTACAGGGTGGTTCCCTGTGGCAAGAGAAGTTTTGCTGTC ACGGAGACTTTGCAAATGGGCATCAAACACTTCTCTGGGCTCTTTGTGCTGCTGTGCATT GGATTTGGTCTGTCCATTTTGACCACCATTGGTGAGCACATAGTATACAGGCTGCTGCTA CCACGAATCAAAAACAAATCCAAGCTGCAATACTGGCTCCACACCAGCCAGAGATTACAC AGAGCAATAAATACATCATTTATAGAGGAAAAGCAGCAGCATTTCAAGACCAAACGTGTG GAAAAGAGGTCTAATGTGGGACCCCGTCAGCTTACCGTATGGAATACTTCCAATCTGAGT CATGACAACCGACGGAAATACATCTTTAGTGATGAGGAAGGACAAAACCAGCTGGGCATC CGGATCCACCAGGACATCCCCCTCCCTCCAAGGAGAAGAGAGCTCCCTGCCTTGCGGACC ACCAATGGGAAAGCAGACTCCCTAAATGTATCTCGGAACTCAGTGATGCAGGAACTCTCA GAGCTCGAGAAGCAGATTCAGGTGATCCGTCAGGAGCTGCAGCTGGCTGTGAGCAGGAAA ACGGAGCTGGAGGAGTATCAAAGGACAAGTCGGACTTGTGAGTCCTAG
pfams:PF00060Lig_chanPF10613Lig_chan-Glu_bd
go-classifiers:componentcell junctioncomponentdendritecomponentintegral component of membranecomponentmembranecomponentneuron projectioncomponentneuronal cell bodycomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic densitycomponentpostsynaptic membranecomponentsynapsefunctioncalcium channel activityfunctionextracellular-glutamate-gated ion channel activityfunctionglycine bindingfunctionidentical protein bindingfunctionNMDA glutamate receptor activityfunctionprotein phosphatase 2A bindingprocesscalcium ion transportprocessdendrite developmentprocession transmembrane transportprocessionotropic glutamate receptor signaling pathwayprocessprepulse inhibitionprocessresponse to ethanolprocesssynaptic transmission, glutamatergic
name:Glutamate receptor ionotropic, NMDA 3B
general-function:Nmda glutamate receptor activity
specific-function:NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine.
gene-name:GRIN3B
locus:19p13.3
cellular-location:Cell membrane
transmembrane-regions:565-585 649-669 831-851
signal-regions:1-22
theoretical-pi:9.5
molecular-weight:112990.98
chromosome-location:19
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:16768GenAtlasGRIN3BGenBank Gene DatabaseAC004528GenBank Protein Database3025446IUPHAR461UniProtKBO60391UniProt AccessionNMD3B_HUMAN
synonyms:GluN3BN-methyl-D-aspartate receptor subtype 3BNMDAR3BNR3B
amino-acid-sequence:>lcl|BSEQ0001066|Glutamate receptor ionotropic, NMDA 3B MEFVRALWLGLALALGPGSAGGHPQPCGVLARLGGSVRLGALLPRAPLARARARAALARA ALAPRLPHNLSLELVVAAPPARDPASLTRGLCQALVPPGVAALLAFPEARPELLQLHFLA AATETPVLSLLRREARAPLGAPNPFHLQLHWASPLETLLDVLVAVLQAHAWEDVGLALCR TQDPGGLVALWTSRAGRPPQLVLDLSRRDTGDAGLRARLAPMAAPVGGEAPVPAAVLLGC DIARARRVLEAVPPGPHWLLGTPLPPKALPTAGLPPGLLALGEVARPPLEAAIHDIVQLV ARALGSAAQVQPKRALLPAPVNCGDLQPAGPESPGRFLARFLANTSFQGRTGPVWVTGSS QVHMSRHFKVWSLRRDPRGAPAWATVGSWRDGQLDLEPGGASARPPPPQGAQVWPKLRVV TLLEHPFVFARDPDEDGQCPAGQLCLDPGTNDSATLDALFAALANGSAPRALRKCCYGYC IDLLERLAEDTPFDFELYLVGDGKYGALRDGRWTGLVGDLLAGRAHMAVTSFSINSARSQ VVDFTSPFFSTSLGIMVRARDTASPIGAFMWPLHWSTWLGVFAALHLTALFLTVYEWRSP YGLTPRGRNRSTVFSYSSALNLCYAILFRRTVSSKTPKCPTGRLLMNLWAIFCLLVLSSY TANLAAVMVGDKTFEELSGIHDPKLHHPAQGFRFGTVWESSAEAYIKKSFPDMHAHMRRH SAPTTPRGVAMLTSDPPKLNAFIMDKSLLDYEVSIDADCKLLTVGKPFAIEGYGIGLPQN SPLTSNLSEFISRYKSSGFIDLLHDKWYKMVPCGKRVFAVTETLQMSIYHFAGLFVLLCL GLGSALLSSLGEHAFFRLALPRIRKGSRLQYWLHTSQKIHRALNTEPPEGSKEETAEAEP SGPEVEQQQQQQDQPTAPEGWKRARRAVDKERRVRFLLEPAVVVAPEADAEAEAAPREGP VWLCSYGRPPAARPTGAPQPGELQELERRIEVARERLRQALVRRGQLLAQLGDSARHRPR RLLQARAAPAEAPPHSGRPGSQE
gene-sequence:>lcl|BSEQ0016125|Glutamate receptor ionotropic, NMDA 3B (GRIN3B) ATGGAGTTTGTGCGGGCGCTGTGGCTGGGCCTGGCGCTGGCGCTGGGGCCGGGGTCCGCG GGGGGCCACCCTCAGCCGTGCGGCGTCCTGGCGCGCCTCGGGGGCTCCGTGCGCCTGGGC GCCCTCCTGCCCCGCGCGCCTCTCGCCCGCGCCCGCGCCCGCGCCGCCCTGGCCCGGGCC GCCCTGGCGCCGCGGCTGCCGCACAACCTGAGCTTGGAGCTGGTGGTCGCCGCGCCCCCC GCCCGCGACCCCGCCTCGCTGACCCGCGGCCTGTGCCAGGCGCTGGTGCCTCCGGGCGTG GCGGCCCTGCTCGCCTTTCCCGAGGCTCGGCCCGAGCTGCTGCAGCTGCACTTCCTGGCG GCGGCCACCGAGACCCCCGTGCTCAGCCTGCTGCGGCGGGAGGCGCGCGCGCCCCTCGGA GCCCCGAACCCATTCCACCTGCAGCTGCACTGGGCCAGCCCCCTGGAGACGCTGCTGGAT GTGCTGGTGGCGGTGCTGCAGGCGCACGCCTGGGAAGACGTCGGCCTGGCCCTGTGCCGC ACTCAGGACCCCGGCGGCCTGGTGGCCCTCTGGACAAGCCGGGCTGGCCGGCCCCCACAG CTGGTCCTGGACCTAAGCCGGCGGGACACGGGAGATGCAGGACTGCGGGCACGCCTGGCC CCGATGGCGGCGCCAGTGGGGGGTGAAGCACCGGTACCCGCGGCGGTCCTCCTCGGCTGT GACATCGCCCGTGCCCGTCGGGTGCTGGAGGCCGTACCTCCCGGCCCCCACTGGCTGTTG GGGACACCACTGCCGCCCAAGGCCCTGCCCACCGCGGGGCTGCCACCAGGGCTGCTGGCG CTGGGCGAGGTGGCACGACCCCCGCTGGAGGCCGCCATCCATGACATTGTGCAACTGGTG GCCCGGGCGCTGGGCAGTGCGGCCCAGGTGCAGCCGAAGCGAGCCCTCCTCCCCGCCCCG GTCAACTGCGGGGACCTGCAGCCGGCCGGGCCCGAGTCCCCGGGGCGCTTCTTGGCACGG TTCCTGGCCAACACGTCCTTCCAGGGCCGCACGGGCCCCGTGTGGGTGACAGGCAGCTCC CAGGTACACATGTCTCGGCACTTTAAGGTGTGGAGCCTTCGCCGGGACCCACGGGGCGCC CCGGCCTGGGCCACGGTGGGCAGCTGGCGGGACGGCCAGCTGGACTTGGAACCGGGAGGT GCCTCTGCACGGCCCCCGCCCCCACAGGGTGCCCAGGTCTGGCCCAAGCTGCGTGTGGTA ACGCTGTTGGAACACCCATTTGTGTTTGCCCGTGATCCAGACGAAGACGGGCAGTGCCCA GCGGGGCAGCTGTGCCTGGACCCTGGCACCAACGACTCGGCCACCCTGGACGCACTGTTC GCCGCGCTGGCCAACGGCTCAGCGCCCCGTGCCCTGCGCAAGTGCTGCTACGGCTACTGC ATTGACCTGCTGGAGCGGCTGGCGGAGGACACGCCCTTCGACTTCGAGCTGTACCTCGTG GGTGACGGCAAGTACGGCGCCCTGCGGGACGGCCGCTGGACCGGCCTGGTCGGGGACCTG CTGGCCGGCCGGGCCCACATGGCGGTCACCAGCTTCAGTATCAACTCCGCCCGCTCACAG GTGGTGGACTTCACCAGCCCCTTCTTCTCCACCAGCCTGGGCATCATGGTGCGGGCACGG GACACGGCCTCACCCATCGGTGCCTTTATGTGGCCCCTGCACTGGTCCACGTGGCTGGGC GTCTTTGCGGCCCTGCACCTCACCGCGCTCTTCCTCACCGTGTACGAGTGGCGTAGCCCC TACGGCCTCACGCCACGTGGCCGCAACCGCAGCACCGTCTTCTCCTACTCCTCAGCCCTC AACCTGTGCTACGCCATCCTCTTCAGACGCACCGTGTCCAGCAAGACGCCCAAGTGCCCC ACGGGCCGCCTGCTCATGAACCTCTGGGCCATCTTCTGCCTGCTGGTGCTGTCCAGCTAC ACGGCCAACCTGGCTGCCGTCATGGTCGGGGACAAGACCTTCGAGGAGCTGTCGGGGATC CACGACCCCAAGCTGCACCACCCGGCGCAGGGCTTCCGCTTCGGCACCGTGTGGGAGAGC AGCGCCGAGGCGTACATCAAGAAGAGCTTCCCCGACATGCACGCACACATGCGGCGCCAC AGCGCGCCCACCACGCCCCGCGGCGTCGCCATGCTCACGAGCGACCCCCCCAAGCTCAAC GCCTTCATCATGGACAAGTCGCTCCTGGACTACGAGGTCTCCATCGACGCCGACTGCAAA CTGCTGACCGTGGGAAAGCCCTTCGCCATTGAGGGCTATGGGATCGGACTGCCCCAGAAC TCGCCGCTCACCTCCAACCTGTCCGAGTTCATCAGCCGCTACAAGTCCTCCGGCTTCATC GACCTGCTCCACGACAAGTGGTACAAGATGGTGCCTTGCGGCAAGCGGGTCTTTGCGGTT ACAGAGACCCTGCAGATGAGCATCTACCACTTCGCGGGCCTCTTCGTGTTGCTGTGCCTG GGCCTGGGCAGCGCTCTGCTCAGCTCGCTGGGCGAGCACGCCTTCTTCCGCCTGGCGCTG CCGCGCATCCGCAAGGGGAGCAGGCTGCAGTACTGGCTGCACACCAGCCAGAAAATCCAC CGCGCCCTCAACACGGAGCCACCAGAGGGGTCGAAGGAGGAGACGGCAGAGGCGGAGCCC AGCGGCCCCGAGGTGGAGCAGCAGCAGCAGCAGCAGGACCAGCCAACGGCTCCGGAGGGC TGGAAACGGGCGCGCCGGGCCGTGGACAAGGAGCGCCGCGTGCGCTTCCTGCTGGAGCCC GCCGTGGTTGTGGCACCCGAAGCGGACGCGGAGGCGGAGGCTGCGCCGCGAGAGGGCCCC GTCTGGCTGTGCTCCTACGGCCGCCCGCCCGCCGCAAGGCCCACGGGGGCCCCCCAGCCC GGGGAGCTGCAGGAGCTGGAGCGCCGCATCGAAGTCGCGCGTGAGCGGCTCCGCCAGGCC CTGGTGCGGCGCGGCCAGCTCCTGGCACAGCTCGGGGACAGCGCACGTCACCGGCCTCGG CGCTTGCTTCAGGCCAGAGCGGCCCCCGCGGAGGCCCCACCACACTCTGGCCGACCGGGG AGCCAGGAATGA
pfams:PF00060Lig_chanPF10613Lig_chan-Glu_bd
go-classifiers:componentcell junctioncomponentdendritecomponentneuronal cell bodycomponentNMDA selective glutamate receptor complexcomponentplasma membranecomponentpostsynaptic membranefunctioncalcium channel activityfunctioncation channel activityfunctionextracellular-glutamate-gated ion channel activityfunctionglycine bindingfunctionneurotransmitter bindingfunctionneurotransmitter receptor activityfunctionNMDA glutamate receptor activityprocession transmembrane transportprocessionotropic glutamate receptor signaling pathwayprocessprotein insertion into membraneprocessregulation of calcium ion transportprocesssynaptic transmission, glutamatergic
id:BE0000013
name:Adenosine receptor A1
organism:Humans
action:stimulator
Sawynok J, Reid AR, Liu J: Spinal and peripheral adenosine A(1) receptors contribute to antinociception by tramadol in the formalin test in mice. Eur J Pharmacol. 2013 Aug 15;714(1-3):373-8. doi: 10.1016/j.ejphar.2013.07.012. Epub 2013 Jul 16.
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:yes
name:Adenosine receptor A1
general-function:Purine nucleoside binding
specific-function:Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
gene-name:ADORA1
locus:1q32.1
cellular-location:Cell membrane
transmembrane-regions:11-33 47-69 81-102 124-146 177-201 236-259 268-292
signal-regions:
theoretical-pi:8.75
molecular-weight:36511.325
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:262GenAtlasADORA1GenBank Gene DatabaseS45235GenBank Protein Database256155IUPHAR18Guide to Pharmacology18UniProtKBP30542UniProt AccessionAA1R_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0000026|Adenosine receptor A1 MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGA LVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVT PRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYM VYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALIL FLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFL KIWNDHFRCQPAPPIDEDLPEERPDD
gene-sequence:>lcl|BSEQ0010133|Adenosine receptor A1 (ADORA1) ATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCTCATCGCC CTGGTCTCTGTGCCCGGGAACGTGCTGGTGATCTGGGCGGTGAAGGTGAACCAGGCGCTG CGGGATGCCACCTTCTGCTTCATCGTGTCGCTGGCGGTGGCTGATGTGGCCGTGGGTGCC CTGGTCATCCCCCTCGCCATCCTCATCAACATTGGGCCACAGACCTACTTCCACACCTGC CTCATGGTTGCCTGTCCGGTCCTCATCCTCACCCAGAGCTCCATCCTGGCCCTGCTGGCA ATTGCTGTGGACCGCTACCTCCGGGTCAAGATCCCTCTCCGGTACAAGATGGTGGTGACC CCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGCTGGATCCTCTCCTTCGTGGTGGGACTG ACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCGGGCCTGGGCAGCCAACGGC AGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCATGGAGTACATG GTCTACTTCAACTTCTTTGTGTGGGTGCTGCCCCCGCTTCTCCTCATGGTCCTCATCTAC CTGGAGGTCTTCTACCTAATCCGCAAGCAGCTCAACAAGAAGGTGTCGGCCTCCTCCGGC GACCCGCAGAAGTACTATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCTCATCCTC TTCCTCTTTGCCCTCAGCTGGCTGCCTTTGCACATCCTCAACTGCATCACCCTCTTCTGC CCGTCCTGCCACAAGCCCAGCATCCTTACCTACATTGCCATCTTCCTCACGCACGGCAAC TCGGCCATGAACCCCATTGTCTATGCCTTCCGCATCCAGAAGTTCCGCGTCACCTTCCTT AAGATTTGGAATGACCATTTCCGCTGCCAGCCTGCACCTCCCATTGACGAGGATCTCCCA GAAGAGAGGCCTGATGACTAG
pfams:PF000017tm_1
go-classifiers:componentasymmetric synapsecomponentaxolemmacomponentbasolateral plasma membranecomponentdendritic spinecomponentendoplasmic reticulumcomponentintegral component of plasma membranecomponentneuronal cell bodycomponentplasma membranecomponentpostsynaptic densitycomponentpostsynaptic membranecomponentpresynaptic active zonecomponentpresynaptic membranecomponentterminal boutonfunctionG-protein coupled adenosine receptor activityfunctionphospholipase C activityfunctionpurine nucleoside bindingprocessactivation of MAPKK activityprocessadenylate cyclase-inhibiting G-protein coupled receptor signaling pathwayprocessapoptotic signaling pathwayprocesscell-cell signalingprocesscognitionprocessdetection of temperature stimulus involved in sensory perception of painprocessexcitatory postsynaptic potentialprocessinflammatory responseprocesslipid catabolic processprocessnegative regulation of acute inflammatory responseprocessnegative regulation of apoptotic processprocessnegative regulation of blood pressureprocessnegative regulation of cardiac muscle contractionprocessnegative regulation of cell proliferationprocessnegative regulation of circadian sleep/wake cycle, non-REM sleepprocessnegative regulation of glutamate secretionprocessnegative regulation of hormone secretionprocessnegative regulation of leukocyte migrationprocessnegative regulation of lipid catabolic processprocessnegative regulation of long term synaptic depressionprocessnegative regulation of mucus secretionprocessnegative regulation of neurotrophin productionprocessnegative regulation of renal sodium excretionprocessnegative regulation of synaptic transmission, GABAergicprocessnegative regulation of synaptic transmission, glutamatergicprocessnegative regulation of vasodilationprocessnervous system developmentprocessphagocytosisprocesspositive regulation of blood pressureprocesspositive regulation of epidermal growth factor-activated receptor activityprocesspositive regulation of nucleoside transportprocesspositive regulation of peptide secretionprocesspositive regulation of potassium ion transportprocesspositive regulation of protein dephosphorylationprocessprotein targeting to membraneprocessregulation of glomerular filtrationprocessregulation of respiratory gaseous exchange by neurological system processprocessregulation of sensory perception of painprocessregulation of synaptic plasticityprocessrelaxation of vascular smooth muscleprocessresponse to hypoxiaprocesssignal transductionprocesstemperature homeostasis
id:BE0004864
name:Alpha-2 adrenergic receptors
organism:Humans
action:stimulator
Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
known-action:yes
name:Alpha-2A adrenergic receptor
general-function:Thioesterase binding
specific-function:Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
gene-name:ADRA2A
locus:10q24-q26
cellular-location:Cell membrane
transmembrane-regions:34-59 71-96 107-129 152-172 195-217 375-395 410-429
signal-regions:
theoretical-pi:10.2
molecular-weight:48956.275
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:281GenAtlasADRA2AGenBank Gene DatabaseM23533GenBank Protein Database178196IUPHAR25Guide to Pharmacology25UniProtKBP08913UniProt AccessionADA2A_HUMAN
synonyms:ADRA2RADRARAlpha-2 adrenergic receptor subtype C10Alpha-2A adrenoceptorAlpha-2A adrenoreceptorAlpha-2AAR
amino-acid-sequence:>lcl|BSEQ0021255|Alpha-2A adrenergic receptor MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS LNPVIYTIFNHDFRRAFKKILCRGDRKRIV
gene-sequence:>lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A) ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC ACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG CTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG GCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC GTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG TGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC GCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC ACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC TTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG CCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC TTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT CGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC ACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG GCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG CGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT CCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG GTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG GCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG CAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG TGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC ACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC TACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC AGGAAGCGGATCGTGTGA
pfams:PF000017tm_1
go-classifiers:componentbasolateral plasma membranecomponentcytoplasmcomponentintegral component of plasma membranecomponentplasma membranecomponentreceptor complexcomponentsynapsefunctionalpha-1B adrenergic receptor bindingfunctionalpha-2C adrenergic receptor bindingfunctionalpha2-adrenergic receptor activityfunctionepinephrine bindingfunctionheterotrimeric G-protein bindingfunctionnorepinephrine bindingfunctionprotein heterodimerization activityfunctionprotein homodimerization activityfunctionprotein kinase bindingfunctionthioesterase bindingprocessactin cytoskeleton organizationprocessactivation of MAPK activity by adrenergic receptor signaling pathwayprocessactivation of protein kinase activityprocessactivation of protein kinase B activityprocessacute inflammatory responseprocessadenylate cyclase-inhibiting adrenergic receptor signaling pathwayprocessblood coagulationprocesscell-cell signalingprocesscellular response to hormone stimulusprocessDNA replicationprocessenergy reserve metabolic processprocessepidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathwayprocessfear responseprocessfemale pregnancyprocessG-protein coupled receptor signaling pathwayprocessglucose homeostasisprocessintestinal absorptionprocessmovement of cell or subcellular componentprocessnegative regulation of adenylate cyclase activityprocessnegative regulation of adrenergic receptor signaling pathwayprocessnegative regulation of calcium ion transmembrane transporter activityprocessnegative regulation of calcium ion transportprocessnegative regulation of calcium ion-dependent exocytosisprocessnegative regulation of cAMP biosynthetic processprocessnegative regulation of epinephrine secretionprocessnegative regulation of insulin secretionprocessnegative regulation of insulin secretion involved in cellular response to glucose stimulusprocessnegative regulation of lipid catabolic processprocessnegative regulation of norepinephrine secretionprocessnegative regulation of uterine smooth muscle contractionprocessphospholipase C-activating adrenergic receptor signaling pathwayprocessplatelet activationprocesspositive regulation of cell migrationprocesspositive regulation of cell proliferationprocesspositive regulation of cytokine productionprocesspositive regulation of epidermal growth factor-activated receptor activityprocesspositive regulation of MAP kinase activityprocesspositive regulation of membrane protein ectodomain proteolysisprocesspositive regulation of potassium ion transportprocesspositive regulation of vasodilationprocesspositive regulation of wound healingprocessRas protein signal transductionprocessregulation of insulin secretionprocessregulation of vasoconstrictionprocessRho protein signal transductionprocesssignal transductionprocesssmall molecule metabolic processprocessthermoception
name:Alpha-2B adrenergic receptor
general-function:Epinephrine binding
specific-function:Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol.
gene-name:ADRA2B
locus:2p13-q13
cellular-location:Cell membrane
transmembrane-regions:13-38 49-69 87-107 129-149 173-193 370-393 403-423
signal-regions:
theoretical-pi:8.52
molecular-weight:49565.8
chromosome-location:2
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:282GenAtlasADRA2BGenBank Gene DatabaseM34041GenBank Protein Database178198IUPHAR26Guide to Pharmacology26UniProtKBP18089UniProt AccessionADA2B_HUMAN
synonyms:ADRA2L1ADRA2RL1Alpha-2 adrenergic receptor subtype C2Alpha-2B adrenoceptorAlpha-2B adrenoreceptorAlpha-2BAR
amino-acid-sequence:>lcl|BSEQ0010396|Alpha-2B adrenergic receptor MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADIL VATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEY NSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGS FFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASV ASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEE EEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQL TREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNP VIYTIFNQDFRRAFRRILCRPWTQTAW
gene-sequence:>lcl|BSEQ0010397|Alpha-2B adrenergic receptor (ADRA2B) ATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC TTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC CGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG GTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC CGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC GTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC AACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC GCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG CGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT TTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA CGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG CCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG GCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG ACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA GGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG GAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC TCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT GGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGACGG GCGCAGCTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT GTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGAGCCATCTGCCCGAAGCAC TGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA CTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC CTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentplasma membranefunctionalpha2-adrenergic receptor activityfunctionepinephrine bindingprocessactivation of MAPK activity by adrenergic receptor signaling pathwayprocessactivation of protein kinase B activityprocessblood coagulationprocesscell-cell signalingprocessepidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessnegative regulation of epinephrine secretionprocessnegative regulation of norepinephrine secretionprocessplatelet activationprocesspositive regulation of neuron differentiationprocessregulation of smooth muscle contractionprocessregulation of vasoconstriction
name:Alpha-2C adrenergic receptor
general-function:Protein homodimerization activity
specific-function:Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
gene-name:ADRA2C
locus:4p16
cellular-location:Cell membrane
transmembrane-regions:52-76 89-114 125-147 169-191 208-231 380-407 421-441
signal-regions:
theoretical-pi:10.69
molecular-weight:49521.585
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:283GenAtlasADRA2CGenBank Gene DatabaseJ03853GenBank Protein Database178194IUPHAR27Guide to Pharmacology27UniProtKBP18825UniProt AccessionADA2C_HUMAN
synonyms:ADRA2L2ADRA2RL2Alpha-2 adrenergic receptor subtype C4Alpha-2C adrenoceptorAlpha-2C adrenoreceptorAlpha-2CAR
amino-acid-sequence:>lcl|BSEQ0000681|Alpha-2C adrenergic receptor MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ
gene-sequence:>lcl|BSEQ0010255|Alpha-2C adrenergic receptor (ADRA2C) ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCC GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC GAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC GCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG TTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG CAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG CCCGGTGGCCGCCTGTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG CGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC ACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC AGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG TTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC AGGCAGTGA
pfams:PF000017tm_1
go-classifiers:componentaxon terminuscomponentcytoplasmcomponentendosomecomponentintegral component of plasma membranecomponentplasma membranefunctionalpha-2A adrenergic receptor bindingfunctionalpha2-adrenergic receptor activityfunctionepinephrine bindingfunctionprotein heterodimerization activityfunctionprotein homodimerization activityprocessactivation of MAPK activity by adrenergic receptor signaling pathwayprocessactivation of protein kinase B activityprocessadenylate cyclase-inhibiting adrenergic receptor signaling pathwayprocessblood coagulationprocesscell-cell signalingprocessenergy reserve metabolic processprocessepidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathwayprocessfemale pregnancyprocessG-protein coupled receptor signaling pathwayprocessnegative regulation of adenylate cyclase activityprocessnegative regulation of epinephrine secretionprocessnegative regulation of insulin secretion involved in cellular response to glucose stimulusprocessnegative regulation of norepinephrine secretionprocessnegative regulation of uterine smooth muscle contractionprocessplatelet activationprocesspositive regulation of neuron differentiationprocesspositive regulation of vasoconstrictionprocessregulation of insulin secretionprocessregulation of sensory perception of painprocesssmall molecule metabolic process
BE0002363Cytochrome P450 2D6HumanssubstrateA426915509185Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.L162Flockhart Table of Drug Interactionshttps://drug-interactions.medicine.iu.edu/Main-Table.aspxunknownCytochrome P450 2D6Steroid hydroxylase activityResponsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.CYP2D622q13.1Endoplasmic reticulum membrane7.2655768.9422HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2625GenAtlasCYP2D6GenBank Gene DatabaseM20403GenBank Protein Database181350Guide to Pharmacology1329UniProtKBP10635UniProt AccessionCP2D6_HUMAN1.14.14.1Cholesterol 25-hydroxylaseCYP2DL1CYPIID6Cytochrome P450-DB1Debrisoquine 4-hydroxylase>lcl|BSEQ0004641|Cytochrome P450 2D6 MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV FAFLVSPSPYELCAVPR>lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6) ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAGPF00067p450componentcytoplasmcomponentendoplasmic reticulumcomponentendoplasmic reticulum membranecomponentmitochondrionfunctionarachidonic acid epoxygenase activityfunctionaromatase activityfunctiondrug bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessalkaloid catabolic processprocessalkaloid metabolic processprocessarachidonic acid metabolic processprocesscoumarin metabolic processprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocessisoquinoline alkaloid metabolic processprocessmonoterpenoid metabolic processprocessnegative regulation of bindingprocessnegative regulation of cellular organofluorine metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic processBE0002638Cytochrome P450 3A4HumanssubstrateA3828611454734Subrahmanyam V, Renwick AB, Walters DG, Young PJ, Price RJ, Tonelli AP, Lake BG: Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001 Aug;29(8):1146-55.A426915509185Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.unknownCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic processBE0003549Cytochrome P450 2B6HumanssubstrateA3828611454734Subrahmanyam V, Renwick AB, Walters DG, Young PJ, Price RJ, Tonelli AP, Lake BG: Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001 Aug;29(8):1146-55.A426915509185Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.unknownCytochrome P450 2B6Steroid hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.CYP2B619q13.2Endoplasmic reticulum membrane8.4456277.8119HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2615GenBank Gene DatabaseM29874GenBank Protein Database181296Guide to Pharmacology1324UniProtKBP20813UniProt AccessionCP2B6_HUMAN1,4-cineole 2-exo-monooxygenase1.14.13.-CYPIIB6Cytochrome P450 IIB1>lcl|BSEQ0006839|Cytochrome P450 2B6 MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFRE KYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNR WKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIIC SIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQE INAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGT ETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFS DLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGAL KKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKI PPTYQIRFLPR>lcl|BSEQ0019435|Cytochrome P450 2B6 (CYP2B6) ATGGAACTCAGCGTCCTCCTCTTCCTTGCACTCCTCACAGGACTCTTGCTACTCCTGGTT CAGCGCCACCCTAACACCCATGACCGCCTCCCACCAGGGCCCCGCCCTCTGCCCCTTTTG GGAAACCTTCTGCAGATGGATAGAAGAGGCCTACTCAAATCCTTTCTGAGGTTCCGAGAG AAATATGGGGACGTCTTCACGGTACACCTGGGACCGAGGCCCGTGGTCATGCTGTGTGGA GTAGAGGCCATACGGGAGGCCCTTGTGGACAAGGCTGAGGCCTTCTCTGGCCGGGGAAAA ATCGCCATGGTCGACCCATTCTTCCGGGGATATGGTGTGATCTTTGCCAATGGAAACCGC TGGAAGGTGCTTCGGCGATTCTCTGTGACCACTATGAGGGACTTCGGGATGGGAAAGCGG AGTGTGGAGGAGCGGATTCAGGAGGAGGCTCAGTGTCTGATAGAGGAGCTTCGGAAATCC AAGGGGGCCCTCATGGACCCCACCTTCCTCTTCCAGTCCATTACCGCCAACATCATCTGC TCCATCGTCTTTGGAAAACGATTCCACTACCAAGATCAAGAGTTCCTGAAGATGCTGAAC TTGTTCTACCAGACTTTTTCACTCATCAGCTCTGTATTCGGCCAGCTGTTTGAGCTCTTC TCTGGCTTCTTGAAATACTTTCCTGGGGCACACAGGCAAGTTTACAAAAACCTGCAGGAA ATCAATGCTTACATTGGCCACAGTGTGGAGAAGCACCGTGAAACCCTGGACCCCAGCGCC CCCAAGGACCTCATCGACACCTACCTGCTCCACATGGAAAAAGAGAAATCCAACGCACAC AGTGAATTCAGCCACCAGAACCTCAACCTCAACACGCTCTCGCTCTTCTTTGCTGGCACT GAGACCACCAGCACCACTCTCCGCTACGGCTTCCTGCTCATGCTCAAATACCCTCATGTT GCAGAGAGAGTCTACAGGGAGATTGAACAGGTGATTGGCCCACATCGCCCTCCAGAGCTT CATGACCGAGCCAAAATGCCATACACAGAGGCAGTCATCTATGAGATTCAGAGATTTTCC GACCTTCTCCCCATGGGTGTGCCCCACATTGTCACCCAACACACCAGCTTCCGAGGGTAC ATCATCCCCAAGGACACAGAAGTATTTCTCATCCTGAGCACTGCTCTCCATGACCCACAC TACTTTGAAAAACCAGACGCCTTCAATCCTGACCACTTTCTGGATGCCAATGGGGCACTG AAAAAGACTGAAGCTTTTATCCCCTTCTCCTTAGGGAAGCGGATTTGTCTTGGTGAAGGC ATCGCCCGTGCGGAATTGTTCCTCTTCTTCACCACCATCCTCCAGAACTTCTCCATGGCC AGCCCCGTGGCCCCAGAAGACATCGATCTGACACCCCAGGAGTGTGGTGTGGGCAAAATA CCCCCAACATACCAGATCCGCTTCCTGCCCCGCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionarachidonic acid epoxygenase activityfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocesscellular ketone metabolic processprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessoxidation-reduction processprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic processBE0003541UDP-glucuronosyltransferase 1-1HumanssubstrateA3424215304429Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10.noUDP-glucuronosyltransferase 1-1Steroid bindingUDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and umbelliferone. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.UGT1A12q37Microsome491-5071-258.0959590.912HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:12530GenBank Gene DatabaseM57899GenBank Protein Database184473UniProtKBP22309UniProt AccessionUD11_HUMAN2.4.1.17Bilirubin-specific UDPGT isozyme 1GNT1hUG-BR1UDP-glucuronosyltransferase 1-AUDP-glucuronosyltransferase 1A1UDPGT 1-1UGT-1AUGT1UGT1A>lcl|BSEQ0006823|UDP-glucuronosyltransferase 1-1 MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVL APDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDS AMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLE FEATQCPNPFSYVPRPLSSHSDHMTFLQRVKNMLIAFSQNFLCDVVYSPYATLASEFLQR EVTVQDLLSSASVWLFRSDFVKDYPRPIMPNMVFVGGINCLHQNPLSQEFEAYINASGEH GIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDL LGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTS EDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHD LTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH>lcl|BSEQ0021360|UDP-glucuronosyltransferase 1-1 (UGT1A1) ATGGCTGTGGAGTCCCAGGGCGGACGCCCACTTGTCCTGGGCCTGCTGCTGTGTGTGCTG GGCCCAGTGGTGTCCCATGCTGGGAAGATACTGTTGATCCCAGTGGATGGCAGCCACTGG CTGAGCATGCTTGGGGCCATCCAGCAGCTGCAGCAGAGGGGACATGAAATAGTTGTCCTA GCACCTGACGCCTCGTTGTACATCAGAGACGGAGCATTTTACACCTTGAAGACGTACCCT GTGCCATTCCAAAGGGAGGATGTGAAAGAGTCTTTTGTTAGTCTCGGGCATAATGTTTTT GAGAATGATTCTTTCCTGCAGCGTGTGATCAAAACATACAAGAAAATAAAAAAGGACTCT GCTATGCTTTTGTCTGGCTGTTCCCACTTACTGCACAACAAGGAGCTCATGGCCTCCCTG GCAGAAAGCAGCTTTGATGTCATGCTGACGGACCCTTTCCTTCCTTGCAGCCCCATCGTG GCCCAGTACCTGTCTCTGCCCACTGTATTCTTCTTGCATGCACTGCCATGCAGCCTGGAA TTTGAGGCTACCCAGTGCCCCAACCCATTCTCCTACGTGCCCAGGCCTCTCTCCTCTCAT TCAGATCACATGACCTTCCTGCAGCGGGTGAAGAACATGCTCATTGCCTTTTCACAGAAC TTTCTGTGCGACGTGGTTTATTCCCCGTATGCAACCCTTGCCTCAGAATTCCTTCAGAGA GAGGTGACTGTCCAGGACCTATTGAGCTCTGCATCTGTCTGGCTGTTTAGAAGTGACTTT GTGAAGGATTACCCTAGGCCCATCATGCCCAATATGGTTTTTGTTGGTGGAATCAACTGC CTTCACCAAAATCCACTATCCCAGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACAT GGAATTGTGGTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATG GCAATTGCTGATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACC CGACCATCGAATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTG CTTGGTCACCCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAA AGCATATGCAATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAAT GCAAAGCGCATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCT GAAGATTTAGAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATC ATGCGCCTCTCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTC TGGGTGGAGTTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGAC CTCACCTGGTACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTG ACAGTGGCCTTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAA AAAGGGCGAGTTAAGAAAGCCCACAAATCCAAGACCCATTGAPF00201UDPGTcomponentcytochrome complexcomponentendoplasmic reticulumcomponentendoplasmic reticulum chaperone complexcomponentendoplasmic reticulum membranecomponentintegral component of plasma membranefunctionenzyme bindingfunctionenzyme inhibitor activityfunctionglucuronosyltransferase activityfunctionprotein heterodimerization activityfunctionprotein homodimerization activityfunctionretinoic acid bindingfunctionsteroid bindingprocessacute-phase responseprocessbilirubin conjugationprocessbiphenyl catabolic processprocesscellular glucuronidationprocesscellular response to ethanolprocesscellular response to glucocorticoid stimulusprocesscellular response to hormone stimulusprocessdigestionprocessdrug metabolic processprocessestrogen metabolic processprocessflavone metabolic processprocessflavonoid biosynthetic processprocessflavonoid glucuronidationprocessheme catabolic processprocessheterocycle metabolic processprocessliver developmentprocessnegative regulation of catalytic activityprocessnegative regulation of cellular glucuronidationprocessnegative regulation of fatty acid metabolic processprocessnegative regulation of glucuronosyltransferase activityprocessnegative regulation of steroid metabolic processprocessorgan regenerationprocessporphyrin-containing compound metabolic processprocessresponse to drugprocessresponse to lipopolysaccharideprocessresponse to nutrientprocessresponse to starvationprocessretinoic acid metabolic processprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic glucuronidationprocessxenobiotic metabolic process
载体
运输工具
药物反应
reactions:1
left-element--drugbank-id:DB00193
left-element--name:Tramadol
right-element--drugbank-id:DBMET00324
right-element--name:O-Desmethyltramadol
enzymes--drugbank-id:BE0002363
enzymes--name:Cytochrome P450 2D6
enzymes--uniprot-id:P10635
reactions:1
left-element--drugbank-id:DB00193
left-element--name:Tramadol
right-element--drugbank-id:DBMET00343
right-element--name:N-Desmethyltramadol
enzymes--drugbank-id:BE0002638
enzymes--name:Cytochrome P450 3A4
enzymes--uniprot-id:P08684
enzymes--drugbank-id:BE0003549
enzymes--name:Cytochrome P450 2B6
enzymes--uniprot-id:P20813
reactions:2
left-element--drugbank-id:DBMET00324
left-element--name:O-Desmethyltramadol
right-element--drugbank-id:DBMET00966
right-element--name:O-Desmethyl-tramado glucuronide
enzymes--drugbank-id:BE0003679
enzymes--name:UDP-glucuronosyltransferase 2B7
enzymes--uniprot-id:P16662
enzymes--drugbank-id:BE0003682
enzymes--name:UDP-glucuronosyltransferase 1-8
enzymes--uniprot-id:Q9HAW9
reactions:2
left-element--drugbank-id:DBMET00324
left-element--name:O-Desmethyltramadol
right-element--drugbank-id:DBMET00957
right-element--name:N,O-didesmethyltramadol
enzymes--drugbank-id:BE0002363
enzymes--name:Cytochrome P450 2D6
enzymes--uniprot-id:P10635
reactions:2
left-element--drugbank-id:DBMET00343
left-element--name:N-Desmethyltramadol
right-element--drugbank-id:DBMET00957
right-element--name:N,O-didesmethyltramadol
enzymes--drugbank-id:BE0002363
enzymes--name:Cytochrome P450 2D6
enzymes--uniprot-id:P10635
reactions:2
left-element--drugbank-id:DBMET00343
left-element--name:N-Desmethyltramadol
right-element--drugbank-id:DBMET00954
right-element--name:N,N-didesmethyltramadol
enzymes--drugbank-id:BE0002638
enzymes--name:Cytochrome P450 3A4
enzymes--uniprot-id:P08684
enzymes--drugbank-id:BE0003549
enzymes--name:Cytochrome P450 2B6
enzymes--uniprot-id:P20813
reactions:3
left-element--drugbank-id:DBMET00957
left-element--name:N,O-didesmethyltramadol
right-element--drugbank-id:DBMET00956
right-element--name:N,N,O-tridesmethyl-tramadol
reactions:3
left-element--drugbank-id:DBMET00954
left-element--name:N,N-didesmethyltramadol
right-element--drugbank-id:DBMET00956
right-element--name:N,N,O-tridesmethyl-tramadol
效应
不良反应